UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Fiscal Year Ended December 31, 2013

Commission File Number 000-22217

AMSURG CORP.

(Exact Name of Registrant as Specified in Its Charter)

Tennessee		62-1493316
(State or Other Jurisdiction of Incorporation)		(I.R.S. Employer Identification No.)

20 Burton Hills Boulevard
Nashville, Tennessee		37215
(Address of Principal Executive Offices)		(Zip Code)

Securities registered pursuant to Section 12(b) of the Act: Common Stock, no par value

(Title of class)

Nasdaq Global Select Market

(Name of each exchange on which registered)

Registrant’s telephone number, including area code: (615) 665-1283

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes [X] No [ ]

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes [ ] No [X]

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X] No [ ]

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of Registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [ ]

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer [X] Accelerated filer [ ] Non-accelerated filer [ ] Smaller reporting Company [ ]

(Do not check if a smaller reporting company)

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

As of February 26, 2014, 32,487,151 shares of the Registrant’s common stock were outstanding. The aggregate market value of the shares of common stock of the Registrant held by nonaffiliates on June 30, 2013 (based upon the closing sale price of these shares as reported on the Nasdaq Global Select Market as of June 30, 2013) was approximately $1,088,000,000. This calculation assumes that all shares of common stock beneficially held by executive officers and members of the Board of Directors of the Registrant are owned by “affiliates,” a status which each of the officers and directors individually may disclaim.

Documents Incorporated by Reference

Portions of the Registrant’s Definitive Proxy Statement for its Annual Meeting of Shareholders to be held on May 20, 2014, are incorporated by reference into Part III of this Annual Report on Form 10-K.

Table of Contents to Annual Report on Form 10-K for the Year Ended December 31, 2013

Part I
	Item 1.	Business	1
		Executive Officers of the Registrant	18
	Item 1A.	Risk Factors	19
	Item 1B.	Unresolved Staff Comments	23
	Item 2.	Properties	23
	Item 3.	Legal Proceedings	23
	Item 4.	Mine Safety Disclosures	23

Part II
	Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	24
	Item 6.	Selected Financial Data	25
	Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	26
	Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	36
	Item 8.	Financial Statements and Supplementary Data	37
	Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	67
	Item 9A.	Controls and Procedures	67
	Item 9B.	Other Information	69

Part III
	Item 10.	Directors, Executive Officers and Corporate Governance	69
	Item 11.	Executive Compensation	69
	Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	69
	Item 13.	Certain Relationships and Related Transactions, and Director Independence	69
	Item 14.	Principal Accounting Fees and Services	69

Part IV
	Item 15.	Exhibits and Financial Statement Schedules	70

	Signatures		74

Part I

Item 1. Business

Company Overview

We are the largest owner and operator of short stay ambulatory surgery centers or “ASC”s in the United States with 242 ASCs in 34 states and the District of Columbia, in partnership with over 2,000 physicians. Our company was formed in 1992 for the purpose of acquiring, developing and operating ASCs in partnership with physicians. Our common stock is traded on the Nasdaq Global Select Market under the symbol “AMSG.” Our surgery centers are typically located adjacent to or in close proximity to the medical practices of our partner physicians. We generally own a majority interest (primarily 51%) in the facilities we operate. Our surgical facilities primarily provide non-elective, high volume, lower-risk surgical procedures across multiple specialties, including among others gastroenterology, ophthalmology, and orthopaedics. For the year ended December 31, 2013, approximately 1.6 million surgical procedures were performed in our ASCs generating approximately $1.079 billion in total revenues. Our ASCs are designed with a cost structure that creates significant savings to patients and payors when compared to surgical services performed in hospital outpatient departments or “HOPD.”

We acquire, develop and operate ASCs through the formation of strategic partnerships with physicians to better serve the communities in our markets. Since physicians are critical to the delivery of healthcare, we have developed our operating model to encourage physicians to affiliate with us. We believe we attract physicians because we design our facilities and adopt staffing, scheduling and clinical systems and protocols with the goal of increasing physician efficiency. We believe that our focus on physician satisfaction combined with providing safe, high-quality healthcare in a friendly and convenient environment for patients will continue to make our ASCs an attractive alternative to HOPDs for physicians, patients and payors.

We focus on providing high-quality surgical facilities that meet the needs of patients, physicians and payors. We believe our facilities (1) enhance the quality of care for our patients, (2) provide significant administrative, clinical and efficiency benefits to physicians, and (3) offer a low cost alternative for patients and payors.

Available Information

We file reports with the Securities and Exchange Commission, or “SEC”, including annual reports on Form 10-K, quarterly reports on Form 10-Q and other reports from time to time. The public may read and copy any materials we file with the SEC at the SEC’s Public Reference Room at 100 F. Street, N.E., Room 1580, Washington, DC 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. We are an electronic filer and the SEC maintains an Internet site at http://www.sec.gov that contains the reports, proxy and information statements and other information filed electronically. Our website address is: http://www.amsurg.com. We make available free of charge through our website our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or furnished to the SEC. The information provided on our website is not part of this report, and is therefore not incorporated by reference unless such information is otherwise specifically referenced elsewhere in this annual report on Form 10-K.

Industry Overview

For many years, government programs, private insurance companies, managed care organizations and self-insured employers have implemented cost containment measures intended to limit the growth of healthcare expenditures. These cost-containment measures, together with technological advances, have contributed to the significant shift in the delivery of healthcare services away from traditional inpatient hospital settings to more cost-effective alternate sites, including ASCs. ASCs have been widely viewed as a successful way to increase efficiency by improving the quality of, and access to, healthcare and increasing patient satisfaction, while simultaneously reducing costs. According to data issued by the Centers for Medicare and Medicaid Services or “CMS” during 2013, there are approximately 5,400 Medicare-certified ASCs. We believe that of those ASCs, approximately 65% performed procedures in a single specialty and approximately 35% performed procedures in more than one specialty, or “multispecialty.” Among the single specialty centers, we believe over 2,000 are in our preferred specialties of gastroenterology, ophthalmology, orthopaedic, ear, nose and throat, or “ENT”, and urology, while the remainder are in specialties such as plastic surgery, podiatry and pain management. We believe approximately 50% of our preferred single specialty ASCs and 30% of multi-specialty ASCs are independently owned.

We believe the following factors have contributed to the increased migration of procedures to outpatient surgical facilities:

Cost‑Effective Alternative. Ambulatory surgery is generally less expensive than hospital-based surgery for a number of reasons, including lower facility development costs, more efficient staffing and space utilization, and a specialized operating environment focused on cost containment. Accordingly, charges to patients and payors by ASCs are generally less than hospital charges.

Physician and Patient Preference. We believe many physicians prefer ASCs because these surgery centers enhance physicians’ productivity by providing them with greater scheduling flexibility, more consistent nurse staffing and faster turnaround time between cases, allowing them to perform more surgeries in a defined period of time. In contrast, HOPDs generally serve a broader group of physicians, including those involved with emergency procedures, which can result in postponed or delayed surgeries for non-emergency procedures. Many patients prefer ambulatory surgical facilities as a result of more convenient locations, shorter waiting times and more convenient scheduling and registration than HOPDs.

Item 1. Business – (continued)

New Technology. New technology and advances in anesthesia, which have been increasingly accepted by physicians and payors, have significantly expanded the types of surgical procedures that can be performed in ASCs. Lasers, enhanced endoscopic techniques and fiber optics have reduced the trauma and recovery time associated with surgical procedures. Improved anesthesia has also shortened recovery time by reducing postoperative side effects thereby avoiding overnight hospitalization.

Our Competitive Strengths

We believe we are distinguished by the following competitive strengths:

Market Leading ASC Provider with Broad Geographic Presence. We are currently the largest outpatient surgical facility operator in the United States based upon the total number of facilities. We operate 242 surgery centers in 34 states and the District of Columbia. We believe our geographic diversification provides us with a strong competitive position within the highly fragmented ASC industry, and our national scale and position as a large, public company ASC operator makes us an attractive partner for physicians.

Attractive Demographic Trends. We are the market leader in the specialties of gastroenterology and ophthalmology. More gastroenterology and ophthalmology procedures are performed in our surgery centers than any other ASC operator. These specialties in particular have a higher concentration of older patients (50 years and older) than other specialties, such as orthopaedics or ENT. We believe the aging demographics of the United States population will continue to act as a source of growth for gastroenterology and ophthalmology procedures at our ASCs. Additionally, we believe the growing overweight and obese population in the United States will drive procedure growth in gastroenterology, ophthalmology, and orthopaedic cases. We believe our market strategy is well aligned to respond to these demographic trends.

Diversified Procedure and Payor Mix. At our 242 ASCs, our physician partners perform a number of different types of surgical procedures. For the year ended December 31, 2013, 50% of our revenues were generated at our gastroenterology centers, 38% of our revenues were generated at our multi-specialty centers, which includes our orthopaedic centers, and 12% of our revenues were generated at our ophthalmology centers. For the year ended December 31, 2013, we derived approximately 75% of our revenues from commercial and private payors. Over the same period, we derived approximately 25% of our revenues from governmental healthcare programs, primarily Medicare. Medicaid represents less than 2% of our revenues. Each of our ASCs contracts individually with the payors in its market area. This contracting diversification reduces our risk with respect to the termination of payor contracts. Because of our payor mix and the non-emergent nature of procedures performed in our ASCs, our bad debt expense has averaged less than 2.5% of our revenues over the last three years.

While we cannot predict how changes in reimbursement trends will impact our business, we believe we are well positioned with respect to possible changes in Medicare reimbursement for several reasons:

· Low Cost Provider: The delivery of healthcare will continue to be directed to low cost venues, including ASCs, therefore we believe governmental healthcare programs will favor ASCs compared to hospitals because of the lower reimbursement rates for the procedures performed in our surgery centers.

· Reimbursement of Procedures Performed in ASCs Comprise a Small Percentage of the Overall Medicare Budget: Reimbursement for procedures performed in ASCs make up less than 1% of the overall Medicare budget, and any future Medicare ASC rate cuts would not likely generate meaningful savings for governmental healthcare programs.

Proven Ability to Identify and Rapidly Integrate Acquisitions. We pursue acquisitions of ASCs through transactions involving single ASCs as well as acquisitions of companies that own and manage ASCs. Over the last five years, we have successfully acquired an ownership interest in 68 ASCs for a combined acquisition price of $739.7 million. A majority of these ASCs were acquired in individual transactions, however we also pursue the acquisition of companies that own and operate multiple ASCs.

We use experienced teams of operations and financial personnel to conduct a review of all aspects of a target center’s operations, including (1) the quality and reputation of the physicians affiliated with the center, (2) the market position of the center and the physicians affiliated with the center, (3) the center’s payor contracts and case mix, (4) competition and growth opportunities in the market, (5) the center’s staffing and supply policies, (6) an assessment of the center’s equipment, and (7) opportunities for operational efficiencies. We also have a dedicated team responsible for the integration of acquired centers. This team is responsible for converting acquired facilities to our reporting, staffing, and performance measurement systems and other operating systems. Once an acquisition is consummated, it is generally fully integrated within 60 days.

Conservative Leverage Profile. We have consistently maintained a leverage profile significantly lower than our comparably sized competitors. We view our conservative financial profile and policies as a competitive advantage, as they provide us with significant access to capital and greater financial flexibility to execute growth initiatives, including opportunistic acquisitions of facilities and multi-facility companies and selective de novo developments. We also believe our conservative leverage profile compared to other ASC owners is a differentiating factor to physicians in selecting a partner.

Item 1. Business – (continued)

Strategy

We believe we are a leader in the acquisition, development and operation of ASCs. The key components of our strategy are to:

· attract and retain physicians that are leaders in their specialty and market;

· increase same-center revenues and profitability at our existing surgery centers;

· expand our national network of ASCs by selectively acquiring both single-specialty ASCs and multi-specialty ASCs, and developing new ASCs in partnership with physicians; and

· pursue the acquisition of companies that own and operate multiple ASCs.

Attract and Retain Physicians that are Leaders in Their Specialty and Market. Physicians are critical to the delivery of healthcare and are a valuable component of our operating model. We currently operate 242 ASCs with over 2,000 physician partners. We typically structure partnerships with physicians in a 51% / 49% ownership relationship, which we believe is mutually beneficial to us and our physician partners. Under our partnership structure, physicians gain a partner in AmSurg who provides management services, including clinical and regulatory support, financial reporting, performance measurement, group purchasing, contracting, and marketing services. According to Syndics Research Corporation, our net promoter score, as defined by their most recent annual survey to measure overall physician satisfaction, was 85% and exceeded industry benchmarks for physician satisfaction. We believe our focus on physician satisfaction, combined with providing safe, high quality healthcare in a patient friendly and convenient environment, helps us attract and retain physician partners.

Increase Same-Center Revenue Growth. We grow revenues in our existing facilities primarily through increasing procedure volume by (1) increasing the number of physicians performing procedures at our centers, (2) marketing our centers to referring physicians, payors and patients, and (3) achieving efficiencies in center operations. For the year ended December 31, 2013, we achieved same-center revenue growth of 1%, which includes the effect of a statutory decrease in reimbursement for procedures associated with worker’s compensation claims at our centers in California and sequestration.

Growth in the Number of Physicians Performing Procedures. The most effective way to increase procedure volume and revenues at our ASCs is to increase the number of physicians who use our centers through:

· the physicians affiliated with the ASCs recruiting new physicians to their practices;

· identifying additional physicians to join the partnerships that own the ASCs; and

· recruiting non-partner physicians in the same or other specialties to use excess capacity at the ASCs.

Marketing Our Centers to Referring Physicians, Payors and Patients. We market our ASCs to referring physicians and payors by emphasizing the quality, high patient satisfaction and lower cost at our ASCs. We have a dedicated business development team that is responsible for negotiating contracts with third party payors. They are responsible for obtaining new contracts for our ASCs with payors that do not currently contract with us and negotiating increases to reimbursement rates pursuant to existing contracts. We also increase awareness of the benefits of our ASCs with employers and patients through public awareness programs, health fairs and screening programs, including programs designed to educate employers and patients as to the health and cost benefits of our services.

Achieving Efficiencies in Center Operations: We have dedicated teams with business and clinical expertise that are responsible for implementing best practices within our ASCs. The implementation of these best practices allows the ASCs to improve operating efficiencies through:

· physician scheduling enhancements;

· improved patient flow; and

· improved operating room turnover.

We also enhance the profitability of our ASCs through benefits we receive through economies of scale such as group purchasing, staffing and clinical efficiencies, and cost containment initiatives. We also track facility performance relative to certain benchmarks in order to maximize center-level revenues and profitability. The information we gather and collect from our ASCs and operations team members allows us to develop best practices and identify those ASCs that could most benefit from improved operating efficiency techniques and cost containment measures.

Expand Our National Network of ASCs. While we have been an active acquirer of ASCs historically, the market remains fragmented, providing many opportunities for additional acquisitions. We target ownership in single-specialty ASCs that perform gastrointestinal endoscopy, ophthalmology and orthopaedic procedures, as well as multi-specialty ASCs that are equipped and staffed to perform surgical procedures in more than one specialty. Currently, approximately 62% of our revenues are from single-specialty centers that perform gastroenterology or ophthalmology procedures. These specialties have a higher concentration of older patients than other specialties, such as orthopaedics or ENT. We believe the aging demographics of the U.S. population will be a source of procedure growth for gastroenterology and ophthalmology ASCs. We will also opportunistically pursue the acquisition of companies that own and operate multiple ASCs.

We typically look to acquire ASCs that meet the following criteria:

· Diversified Physician Group: ASCs that have eight to ten (or more) physicians. In order to manage succession planning, we look to acquire ASCs where physicians vary in age in order to limit the risk of several physicians exiting the practice in a short period of time.

· Market Leader: ASCs that are market leaders for the procedures performed in that facility.

· Contracts with Payors: ASCs that contract with all or most of the major commercial payors in their market.

· History of Growth: ASCs with a track record of consistent case and revenue growth.

Item 1. Business – (continued)

Our development staff identifies existing centers that are potential acquisition candidates and physicians who are potential partners for new center development. We begin our acquisition process with a due diligence review of the target center and its market. We use experienced teams of operations and financial personnel to conduct a review of all aspects of the center’s operations, including the following:

· quality and reputation of the physicians affiliated with the center;

· market position of the center and the physicians affiliated with the center;

· payor and case mix;

· competition and growth opportunities in the market;

· staffing and supply review;

· equipment assessment; and

· opportunities for operational efficiencies.

In presenting the advantages to physicians of developing a new ASC in partnership with us, our development staff emphasizes the proximity of a surgery center to a physician’s office, the simplified administrative procedures, the ability to schedule consecutive cases without preemption by inpatient or emergency procedures, the rapid turnaround time between cases, the high technical competency of the center’s clinical staff and the state-of-the-art surgical equipment. We also focus on our expertise in developing and operating centers, including contracting with vendors and third-party payors. In a development project, we provide services, such as financial feasibility pro forma analysis, site selection, financing for construction, equipment and build out, and architectural oversight. Capital contributed by the physicians and AmSurg plus debt financing provides the funds necessary to construct and equip a new surgery center and initial working capital.

As part of each acquisition or development transaction, we form a limited partnership or limited liability company and enter into a limited partnership agreement or operating agreement with our physician partners. We generally own 51% of the limited partnerships or limited liability companies. Under these agreements, we receive a percentage of the net income and cash distributions of the entity equal to our percentage ownership interest in the entity and have the right to the same percentage of the proceeds of a sale or liquidation of the entity. In the limited partnership structure, as the sole general partner, one of our affiliates is generally liable for the debts of the limited partnership. However, the physician partners are generally required to guarantee their pro rata share of any indebtedness or lease agreements to which the limited partnership is a party in proportion to their ownership interest in the limited partnership.

We manage each limited partnership and limited liability company and oversee the business office, contracting, marketing, financial reporting, accreditation, clinical, regulatory and administrative operations of the surgery center. The physician partners provide the center with a medical director and performance improvement chairman and may provide certain other specified services such as billing and collections, transcription and accounts payable processing. In addition, the limited partnership or limited liability company may lease the services of certain non-physician personnel from entities affiliated with the physician partners, who will provide services at the center. Certain significant aspects of the limited partnership’s or limited liability company’s governance are overseen by an operating board, which is comprised of equal representation by AmSurg and our physician partners. We work closely with our physician partners to increase the likelihood of a successful partnership.

A majority of the limited partnership and operating agreements provide that, if certain regulatory changes take place, we will be obligated to purchase some or all of the noncontrolling interests of our physician partners. The regulatory changes that could trigger such obligations include changes that: (i) make the referral of Medicare and other patients to our surgery centers by physicians affiliated with us illegal; (ii) create the substantial likelihood that cash distributions from the limited partnerships or limited liability companies to the affiliated physicians will be illegal; or (iii) cause the ownership by the physicians of interests in the limited partnerships or limited liability companies to be illegal. There can be no assurance that our existing capital resources would be sufficient for us to meet the obligations, if they arise, to purchase these noncontrolling interests held by physicians. The determination of whether a triggering event has occurred generally would be made by the concurrence of our legal counsel and counsel for the physician partners or, in the absence of such concurrence, by independent counsel having expertise in healthcare law chosen by both parties. Such determination therefore would not be within our control. The triggering of these obligations could have a material adverse effect on our financial condition and results of operations. See “– Government Regulation.”

Surgery Center Operations

The size of our typical single-specialty ASC is approximately 3,000 to 6,000 square feet. The size of our typical multi-specialty ASC is approximately 8,000 to 12,000 square feet. Each center typically has two to three operating or procedure rooms with areas for reception, preparation, recovery and administration. Each surgery center is specifically tailored to meet the needs of its physician partners. Our surgery centers perform an average of approximately 6,800 procedures per year, though there is a wide range among centers from a low of approximately 1,000 procedures per year to a high of 32,000 procedures per year. The cost of developing a typical surgery center is approximately $3.5 million. Constructing, equipping and licensing a surgery center generally takes 12 to 15 months. As of December 31, 2013, 151 of our centers performed gastrointestinal endoscopy procedures, 48 centers were multi-specialty centers, 36 centers performed ophthalmology surgery procedures and seven centers performed orthopaedic procedures. The procedures performed at our centers generally do not require an extended recovery period. Our centers are staffed with approximately 10 to 15 clinical professionals and administrative personnel, including nurses and surgical technicians, some of whom may be leased on a full or part-time basis from entities affiliated with our physician partners.

The types of procedures performed at each center depend on the specialty of the practicing physicians. The procedures most commonly performed at our surgery centers are:

· gastroenterology - colonoscopy and other endoscopy procedures;

· ophthalmology - cataracts and retinal laser surgery; and

· orthopaedic - knee and shoulder arthroscopy and carpal tunnel repair.

Item 1. Business – (continued)

We market our surgery centers directly to patients, referring physicians and third‑party payors, including health maintenance organizations, or “HMO”s, preferred provider organizations, or “PPO”s, other managed care organizations, and employers. Marketing activities conducted by our management and center administrators emphasize the high quality of care, cost advantages and convenience of our surgery centers and are focused on making each center an approved provider under local managed care plans.

Accreditation

Managed care organizations in certain markets will only contract with a facility that is accredited by either the Accreditation Association for Ambulatory Health Care, or “AAAHC”, or The Joint Commission. We generally seek accreditation for all of our ASCs. Currently, 238 of our 242 surgery centers are accredited by AAAHC or The Joint Commission, and three of our surgery centers are scheduled for initial accreditation surveys during 2014. All of the accredited centers received three-year certifications.

Item 1. Business – (continued)

Surgery Center Locations

The following table sets forth certain information relating to our surgery centers as of December 31, 2013:

		Acquired (A)
		Developed (D)		Acquisition/	Operating or
Location		Unconsolidated (U)	Specialty	Opening Date	Procedure Rooms

*Alabama*
	Montgomery	D	Ophthalmology	May 1997	2
*Arizona*
	Glendale	A	Gastroenterology	October 2007	3
	Lakeside	A	Multispecialty	October 2012	4
	Mesa	A	Gastroenterology	April 2011	4
	Peoria	A	Multispecialty	October 2002	2
	Phoenix	A	Ophthalmology	February 1998	2
	Phoenix	A	Gastroenterology	December 2008	3
	Phoenix	A	Orthopaedic	December 2008	8
	Phoenix	A	Orthopaedic	December 2009	4
	Phoenix	A	Gastroenterology	November 2010	3
	Phoenix	A	Gastroenterology	February 2011	3
	Sun City	A	Ophthalmology	May 1998	5
	Sun City	A	Gastroenterology	September 2004	3
	Sun City	D	Multispecialty	November 2005	3
	Yuma	A	Gastroenterology	October 2005	3
*Arkansas*
	El Dorado	D	Multispecialty	December 2007	2
	Fayetteville	A	Gastroenterology	May 1997	3
	Rogers	A	Ophthalmology	December 2002	2
*California*
	Arcadia	A	Gastroenterology	March 2006	2
	Burbank	A	Ophthalmology	December 1999	1
	Colton	A	Multispecialty	December 2012	4
	Davis	A	Multispecialty	September 2011	2
	Escondido	D	Gastroenterology	December 2004	2
	Fresno	A	Multispecialty	December 2011	7
	Fresno	A	Multispecialty	November 2012	2
	Fresno	A	Gastroenterology	December 2013	5
	Fullerton	A	Multispecialty	September 2011	6
	Glendale	A	Ophthalmology	January 2000	1
	Glendora	A	Gastroenterology	August 2007	4
	Greenbrae	A	Gastroenterology	August 2008	3
	Inglewood	D	Gastroenterology	May 2001	3
	La Jolla	A	Gastroenterology	December 1999	2
	Long Beach	A	Multispecialty	September 2011	4
	Oakland	A	Gastroenterology	October 2006	3
	Pomona	A	Multispecialty	September 2008	5
	Poway	A	Multispecialty	November 2007	2
	Redding	A	Gastroenterology	December 2008	2
	San Diego	A	Orthopaedic	November 2007	5
	San Luis Obispo	A	Gastroenterology	December 2004	2
	Temecula	D	Gastroenterology	November 2004	2
	Templeton	A	Gastroenterology	December 2004	2
	Torrance	A	Gastroenterology	February 1994	2
	Torrance	A	Multispecialty	February 2006	4
	Torrance	A	Multispecialty	September 2011	3

Item 1. Business – (continued)

		Acquired (A)
		Developed (D)		Acquisition/	Operating or
Location		Unconsolidated (U)	Specialty	Opening Date	Procedure Rooms
*Colorado*
	Canon City	A	Multispecialty	June 2009	3
	Denver	A	Gastroenterology	April 1998	3
	Pueblo	A	Ophthalmology	September 2003	2
*Connecticut*
	Bloomfield	A	Ophthalmology	July 2001	1
	Milford	A	Ophthalmology	December 2012	2
	Norwich	A	Gastroenterology	December 2012	3
	Stamford	A	Gastroenterology	April 2013	4
	Wilton	A	Multispecialty	September 2011	4
*Delaware*
	Dover	A	Multispecialty	February 2001	3
	Lewes	A	Gastroenterology	December 2002	2
	Newark	A	Gastroenterology	October 2001	5
	Newark	A	Gastroenterology	July 2012	3
*Florida*
	Altamonte Springs	A	Gastroenterology	September 2007	3
	Boca Raton	A	Ophthalmology	December 1998	2
	Boynton Beach	A	Multispecialty	May 2010	3
	Coral Springs	A	Multispecialty	September 2011	8
	Crystal River	A	Gastroenterology	January 1997	2
	Ft. Lauderdale	A	Ophthalmology	March 2001	3
	Ft. Myers	D	Gastroenterology	October 2000	2
	Gainesville	A	Orthopaedic	February 2004	5
	Hialeah	D	Gastroenterology	December 1997	3
	Inverness	A	Gastroenterology	December 2000	2
	Kissimmee	A	Gastroenterology	July 2007	2
	Lakeland	D	Gastroenterology	May 2005	4
	Melbourne	D	Gastroenterology	August 1997	2
	Miami	D	Gastroenterology	June 2011	4
	Mount Dora	A	Ophthalmology	September 1999	2
	Ocala	A	Gastroenterology	August 1996	3
	Ocoee	A	Gastroenterology	June 2005	1
	Orlando	A	Gastroenterology	June 2005	4
	Orlando	A	Gastroenterology	May 2008	4
	Panama City	A	Gastroenterology	July 1996	4
	Pinellas Park	A	Multispecialty	September 2011	3
	Port Orange	A	Multispecialty	October 2010	6
	Port St. Lucie	A	Ophthalmology	August 2010	2
	Rockledge	D	Gastroenterology	May 2005	3
	Sarasota	D	Gastroenterology	December 2000	2
	Sebring	D	Ophthalmology	November 2004	2
	Tampa	D	Gastroenterology	January 2005	8
	Trinity	A,U	Multispecialty	March 2013	4
	West Palm Beach	A	Gastroenterology	March 2004	2
	West Palm Beach	A	Multispecialty	September 2011	8
	Weston	A	Multispecialty	September 2011	9
	Winter Haven	A	Ophthalmology	December 2002	2

Item 1. Business – (continued)

		Acquired (A)
		Developed (D)		Acquisition/	Operating or
Location		Unconsolidated (U)	Specialty	Opening Date	Procedure Rooms
*Idaho*
	Meridian	A	Ophthalmology	July 2011	2
	Twin Falls	A	Multispecialty	September 2011	5
*Illinois*
	Glenview	A	Gastroenterology	November 2012	3
	Lake Bluff	A	Gastroenterology	November 2004	2
	Oak Lawn	A	Gastroenterology	June 2013	2
*Indiana*
	Evansville	D	Ophthalmology	February 1998	2
	Indianapolis	A	Gastroenterology	June 1999	4
	South Bend	A	Gastroenterology	January 2007	4
*Kansas*
	Hutchinson	A	Multispecialty	June 2000	4
	Overland Park	A	Gastroenterology	October 2004	3
	Shawnee	D	Gastroenterology	April 1998	3
	Topeka	A	Gastroenterology	November 1992	3
	Wichita	A	Orthopaedic	November 1996	5
*Kentucky*
	Crestview Hills	D	Gastroenterology	September 2000	3
	Louisville	D	Gastroenterology	September 2000	3
	Louisville	D	Ophthalmology	September 2000	2
	Paducah	A	Ophthalmology	May 2002	2
*Louisiana*
	Alexandria	A	Ophthalmology	December 2001	2
	Baton Rouge	A	Gastroenterology	December 2007	10
	Harvey	A	Multispecialty	December 2012	4
	Marrero	A	Gastroenterology	January 2007	3
	Metairie	A	Ophthalmology	July 2000	2
	Metairie	A	Gastroenterology	January 2007	3
	New Orleans	A	Gastroenterology	January 2007	3
	Shreveport	A	Multispecialty	December 2012	4
*Maryland*
	Baltimore	A	Gastroenterology	November 1998	2
	Baltimore	A	Gastroenterology	January 2008	4
	Bel Air	A	Gastroenterology	February 2001	2
	Chevy Chase	D	Gastroenterology	July 1997	4
	Glen Burnie	A	Gastroenterology	January 2008	2
	Laurel	A	Gastroenterology	December 2005	3
	Lutherville	A	Gastroenterology	January 2005	2
	Rockville	A	Gastroenterology	October 2004	5
	Rockville	A	Gastroenterology	January 2007	3
	Silver Spring	A	Gastroenterology	January 2007	2
	Silver Spring	A	Ophthalmology	December 2008	2
	Towson	A	Gastroenterology	August 2005	4
	Towson	A	Multispecialty	September 2011	2
	Waldorf	A	Gastroenterology	December 1999	4
	Westminster	A	Gastroenterology	December 2008	2

Item 1. Business – (continued)

		Acquired (A)
		Developed (D)		Acquisition/	Operating or
Location		Unconsolidated (U)	Specialty	Opening Date	Procedure Rooms
*Massachusetts*
	Acton	A	Gastroenterology	February 2012	3
	Norwood	A	Multispecialty	December 2011	3
	Springfield	A	Multispecialty	April 2011	6
	Springfield	A	Multispecialty	April 2011	4
	Waltham	A	Orthopaedic	March 2010	4
	Wellesley Hills	A	Gastroenterology	December 2012	4
	West Bridgewater	A	Gastroenterology	February 2009	2
*Michigan*
	Port Huron	D	Orthopaedic	March 2006	2
	St. Clair Shores	A	Ophthalmology	May 2008	2
	Troy	D	Gastroenterology	August 2003	2
*Minnesota*
	Blaine	D	Multispecialty	November 2009	3
	Edina	A	Ophthalmology	December 2003	1
	Minneapolis	D	Ophthalmology	June 2000	2
	St. Cloud	A	Ophthalmology	December 2005	2
*Missouri*
	Independence	A	Gastroenterology	September 1997	1
	Joplin	A	Multispecialty	December 2012	4
	Kansas City	A	Gastroenterology	September 1997	1
	Liberty	D	Gastroenterology	June 2005	1
	St. Louis	A	Orthopaedic	November 2005	2
*Nevada*
	Las Vegas	A	Ophthalmology	May 2000	2
	Reno	A	Gastroenterology	December 2003	4
*New Hampshire*
	Newington	A	Multispecialty	December 2011	1
*New Jersey*
	Edison	A	Gastroenterology	May 2011	2
	Florham Park	D	Gastroenterology	December 1999	3
	Fort Lee	A	Multispecialty	December 2012	5
	Hanover	D	Gastroenterology	October 2006	3
	Lawrenceville	A	Multispecialty	October 2001	3
	Millburn	A	Multispecialty	December 2012	8
	Mountainside	A	Multispecialty	August 2013	5
	Oakhurst	A	Gastroenterology	September 1999	2
	Tom’s River	A	Gastroenterology	May 2007	2
	Voorhees	A	Gastroenterology	March 2003	6
	West Orange	A	Gastroenterology	December 2005	3
*New Mexico*
	Santa Fe	D	Gastroenterology	May 1994	3
*North Carolina*
	Cary	D	Gastroenterology	November 2007	4
	Durham	A	Gastroenterology	December 2008	4
	Greensboro	D	Gastroenterology	August 2008	2
	Raleigh	A	Gastroenterology	April 2004	4
	Raleigh	D	Gastroenterology	December 2006	3

Item 1. Business – (continued)

		Acquired (A)
		Developed (D)		Acquisition/	Operating or
Location		Unconsolidated (U)	Specialty	Opening Date	Procedure Rooms
*Ohio*
	Akron	A	Gastroenterology	November 2008	3
	Cincinnati	D	Gastroenterology	January 1998	3
	Columbus	A	Ophthalmology	December 2010	3
	Dayton	A	Gastroenterology	December 2008	2
	Huber Heights	A	Gastroenterology	December 2008	1
	Kenwood	A	Multispecialty	September 2011	4
	Kettering	A	Gastroenterology	December 2008	3
	Middletown	D	Gastroenterology	October 2002	3
	Sidney	D	Multispecialty	December 1996	4
	Springboro	A	Gastroenterology	December 2008	3
	Toledo	D	Gastroenterology	December 1998	3
	Willoughby	D	Gastroenterology	July 1997	2
*Oklahoma*
	Oklahoma City	D	Gastroenterology	May 1998	3
	Tulsa	A	Ophthalmology	July 2002	2
	Tulsa	A	Gastroenterology	December 2005	3
*Oregon*
	Bend	A	Urology	August 2011	4
	Salem	A	Ophthalmology	December 2005	2
	Springfield	A	Gastroenterology	December 2012	3
*Pennsylvania*
	Allentown	A	Multispecialty	December 2012	7
	Bala Cynwyd	A	Gastroenterology	September 2006	2
	Flourtown	D	Gastroenterology	October 1997	4
	Kingston	A	Ophthalmology	December 2000	3
	Lancaster	A	Gastroenterology	January 2007	3
	Malvern	A	Gastroenterology	September 2006	3
	Media	A	Gastroenterology	July 2009	1
	Pottsville	A	Gastroenterology	June 2007	3
	Scranton	A	Gastroenterology	August 2005	3
*South Carolina*
	Charleston	A	Gastroenterology	January 2009	3
	Charleston	A	Ophthalmology	September 2013	5
	Clemson	D	Multispecialty	September 2002	3
	Columbia	A	Gastroenterology	October 1996	4
	Columbia	D	Gastroenterology	November 2003	2
	Greenville	D	Gastroenterology	August 2004	4
*Tennessee*
	Chattanooga	A	Gastroenterology	July 1999	2
	Columbia	A	Multispecialty	February 2001	4
	Columbia	A	Gastroenterology	June 2002	2
	Goodlettsville	A	Ophthalmology	February 2006	2
	Hermitage	A	Gastroenterology	October 2009	3
	Kingsport	D	Ophthalmology	October 2003	2
	Knoxville	A	Gastroenterology	November 1992	4
	Knoxville	D	Ophthalmology	June 1996	2
	Knoxville	D	Gastroenterology	September 2005	4
	Maryville	A	Gastroenterology	January 1995	3
	Nashville	A	Gastroenterology	November 1992	3
	Powell	A	Gastroenterology	January 2009	4

Item 1. Business – (continued)

		Acquired (A)
		Developed (D)		Acquisition/	Operating or
Location		Unconsolidated (U)	Specialty	Opening Date	Procedure Rooms
*Texas*
	Abilene	A	Ophthalmology	March 1997	2
	Abilene	D	Gastroenterology	December 1994	3
	Austin	A	Multispecialty	September 2011	4
	Austin	A,U	Gastroenterology	September 2011	3
	Austin	A,U	Gastroenterology	September 2011	3
	Beaumont	D	Gastroenterology	October 1994	3
	Bedford	A	Gastroenterology	December 2009	3
	Bryan	A	Gastroenterology	December 2008	3
	Conroe	A	Gastroenterology	August 2007	4
	Dallas	A	Gastroenterology	December 2009	4
	Dallas	A	Gastroenterology	December 2009	3
	El Paso	D	Gastroenterology	December 1998	4
	Mesquite	A	Gastroenterology	August 2007	2
	North Richland Hills	A	Gastroenterology	December 2009	4
	Plano	A	Gastroenterology	December 2009	4
	San Antonio	A	Gastroenterology	July 2003	4
	San Antonio	A	Multispecialty	September 2011	5
	San Antonio	D	Gastroenterology	May 2007	3
	San Antonio	D	Gastroenterology	June 2012	3
	Waco	A	Gastroenterology	July 2010	3
	Woodlands	A	Gastroenterology	September 2006	2
*Utah*
	Salt Lake City	D	Gastroenterology	April 1998	2
	St. George	A	Gastroenterology	July 2003	2
*Washington D.C.*		A	Gastroenterology	November 1993	2
*Washington*
	Puyallup	A	Gastroenterology	March 2005	2
	Puyallup	D	Gastroenterology	May 2009	3
	Tacoma	A	Gastroenterology	March 2005	5
	Tacoma	A	Gastroenterology	March 2005	2
	Tacoma	A	Gastroenterology	March 2005	2
*Wyoming*
	Casper	A	Gastroenterology	October 2004	2

					759

Our limited partnerships and limited liability companies lease the real property on which our surgery centers operate, either from entities affiliated with our physician partners or from unaffiliated parties.

Revenues

Our revenues are derived from facility fees charged for surgical procedures performed in our surgery centers and, at certain of our surgery centers (primarily centers that perform gastrointestinal endoscopy procedures), charges for anesthesia services provided by medical professionals employed or contracted by our centers. These fees vary depending on the procedure, but usually include all charges for operating room usage, special equipment usage, supplies, recovery room usage, nursing staff and medications. Facility fees do not include professional fees charged by the physicians that perform the surgical procedures. Revenues are recorded at the time of the patient encounter and billings for such procedures are made on or about that same date. At the majority of our centers, it is our policy to collect patient co-payments and deductibles at the time the surgery is performed. Our revenues are recorded net of estimated contractual adjustments from third-party medical service payors. Our billing and accounting systems provide us historical trends of the surgery centers’ cash collections and contractual write-offs, accounts receivable agings and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly for each of our surgery centers as revenues are recognized. Our ability to accurately estimate contractual adjustments is dependent upon and supported by the fact that our surgery centers perform and bill for limited types of procedures, the range of reimbursement for those procedures within each surgery center specialty is very narrow and payments are typically received within 15 to 45 days of billing. Except in certain limited instances, these estimates are not, however, established from billing system generated contractual adjustments based on fee schedules for the patient’s insurance plan for each patient encounter.

ASCs depend upon third-party reimbursement programs, including governmental and private insurance programs, to pay for substantially all of the

Item 1. Business – (continued)

services rendered to patients. We derived approximately 25%, 27% and 29% of our revenues in the years ended December 31, 2013, 2012 and 2011, respectively, from governmental healthcare programs, primarily Medicare and managed Medicare programs, and the remainder from a wide mix of commercial payors and patient co-pays and deductibles. The Medicare program currently pays ASCs in accordance with predetermined fee schedules. Our surgery centers are not required to file cost reports and, accordingly, we have no unsettled amounts from governmental third-party payors.

ASCs are paid under the Medicare program based upon a percentage of the payments to hospital outpatient departments pursuant to the hospital outpatient prospective patient system and reimbursement rates for ASCs are increased annually based on increases in the consumer price index, or “CPI.” Effective for federal fiscal year or “FFY” 2011 and subsequent years, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or the “Health Reform Law”, provides for the annual CPI increases applicable to ASCs to be reduced by a productivity adjustment, which is based on historical nationwide productivity gains. In 2012, reimbursement rates increased by 1.6%, which positively impacted our 2012 revenues by approximately $5.0 million and our net earnings per diluted share by $0.05. In 2013, reimbursement rates increased by 0.6%, which positively impacted our 2013 revenues by approximately $2.5 million and our net earnings per diluted share by $0.02. CMS has announced that ASC reimbursement rates will increase by 1.2% for 2014, which we estimate will positively impact our 2014 revenues by approximately $6.0 million, net of the continued effects of sequestration, as discussed below. There can be no assurance that CMS will not revise the ASC payment system or that any annual CPI increases will be material.

The Budget Control Act of 2011, or “BCA”, requires automatic spending reductions of $1.2 trillion for FFYs 2013 through 2021, minus any deficit reductions enacted by Congress and debt service costs. The percentage reduction for Medicare may not be more than 2% for a FFY, with a uniform percentage reduction across all Medicare programs. These BCA-mandated spending cuts are commonly referred to as "sequestration." Sequestration began on March 1, 2013, and CMS imposed a 2% reduction on Medicare claims as of April 1, 2013. The Bipartisan Budget Act of 2013 extends these reductions through 2023. We cannot predict with certainty what other deficit reduction initiatives may be proposed by Congress, whether Congress will attempt to restructure or suspend sequestration or the impact of sequestration may have on our centers. We estimate that the imposed spending reductions reduced our 2013 revenues and net earnings per diluted share by approximately $5.0 million and $0.05, respectively. Based on current volumes, we estimate that the imposed spending reductions will have an incremental negative impact on 2014 revenues of approximately $1.5 million.

In September 2012, the State of California enacted legislation that reduced the reimbursement rate beginning in 2013 for patients receiving care through the state’s workers’ compensation program. We estimate that the reduced rates negatively impacted our 2013 net earnings per diluted share by approximately $0.06.

The Health Reform Law represents significant change across the healthcare industry. The Health Reform Law contains a number of provisions designed to reduce Medicare program spending, including the annual productivity adjustment discussed above that reduces payment updates to ASCs. However, the Health Reform Law also expands coverage of uninsured individuals through a combination of public program expansion and private sector health insurance reforms. For example, the Health Reform Law expands eligibility under existing Medicaid programs in states that have not opted out of the expansion, imposes financial penalties on individuals who fail to carry insurance coverage, creates affordability credits for those not enrolled in an employer-sponsored health plan, required establishment of, or participation in, a health insurance exchange for each state and allowed states to create federally funded, non-Medicaid plans for low-income residents not eligible for Medicaid. The Health Reform Law also establishes a number of private health insurance market reforms, including a ban on lifetime limits and pre-existing condition exclusions, new benefit mandates, and increased dependent coverage.

Many health plans are required to cover, without cost-sharing, certain preventive services designated by the U.S. Preventive Services Task Force, including screening colonoscopies. Medicare now covers these preventive services without cost-sharing, and, beginning in 2013, states that provide Medicaid coverage of these preventive services without cost-sharing receive a one percentage point increase in their federal medical assistance percentage for these services.

Health insurance market reforms that expand insurance coverage may result in an increased volume for certain procedures at our centers. However, certain of the provisions of the Health Reform Law are not currently effective, and the provisions may be amended, repealed or delayed or their impact could be offset by reductions in reimbursement under the Medicare program. It is unclear what the resulting impact of the Health Reform Law will be on the number of uninsured individuals or what the payment terms will be for individuals covered by the Medicaid expansion or who purchase coverage through health insurance exchanges. Further, the employer mandate, which requires firms with 50 or more full-time employees to offer health insurance or pay fines, has been delayed until January 1, 2015 and will not be fully implemented until January 1, 2016. The federal online insurance marketplace experienced significant technical issues that negatively impacted the ability of individuals to purchase health insurance. These technical issues or additional implementation issues could lead to the delay of the individual mandate tax penalties past the current March 31, 2014 deadline, delays in individuals obtaining health insurance and a reduction in the number of individuals choosing to purchase health insurance rather than paying the individual mandate tax penalties.

In addition, the Health Reform Law established a Medicare Shared Savings Program, which created Accountable Care Organizations, or “ACOs,” to allow groups of doctors, hospitals and other healthcare providers to come together voluntarily to provide coordinated high quality care to Medicare patients. Under the Health Reform Law, CMS may contract directly with ACOs. The formation of ACOs or other coordinated care models could negatively impact our centers and the medical practices of our physician partners.

Because of the many variables involved, including the law’s complexity, lack of implementing definitive regulations or interpretive guidance, gradual or partially delayed implementation, amendments, repeal, or further implementation delays, we are unable to predict the net effect of the reductions in Medicare spending, the expected increases in revenues from increased procedure volumes, and numerous other provisions in the law that may affect the Company. We are further unable to foresee how individuals and employers will respond to the choices afforded them by the Health Reform Law. Thus, we cannot predict the full impact of the Health Reform Law on the Company at this time.

Item 1. Business – (continued)

CMS is increasing its administrative audit efforts through the nationwide expansion of the recovery audit contractor, or “RAC”, program. RACs are private contractors that have historically conducted post-payment reviews of providers and suppliers that bill Medicare to detect and correct improper payments for services. CMS has also established the Recovery Audit Prepayment Review or “RAPR” demonstration that allows RACs to perform pre-payment reviews on certain types of claims that historically result in high rates of improper payments, beginning with claims for certain hospital services, but potentially including other facility types in the future. The RAPR demonstration began in 2012 and runs for a three year period. HHS has suspended the assignment of new Medicare appeals to Administrative Law Judges for at least two years beginning July 16, 2013, so that HHS may work through a backlog of appeals. Thus, we will experience a significant delay in appealing any RAC payment denials that occur during the suspension period. The Health Reform Law expands the RAC program’s scope to include Medicaid claims. In addition to RACs, other contractors, such as Medicaid Integrity Contractors, perform payment audits to identify and correct improper payments. We could incur costs associated with appealing any alleged overpayments and be required to repay any alleged overpayments identified by these or other administrative audits.

We expect value-based purchasing programs, including programs that condition reimbursement on patient outcome measures, to become more common and to involve a higher percentage of reimbursement amounts. CMS has promulgated three national coverage determinations that prevent Medicare from paying for certain serious, preventable medical errors performed in any healthcare facility, such as surgery performed on the wrong patient or the wrong site. Several commercial payors also do not reimburse providers for certain preventable adverse events. CMS established a quality reporting program for ASCs under which ASCs that fail to report on certain required quality measures will receive a 2% reduction in reimbursement for calendar year 2014. We have implemented programs and procedures at each of our centers to comply with the quality reporting program prescribed by CMS. Further, as required by the Health Reform Law, the U.S. Department of Health and Human Services or “HHS” reported to Congress on its plan for implementing a value-based purchasing program for ASCs that would tie Medicare payments to quality and efficiency measures. As required by the Health Reform Law, HHS studied whether to expand to ASCs its current policy of not paying additional amounts for care provided to treat conditions acquired during an inpatient hospital stay and reported to Congress that it would not be feasible to expand the policy in its current form, but that further exploration of other payment policies aimed at this same goal should be undertaken.

In addition to payment from governmental programs, ASCs derive a significant portion of their revenues from private healthcare insurance plans. These plans include both standard indemnity insurance programs as well as managed care programs, such as PPOs and HMOs. The strengthening of managed care systems nationally has resulted in substantial competition among providers of surgery center services that contract with these systems. Further, most of the plans offered through the health insurance exchanges provide for narrow networks that restrict the number of participating providers or tiered networks that impose significantly higher cost sharing obligations on patients who obtain services from providers in a disfavored tier. Exclusion from participation in a managed care network or assignment to a disfavored tier could result in material reductions in patient volume and revenue. Some of our competitors have greater financial resources and market penetration than we do. We believe that all payors, both governmental and private, will continue their efforts over the next several years to reduce healthcare costs and that their efforts will generally result in a less stable market for healthcare services. While no assurances can be given concerning the ultimate success of our efforts to contract with healthcare payors, we believe that our position as a low‑cost alternative for certain surgical procedures should enable our surgery centers to compete effectively in the evolving healthcare marketplace.

Competition

We encounter competition in three separate areas: competition with other providers for physicians to utilize our centers, patients and managed care contracts; competition with other companies for acquisitions; and competition for joint venture development of new centers.

Competition for Physicians to Utilize Our Centers, Patients and Managed Care Contracts. We compete with hospitals and other surgery centers in recruiting physicians to utilize our surgery centers, for patients and for the opportunity to contract with payors. In some of the markets in which we operate, there are shortages of physicians in certain specialties, including gastroenterology. In several of the markets in which we operate, hospitals are recruiting physicians or groups of physicians to become employed by the hospitals, including primary care physicians and physicians in certain specialties, including gastroenterology. In many cases the hospitals have restricted those physicians’ ability to refer patients to physicians and facilities not affiliated with the hospital. In addition, physicians, hospitals, payors and other providers may form integrated delivery systems that restrict the physicians who may treat certain patients or the facilities at which patients may be treated, and payors may utilize plan structures, such as narrow networks and tiered networks, that further restrict patient facility choice. Competition with hospitals and other surgery centers may limit our ability to contract with payors or negotiate favorable payment rates.

Competition for Acquisitions. There are several public and private companies that compete with us for the acquisition of existing ASCs and companies that own and manage ASCs. We may also compete with local hospitals in certain transactions. Some of these competitors may have greater resources than we have. The principal competitive factors that affect our and our competitors’ ability to complete acquisitions are price, experience and reputation, and access to capital.

Competition for Joint Venture Development of Centers. We believe that we do not have a direct corporate competitor in the development of single-specialty ASCs across the specialties of gastroenterology and ophthalmology. There are, however, several publicly and privately held companies that develop multi-specialty surgery centers, and these companies may compete with us in the development of multi-specialty centers. Further, many physicians develop surgery centers without a corporate partner, utilizing consultants who typically perform these services for a fee and who take a small equity interest or no equity interest in the ongoing operations of the center.

Government Regulation

The healthcare industry is subject to extensive regulation by a number of governmental entities at the federal, state and local level. Government regulation affects our business activities by controlling our growth, requiring licensure and certification for our facilities, regulating the use of our properties and controlling reimbursement to us for the services we provide.

Item 1. Business – (continued)

Certification. We depend on third-party programs, including governmental and private health insurance programs, to reimburse us for services rendered to patients in our ASCs. In order to receive Medicare reimbursement, each surgery center must meet the applicable conditions of coverage set forth by HHS, relating to the type of facility, its equipment, personnel and standard of medical care, as well as compliance with state and local laws and regulations, all of which are subject to change from time to time. ASCs undergo periodic on-site Medicare certification surveys. Each of our existing centers is certified as a Medicare provider. Although we intend for our centers to participate in Medicare and other government reimbursement programs, there can be no assurance that these centers will continue to qualify for participation.

Medicare-Medicaid Fraud and Abuse Provisions. The federal Anti-Kickback Statute prohibits healthcare providers and others from soliciting, receiving, offering or paying, directly or indirectly, any remuneration (including any kickback, bribe or rebate) with the intent of generating referrals or orders for services or items covered by a federal healthcare program. The Anti-Kickback Statute is very broad in scope, and many of its provisions have not been uniformly or definitively interpreted by case law or regulations. Courts have found a violation of the Anti-Kickback Statute if just one purpose of the remuneration is to generate referrals, even if there are other lawful purposes. Furthermore, the Health Reform Law provides that knowledge of the law or intent to violate the law is not required to establish a violation of the Anti-Kickback Statute. Violations may result in criminal penalties or fines of up to $25,000 or imprisonment for up to five years, or both. Violations of the Anti-Kickback Statute may also result in substantial civil penalties, including penalties of up to $50,000 for each violation, plus three times the amount claimed, and exclusion from participation in the Medicare and Medicaid programs. Exclusion from these programs would result in significant reduction in revenues and would have a material adverse effect on our business. The Health Reform Law provides that submission of a claim for services or items generated in violation of the Anti-Kickback Statute constitutes a false or fraudulent claim and may be subject to additional penalties under the federal False Claims Act, or “FCA.”

HHS has published final safe harbor regulations that outline categories of activities that are deemed protected from prosecution under the Anti-Kickback Statute. Two of the safe harbor regulations relate to investment interests in general: the first concerning investment interests in large publicly traded companies ($50,000,000 in net tangible assets) and the second for investments in smaller entities. The safe harbor regulations also include safe harbors for investments in certain types of ASCs. The limited partnerships and limited liability companies that own our surgery centers do not meet all of the criteria of either of the investment interests safe harbors or the surgery center safe harbor. Thus, they do not qualify for safe harbor protection from government review or prosecution under the Anti-Kickback Statute. However, a business arrangement that does not substantially comply with a safe harbor is not necessarily illegal under the Anti-Kickback Statute.

The HHS Office of Inspector General, or “OIG”, is authorized to issue advisory opinions regarding the interpretation and applicability of the federal Anti-Kickback Statute, including whether an activity constitutes grounds for the imposition of civil or criminal sanctions. We have not sought such an opinion regarding any of our arrangements. Although advisory opinions are not binding on any entity other than the parties who submitted the requests, advisory opinions provide some guidance as to how the OIG would analyze joint ventures involving surgeons such as our physician partners. We believe our arrangements are structured to be consistent with OIG guidance.

While several federal court decisions have aggressively applied the restrictions of the Anti-Kickback Statute, they provide little guidance as to the application of the Anti-Kickback Statute to our limited partnerships and limited liability companies. We believe that we are in compliance with the current requirements of applicable federal and state law because, among other factors:

· the limited partnerships and limited liability companies exist to effect legitimate business purposes, including the ownership, operation and continued improvement of high quality, cost-effective and efficient services to the patients served;

· the limited partnerships and limited liability companies function as an extension of the group practices of physicians who are affiliated with the surgery centers and the surgical procedures are performed personally by these physicians without referring the patients outside of their practice;

· our physician partners have a substantial investment at risk in the limited partnerships and limited liability companies;

· terms of the investment do not take into account the volume of the physician partners’ past or anticipated future services provided to patients of the centers;

· the physician partners are not required or encouraged as a condition of the investment to treat Medicare or Medicaid patients at the centers or to influence others to refer such patients to the centers for treatment;

· the limited partnerships, the limited liability companies, our subsidiaries and our affiliates will not loan any funds to or guarantee any debt on behalf of the physician partners with respect to their investment; and

· distributions by the limited partnerships and limited liability companies are allocated uniformly in proportion to ownership interests.

The safe harbor regulations also set forth a safe harbor for personal services and management contracts. Certain of our limited partnerships and limited liability companies have entered into ancillary services agreements with our physician partners’ group practices, pursuant to which the practice may provide the center with billing and collections, transcription, payables processing, payroll and other ancillary services. The consideration payable by a limited partnership or limited liability company for certain of these services may be based on the volume of services provided by the practice, which is measured by the limited partnership’s or limited liability company’s revenues. Although these relationships do not meet all of the criteria of the personal services and management contracts safe harbor, we believe that the ancillary services agreements are in compliance with the current requirements of applicable federal and state law because, among other factors, the fees payable to the physician practices are equal to the fair market value of the services provided thereunder.

In addition, certain of our limited partnerships and limited liability companies have entered into certain arrangements for professional services, including arrangements for anesthesia services. The OIG has issued advisory opinions in which it concluded that proposed arrangements between anesthesia groups and facilities, including physician-owned ASCs, could result in prohibited remuneration under the federal Anti-Kickback Statute.

Item 1. Business – (continued)

We believe our arrangements for anesthesia services are unlike those described in the OIG advisory opinions and are in compliance with the requirements of the federal Anti-Kickback Statute.

Many of the states in which we operate also have adopted laws that prohibit payments to physicians in exchange for referrals similar to the federal Anti-Kickback Statute, some of which apply regardless of the source of payment for care. These statutes typically provide criminal and civil penalties as well as loss of licensure.

Notwithstanding our belief that the relationship of physician partners to our surgery centers should not constitute illegal remuneration under the federal Anti-Kickback Statute or similar laws, we cannot assure you that a federal or state agency charged with enforcement of the Anti-Kickback Statute and similar laws might not assert a contrary position or that new federal or state laws might not be enacted that would cause the physician partners' ownership interests in our centers to become illegal, or result in the imposition of penalties on us or certain of our facilities. Even the assertion of a violation could have a material adverse effect upon us.

In addition to the Anti-Kickback Statute, the Health Insurance Portability and Accountability Act of 1996, or “HIPAA”, provides for criminal penalties for healthcare fraud offenses that apply to all health benefit programs, including the payment of inducements to Medicare and Medicaid beneficiaries in order to influence those beneficiaries to order or receive services from a particular provider or practitioner. Federal enforcement officials have numerous enforcement mechanisms to combat fraud and abuse, including the Medicare Integrity Program and an incentive program under which individuals can receive up to $1,000 for providing information on Medicare fraud and abuse that leads to the recovery of at least $100 of Medicare funds. In addition, federal enforcement officials have the ability to exclude from Medicare and Medicaid any investors, officers and managing employees associated with business entities that have committed healthcare fraud.

Evolving interpretations of current, or the adoption of new, federal or state laws or regulations could affect many of our arrangements. Law enforcement authorities, including the OIG, the courts and Congress, are increasing their scrutiny of arrangements between healthcare providers and potential referral sources to ensure that the arrangements are not designed as a mechanism to exchange remuneration for patient care referrals or opportunities. Investigators also have demonstrated a willingness to look behind the formalities of a business transaction to determine the underlying purposes of payments between healthcare providers and potential referral sources.

Prohibition on Certain Self-Referrals and Physician Ownership of Healthcare Facilities. The federal physician self-referral law, commonly referred to as the “Stark Law”, prohibits a physician from making a referral for a designated health service to an entity if the physician or a member of the physician's immediate family has a financial relationship with the entity, unless an exception applies. Sanctions for violating the Stark Law include denial of payment, refunding amounts received for services provided pursuant to prohibited referrals, civil money penalties of up to $15,000 per prohibited service provided and exclusion from the federal healthcare programs. The Stark Law applies to referrals involving the following services under the definition of “designated health services”: clinical laboratory services; physical therapy services; occupational therapy services; radiology and imaging services; radiation therapy services and supplies; durable medical equipment and supplies; parenteral and enteral nutrients, equipment and supplies; prosthetics, orthotics and prosthetic devices and supplies; home health services; outpatient prescription drugs; and inpatient and outpatient hospital services.

Through a series of rulemakings, CMS has issued final regulations interpreting the Stark Law. While the regulations help clarify the requirements of the exceptions to the Stark Law, it is difficult to determine the full effect of the regulations. Under these regulations, services that would otherwise constitute a designated health service, but that are paid by Medicare as a part of the surgery center payment rate, are not a designated health service for purposes of the Stark Law. In addition, there is a Stark Law exception covering implants, prosthetics, implanted prosthetic devices and implanted durable medical equipment provided in a surgery center setting under certain circumstances. The so-called ASC exemption to the Stark Law also applies to any radiology and imaging procedures that are integral to a covered ASC surgical procedure and that are performed immediately before, during, or immediately following the surgical procedure (that is, on the same day). Similarly, CMS has excluded from the Stark Law definition of “outpatient prescription drugs” any drugs that are “covered as ancillary services” under the revised ASC payment system. These drugs include those furnished during the immediate postoperative recovery period to a patient to reduce suffering from nausea or pain. CMS cautioned, however, that only those radiology, imaging and outpatient prescription drug items and services that are integral to an ASC procedure and performed on the same day as the covered surgical procedure will qualify for the ASC exemption. The Stark Law prohibition continues to prohibit a physician-owned ASC from furnishing outpatient prescription drugs for use in a patient’s home. Because of these exemptions, we believe the Stark Law does not prohibit physician ownership or investment interests in our surgery centers to which they refer patients. Several states in which we operate have self-referral statutes similar to the Stark Law. We believe that physician ownership of surgery centers is not prohibited by these state self-referral statutes. However, the Stark Law and similar state statutes are subject to different interpretations. Violations of any of these self-referral laws may result in substantial civil or criminal penalties, including large civil monetary penalties and exclusion from participation in the Medicare and Medicaid programs. Exclusion of our surgery centers from these programs could result in significant loss of revenues and could have a material adverse effect on us. We can give you no assurances that further judicial or agency interpretations of existing laws or further legislative restrictions on physician ownership or investment in healthcare entities will not be issued that could have a material adverse effect on us.

The Federal False Claims Act and Similar Federal and State Laws. We are subject to state and federal laws that govern the submission of claims for reimbursement. These laws generally prohibit an individual or entity from knowingly and willfully presenting a claim (or causing a claim to be presented) for payment from Medicare, Medicaid or other third-party payors that is false or fraudulent. Penalties under these statutes include substantial civil and criminal fines, exclusion from the Medicare program, and imprisonment. The standard for "knowing and willful" often includes conduct that amounts to a reckless disregard for whether accurate information is presented by claims processors. One of the most prominent of these laws is the federal FCA, which may be enforced by the federal government directly, or by a qui tam plaintiff (or whistleblower) on the government's behalf. There are many potential bases for liability under the FCA, including knowingly and improperly avoiding repayment of an overpayment received from the government and the knowing failure to report and return an overpayment within 60 days of identifying the overpayment. The Health Reform Law expanded the scope of the federal FCA to cover payments in connection to the health insurance exchanges created under the Health Reform Law, if those payments include any federal funds. When a private plaintiff brings a qui tam action under the FCA, the defendant often

Item 1. Business – (continued)

will not be made aware of the lawsuit until the government commences its own investigation or makes a determination whether it will intervene. The Health Reform Law provides that submission of claims for services or items generated in violation of the Anti-Kickback Statute constitutes a false or fraudulent claim under the FCA. In some cases, qui tam plaintiffs and the federal government have taken the position, and some courts have held, that providers who allegedly have violated other statutes, such as the Stark Law, have thereby submitted false claims under the FCA. When a defendant is determined by a court of law to be liable under the FCA, the defendant may be required to pay three times the amount of the alleged false claim, plus mandatory civil penalties of between $5,500 and $11,000 for each separate false claim. The private plaintiff may receive a share of any settlement or judgment. We believe that we have procedures in place to ensure the accurate completion of claims forms and requests for payment. However, the laws and regulations defining proper Medicare or Medicaid billing are complex and have not been subjected to extensive judicial or agency interpretation. Billing errors can occur despite our best efforts to prevent or correct them, and we cannot assure you that the government will regard such errors as inadvertent and not in violation of the FCA or related statutes.

Every entity that receives at least $5.0 million annually in Medicaid payments must have written policies for all employees, contractors or agents, providing detailed information about false claims, false statements and whistleblower protections under certain federal laws, including the federal FCA, and similar state laws.

A number of states, including states in which we operate, have adopted their own false claims provisions as well as their own qui tam provisions whereby a private party may file a civil lawsuit in state court. States that enact false claims laws that are comparable to the federal FCA are entitled to an increased share of FCA recoveries.

Healthcare Industry Investigations. Both federal and state government agencies have heightened and coordinated civil and criminal enforcement efforts as part of numerous ongoing investigations of healthcare companies, as well as their executives and managers. These investigations relate to a wide variety of topics, including referral and billing practices. The Health Reform Law includes additional federal funding of $350 million over 10 years to fight healthcare fraud, waste and abuse, including $40 million for FFY 2014. From time to time, the OIG and the Department of Justice have established national enforcement initiatives that focus on specific billing practices or other suspected areas of abuse. Some of our activities could become the subject of governmental investigations or inquiries. For example, we have significant Medicare billings and we have joint venture arrangements involving physician investors. In addition, our executives and managers, many of whom have worked at other healthcare companies that are or may become the subject of federal and state investigations and private litigation, could be included in governmental investigations or named as defendants in private litigation. We are not aware of any governmental investigations involving any of our facilities, our executives or our managers. A future adverse investigation of us, our executives or our managers could result in significant expense to us, as well as adverse publicity.

Privacy and Security Requirements. There are currently numerous legislative and regulatory initiatives at the state and federal levels addressing the privacy and security of patient health and other identifying information. The privacy and security regulations promulgated pursuant to HIPAA extensively regulate the use and disclosure of individually identifiable health information and require healthcare providers to implement administrative, physical and technical safeguards to protect the security of such information. Violations of the regulations may result in civil and criminal penalties. The American Recovery and Reinvestment Act of 2009, or “ARRA”, strengthened the requirements of the HIPAA privacy and security regulations and significantly increased the penalties for violations, with penalties of up to $50,000 per violation and a maximum civil penalty of $1.5 million in a calendar year for violations of the same requirement and requires HHS to perform compliance audits. ARRA authorizes State Attorneys General to bring civil actions seeking either injunction or damages in response to violations of HIPAA privacy and security regulations that threaten the privacy of state residents. ARRA also extends the application of certain provisions of the security and privacy regulations to business associates (entities that handle identifiable health information on behalf of covered entities) and subjects business associates to civil and criminal penalties for violation of the regulations. HHS has implemented many of the ARRA requirements through a final rule that became effective March 26, 2013. Compliance with the final rule was required beginning September 23, 2013, except that existing business associate agreements may qualify for an extended compliance date of September 23, 2014.

As required by ARRA, covered entities must report breaches of unsecured protected health information to affected individuals without unreasonable delay, but not to exceed 60 days following discovery of the breach by the covered entity or its agents. Notification must also be made to HHS and, in certain situations involving large breaches, to the media. The 2013 final rule modified this breach notification requirement by creating a presumption that all non-permitted uses or disclosures of unsecured protected health information are breaches unless the covered entity or business associate establishes that there is a low probability the information has been compromised.

Our facilities remain subject to any state laws that relate to privacy or the reporting of security breaches that are more restrictive than the regulations issued under HIPAA and the requirements of ARRA. For example, various state laws and regulations may require us to notify affected individuals in the event of a data breach involving certain individually identifiable health or financial information.

HIPAA Administrative Simplification Requirements. Pursuant to HIPAA, HHS has adopted regulations establishing electronic data transmission standards that all healthcare providers must use when submitting or receiving certain healthcare transactions electronically. HIPAA also requires that each provider use a National Provider Identifier. In addition, CMS has published a final rule regarding updated standard code sets for certain diagnoses and procedures known as ICD-10 code sets and related changes to the formats used for certain electronic transactions. While use of the ICD-10 code sets is not mandatory until October 1, 2014, we will be modifying our payment systems and processes to prepare for the implementation. Use of the ICD-10 code sets will require significant administrative changes. In addition to these upfront costs of transition to ICD-l0, it is possible that our ASCs could experience disruption or delays in payment due to technical or coding errors or other implementation issues involving our systems or the systems and implementation efforts of health plans and their business partners. Further, the transition to the more detailed ICD-10 coding system could result in decreased reimbursement if the use of ICD-10 codes results in conditions being reclassified with lower levels of reimbursement than assigned under the previous system, however, we believe that the cost of compliance with these regulations has not had and is not expected to have a material adverse effect on our business, financial position or results of operations.

Item 1. Business – (continued)

Obligations to Buy Out Physician Partners. Under many of our agreements with physician partners, we are obligated to purchase the interests of the physicians at an amount as specified in the limited partnership and operating agreements in the event that their continued ownership of interests in the limited partnerships and limited liability companies becomes prohibited by the statutes or regulations described above. The determination of such a prohibition generally is required to be made by our counsel in concurrence with counsel of the physician partners or, if they cannot concur, by a nationally recognized law firm with expertise in healthcare law jointly selected by us and the physician partners. The interest we are required to purchase will not exceed the minimum interest required as a result of the change in the law or regulation causing such prohibition.

CONs and State Licensing. Certificate of Need, or “CON”, statutes and regulations control the development of ASCs in certain states. CON statutes and regulations generally provide that, prior to the expansion of existing centers, the construction of new centers, the acquisition of major items of equipment or the introduction of certain new services, approval must be obtained from the designated state health planning agency. In giving approval, a designated state health planning agency must determine that a need exists for expanded or additional facilities or services. Our development of ASCs focuses on states that do not require CONs. Acquisitions of existing surgery centers usually do not require CON approval.

State licensing of ASCs is generally a prerequisite to the operation of each center and to participation in federally funded programs, such as Medicare and Medicaid. Once a center becomes licensed and operational, it must continue to comply with federal, state and local licensing and certification requirements, as well as local building and safety codes. In addition, every state imposes licensing requirements on individual physicians, and many states impose licensing requirements on facilities and services operated and owned by physicians. Physician practices are also subject to federal, state and local laws dealing with issues such as occupational safety, employment, medical leave, insurance regulations, civil rights and discrimination and medical waste and other environmental issues.

Corporate Practice of Medicine. The laws of several states in which we operate or may operate in the future do not permit business corporations to practice medicine, exercise control over physicians who practice medicine or engage in various business practices, such as fee-splitting with physicians. The physicians who perform procedures at the surgery centers are individually licensed to practice medicine. In most instances, the physicians and physician group practices are not affiliated with us other than through the physicians' ownership in the limited partnerships and limited liability companies that own the surgery centers and through the service agreements we have with some physicians. The laws in most states regarding the corporate practice of medicine have been subjected to limited judicial and regulatory interpretation, and interpretation and enforcement of these laws vary significantly from state to state. Therefore, we cannot provide assurances that our activities, if challenged, will be found to be in compliance with these laws.

Employees

As of December 31, 2013, we and our affiliated entities employed approximately 6,200 persons, approximately 4,100 of whom were full‑time employees and 2,100 of whom were part‑time employees. Of our employees, approximately 435 are corporate employees, primarily based at our headquarters in Nashville, Tennessee. In addition, we lease the services of approximately 1,000 full-time employees and 500 part‑time employees from entities affiliated with our physician partners. None of these employees are represented by a union. We believe our relationships with our employees to be good.

Legal Proceedings and Insurance

From time to time, we may be named a party to legal claims and proceedings in the ordinary course of business. We are not aware of any claims or proceedings against us or our limited partnerships and limited liability companies that we believe will have a material financial impact on us. Currently, we maintain professional and general liability insurance that, subject to certain deductibles, provides coverage on a claims-made basis of $1.0 million per incident and $3.0 million in annual aggregate coverage per center, including the facility and employed staff. We also maintain insurance for general liability, director and officer liability, business interruption and property damage, as well as an additional umbrella liability insurance policy in the aggregate amount of $25.0 million. Coverage under certain of these policies is contingent upon the policy being in effect when a claim is made regardless of when the events which caused the claim occurred. In addition, physicians who provide professional services in our surgical facilities are generally required to maintain separate malpractice coverage with similar minimum coverage limits. We routinely assess the adequacy of our insurance coverage and believe that our insurance policies are appropriate in amount and coverage for our anticipated operations. However, we cannot assure you that the insurance coverage is sufficient to cover all future claims or will continue to be available in adequate amounts or at a reasonable cost.

Item 1. Business – (continued)

Executive Officers of the Registrant

The following table sets forth certain information regarding the persons serving as our executive officers. Our executive officers serve at the pleasure of the Board of Directors.

Name	Age	Experience

Christopher A. Holden	49	Chief Executive Officer and Director since October 2007; Senior Vice President and a Division President of Triad Hospitals Inc. from May 1999 to July 2007; President – West Division of the Central Group of Columbia/HCA Healthcare Corporation from January 1998 to May 1999.

Claire M. Gulmi	60	Executive Vice President since February 2006; Chief Financial Officer since September 1994; Director since May 2004; Senior Vice President from March 1997 to February 2006; Secretary since December 1997; Vice President from September 1994 through March 1997.

David L. Manning	64	Executive Vice President and Chief Development Officer since February 2006; Senior Vice President of Development from April 1992 to February 2006.

Phillip A. Clendenin	49	Executive Vice President-Operations since February 2013; Senior Vice President of Corporate Services from March 2009 to February 2013; Chief Executive Officer of River Region Health System, a hospital located in Vicksburg, Mississippi, from July 2001 to July 2008; Chief Executive Officer of Greenview Regional Hospital, a hospital located in Bowling Green, Kentucky, from November 1997 to June 2001.

Kevin D. Eastridge	48	Senior Vice President of Finance since July 2008; Vice President of Finance from April 1998 to July 2008; Chief Accounting Officer since July 2004; Controller from March 1997 to June 2004.

Shawn G. Strash	51	Senior Vice President of Corporate Services since February 2013; Chief Executive Officer of Paradise Valley Hospital, a hospital located in Phoenix, Arizona from July 2011 to September 2012; Chief Executive Officer of Oro Valley Hospital, a hospital located in Tucson, Arizona from 2007 to 2011.

Item 1A. Risk Factors

The following factors affect our business and the industry in which we operate. The risks and uncertainties described below are not the only ones facing our company. Additional risks and uncertainties not presently known to us or that we currently consider immaterial may also have an adverse effect on us. If any of the matters discussed in the following risk factors were to occur, our business, financial condition, results of operations, cash flows or prospects could be materially adversely affected.

We depend on payments from third-party payors, including government healthcare programs. If these payments decrease or do not increase as our costs increase, our operating margins and profitability would be adversely affected. We depend on private and governmental third-party sources of payment for the services provided to patients in our surgery centers. We derived approximately 25% of our revenues in 2013 from U.S. government healthcare programs, primarily Medicare. The amount our surgery centers receive for their services may be adversely affected by market and cost factors as well as other factors over which we have no control, including future changes to the Medicare and Medicaid payment systems and the cost containment and utilization decisions of third-party payors. Although the Health Reform Law expands coverage of preventive care and the number of individuals with healthcare coverage, the law also provides for reductions to Medicare and Medicaid program spending. It is impossible to predict how the various components of the Health Reform Law, some of which are not currently in effect, will affect our business and the businesses of our physician partners. Several states are also considering healthcare reform measures. This focus on healthcare reform at the federal and state levels may increase the likelihood of significant changes affecting government healthcare programs in the future.

The BCA requires automatic spending reductions of $1.2 trillion for FFYs 2013 through 2021, minus any deficit reductions enacted by Congress and debt service costs and the Bipartisan Budget Act of 2013 extends these reductions through 2023. The percentage reduction for Medicare may not be more than 2% for a FFY, with a uniform percentage reduction across all Medicare programs. These BCA-mandated spending cuts are commonly referred to as "sequestration." Sequestration began on March 1, 2013, and CMS imposed a 2% reduction on Medicare claims as of April 1, 2013. We cannot predict with certainty what other deficit reduction initiatives may be proposed by Congress or whether Congress will attempt to restructure or suspend sequestration. We estimate that the imposed spending reductions reduced our 2013 revenues and net earnings per diluted share by approximately $5.0 million and $0.05, respectively. Based on current volumes, we estimate that the imposed spending reductions will have an incremental negative impact on 2014 revenues of approximately $1.5 million.

Managed care plans have increased their market share in some areas in which we operate, which has resulted in substantial competition among healthcare providers for inclusion in managed care contracting and may limit the ability of healthcare providers to negotiate favorable payment rates. In addition, managed care payors may lower reimbursement rates in response to increased obligations on payors imposed by the Health Reform Law or future reductions in Medicare reimbursement rates. Further, payors may utilize plan structures, such as narrow networks or tiered networks, that limit patient provider choices or impose significantly higher cost sharing obligations when care is obtained from providers in a disfavored tier. We can give you no assurances that future changes to reimbursement rates by government healthcare programs, cost containment measures by private third-party payors, including fixed fee schedules and capitated payment arrangements, or other factors affecting payments for healthcare services will not adversely affect our future revenues, operating margins or profitability.

If we fail to acquire and develop additional surgery centers on favorable terms, our future growth and operating results could be adversely affected. Our growth strategy includes increasing our revenues and earnings by acquiring existing surgery centers and developing new surgery centers. Our efforts to execute our acquisition and development strategy may be affected by our ability to identify suitable acquisition and development opportunities and negotiate and close transactions in a timely manner and on favorable terms. The surgery centers we develop typically incur losses during the initial months of operation. We can give you no assurances that we will be successful in acquiring and developing additional surgery centers, that the surgery centers we acquire and develop will achieve satisfactory operating results or that newly developed centers will not incur greater than anticipated operating losses.

If we are unable to effectively compete for physician partners, managed care contracts, patients and strategic relationships, our business would be adversely affected. The healthcare business is highly competitive. We compete with other healthcare providers, primarily hospitals and other surgery centers, in recruiting physicians to utilize our surgery centers, for patients and in contracting with managed care payors. In some of the markets in which we operate, there are shortages of physicians in our targeted specialties. In several of the markets in which we operate, hospitals are recruiting physicians or groups of physicians to become employed by the hospitals, including primary care physicians and physicians in our targeted specialties, and restricting those physicians’ ability to refer patients to physicians and facilities not affiliated with the hospital. In addition, physicians, hospitals, payors and other providers may form integrated delivery systems or utilize plan structures that restrict the physicians who may treat certain patients or the facilities at which patients may be treated. These restrictions may impact our surgery centers and the medical practices of our physician partners. Some of our competitors may have greater resources than we do, including financial, marketing, staff and capital resources, have or may develop new technologies or services that are attractive to physicians or patients, or have established relationships with physicians and payors.

We compete with public and private companies in the development and acquisition of ASCs. Further, many physician groups develop ASCs without a corporate partner. We can give you no assurances that we will be able to compete effectively in any of these areas or that our results of operations will not be adversely impacted.

Item 1A. Risk Factors – (continued)

Our business may be adversely affected by changes to the medical practices of our physician partners or if we fail to maintain good relationships with the physician partners who use our surgery centers. Our business depends on, among other things, the efforts and success of the physician partners who perform procedures at our surgery centers and the strength of our relationship with these physicians. The medical practices of our physician partners may be negatively impacted by general economic conditions, changes in payment rates or systems by payors (including Medicare), actions taken by referring physicians, other providers and payors, and other factors impacting their practices. Adverse economic conditions, including high unemployment rates, could cause patients of our physician partners and our ASCs to cancel or delay procedures. Our physician partners may perform procedures at other facilities and are not required to use our surgery centers. From time to time, we have had and may have future disputes with physicians who use or own interests in our surgery centers. Our revenues and profitability may be adversely affected if a key physician or group of physicians stopped using or reduced their use of our surgery centers as a result of changes in their physician practice, changes in payment rates or systems, or a disagreement with us. In addition, if the physicians who use our surgery centers do not provide quality medical care or follow required professional guidelines at our facilities or there is damage to the reputation of a physician or group of physicians who use our surgery centers, our business and reputation could be damaged.

If we are unable to increase procedure volume at our existing centers, our operating margins and profitability could be adversely affected. Our growth strategy includes increasing our revenues and earnings primarily by increasing the number of procedures performed at our surgery centers. We seek to increase procedure volume at our surgery centers by increasing the number of physicians performing procedures at our centers, obtaining new or more favorable managed care contracts, improving patient flow at our centers, increasing the capacity at our centers, promoting screening programs and increasing patient and physician awareness of our centers. Procedure volume at our centers may be adversely impacted by economic conditions, high unemployment rates and other factors that may cause patients to delay or cancel procedures. We can give you no assurances that we will be successful at increasing or maintaining procedure volumes, revenues and operating margins at our centers.

If we are unable to manage the growth in our business and integrate acquired businesses, our operating results could be adversely affected. To accommodate our past and anticipated future growth, we will need to continue to implement and improve our management, operational and financial information systems and to expand, train, manage and motivate our workforce. We can give you no assurances that our personnel, systems, procedures or controls will be adequate to support our operations in the future or that the costs and management attention related to the expansion of our operations and the integration of acquired businesses will not adversely affect our results of operations.

If we do not have sufficient capital resources to complete acquisitions and develop new surgery centers, our growth and results of operations could be adversely affected. We will need capital to execute our growth strategy and may finance future acquisition and development projects through debt or equity financings. Disruptions to financial markets or other adverse economic conditions may adversely impact our ability to complete any such financing or the terms of any such financing. To the extent that we undertake these financings, our shareholders may experience ownership dilution. To the extent we incur debt, we may have significant interest expense and may be subject to covenants in the related debt agreements that affect the conduct of our business. If we do not have sufficient capital resources, our growth could be limited and our results of operations could be adversely impacted. Our debt agreements require that we comply with financial covenants and may not permit additional borrowing or other sources of debt financing if we are not in compliance with those covenants. We can give you no assurances that we will be able to obtain financing necessary for our acquisition and development strategy or that, if available, the financing will be available on terms acceptable to us.

We may not be able to generate sufficient cash to service all of our indebtedness and may be forced to take other actions to satisfy our obligations under our indebtedness, which may not be successful. Our ability to make scheduled payments on or to refinance our debt obligations depends on our financial condition and operating performance, which is subject to prevailing economic and competitive conditions and to certain financial, business, and other factors beyond our control. We may not be able to maintain a level of cash flows from operating activities sufficient to permit us to pay the principal, premium, if any, and interest on our indebtedness.

If our cash flows and capital resources are insufficient to fund our debt service obligations, we may be forced to reduce or delay investments and capital expenditures, or to sell assets, seek additional capital, or restructure or refinance our indebtedness. Our ability to restructure or refinance our debt will depend on the condition of the capital markets and our financial condition at such time. Any refinancing of our debt could be at higher interest rates and may require us to comply with more onerous covenants, which could further restrict our business operations. The terms of existing or future debt instruments may restrict us from adopting some of these alternatives. In addition, any failure to make payments of interest and principal on our outstanding indebtedness on a timely basis would likely result in a reduction of our credit rating, which could harm our ability to incur additional indebtedness. These alternative measures may not be successful and may not permit us to meet our scheduled debt service obligations.

Our surgery centers may be negatively impacted by weather and other factors beyond our control. The results of operations of our surgery centers may be adversely impacted by adverse weather conditions, including hurricanes, or other factors beyond our control that cause disruption of patient scheduling, displacement of our patients, employees and physician partners, and force certain of our surgery centers to close temporarily. In certain geographic areas, we have a large concentration of surgery centers that may be simultaneously affected by adverse weather conditions or events. Our future financial and operating results may be adversely affected by weather and other factors that disrupt the operation of our surgery centers.

If we fail to comply with applicable laws and regulations, we could suffer penalties or be required to make significant changes to our operations. We are subject to many laws and regulations at the federal, state and local government levels in the jurisdictions in which we operate. These laws and regulations require that our surgery centers and our operations meet various licensing, certification and other requirements, including those relating to:

· physician ownership of our surgery centers;

· our and our surgery centers’ relationships with physicians and other referral sources;

· CON approvals and other regulations affecting the construction or acquisition of centers, capital expenditures or the addition of services;

· the adequacy of medical care, equipment, personnel, and operating policies and procedures;

Item 1A. Risk Factors – (continued)

· qualifications of medical and support personnel;

· maintenance and protection of records;

· billing for services by healthcare providers, including appropriate treatment of overpayments and credit balances;

· privacy and security of individually identifiable health information; and

· environmental protection.

If we fail to comply with applicable laws and regulations, we could suffer civil or criminal penalties, including the loss of our licenses to operate and our ability to participate in Medicare, Medicaid and other government sponsored and third-party healthcare programs. CMS has enacted additional conditions for coverage that ASCs must meet to enroll and remain enrolled in Medicare, and a number of states have adopted or are considering legislation or regulations imposing additional restrictions on or otherwise affecting ASCs, including expansion of CON requirements, restrictions on ownership, taxes on gross receipts, data reporting requirements and restrictions on the enforceability of covenants not to compete affecting physicians. Different interpretations or enforcement of existing or new laws and regulations could subject our current practices to allegations of impropriety or illegality, or require us to make changes in our operations, facilities, equipment, personnel, services, capital expenditure programs or operating expenses to comply with the evolving rules. We can give you no assurances that current or future legislative initiatives, government regulation or judicial or regulatory interpretations thereof will not have a material adverse effect on us, subject us to fines or penalties, require us to expend significant amounts or reduce the demand for our services.

If we fail to effectively and timely transition to the ICD-10 coding system, our operations could be adversely affected. Health plans and providers, including our ASCs, are required to transition to the new ICD-10 coding system, which greatly expands the number and detail of billing codes used for third-party claims. Use of the ICD-10 system is required beginning October 1, 2014. Transition to the new ICD-10 system requires significant investment in coding technology and software as well as the training of staff involved in the coding and billing process. In addition to these upfront costs of transition to ICD-10, it is possible that our ASCs could experience disruption or delays in payment due to technical or coding errors or other implementation issues involving our systems or the systems and implementation efforts of health plans and their business partners. Further, the extent to which the transition to the more detailed ICD-10 coding system could result in decreased reimbursement, because the use of ICD-10 codes results in conditions being reclassified to payment groupings with lower levels of reimbursement than assigned under the previous system, is unknown at this time.

If a federal or state agency asserts a different position or enacts new laws or regulations regarding illegal remuneration or other forms of fraud and abuse, we could suffer penalties or be required to make significant changes to our operations. The federal Anti-Kickback Statute prohibits healthcare providers and others from soliciting, receiving, offering or paying, directly or indirectly, any remuneration with the intent of generating referrals or orders for services or items covered by a federal healthcare program. The Anti-Kickback Statute is very broad in scope and many of its provisions have not been uniformly or definitively interpreted by case law or regulations. Courts have found a violation of the anti-kickback statute if just one purpose of the remuneration is to generate referrals, even if there are other lawful purposes. Furthermore, the Health Reform Law provides that knowledge of the law or intent to violate the law is not required to establish a violation of the Anti-Kickback Statute. Violations of the anti-kickback statute may result in substantial civil or criminal penalties and exclusion from participation in the Medicare and Medicaid programs. Exclusion from these programs would result in significant reduction in revenues and would have a material adverse effect on our business.

HHS has published regulations that outline categories of activities that are deemed protected from prosecution under the Anti-Kickback Statute. Three of the safe harbors apply to business arrangements similar to those used in connection with our surgery centers: the "surgery centers," "investment interest" and "personal services and management contracts" safe harbors. The structure of the limited partnerships and limited liability companies operating our surgery centers, as well as our various business arrangements involving physician group practices, are unlikely to satisfy all of the requirements of any safe harbor. Nevertheless, a business arrangement that does not substantially comply with a safe harbor is not necessarily illegal under the Anti-Kickback Statute. In addition, many of the states in which we operate also have adopted laws, similar to the Anti-Kickback Statute, that prohibit payments to physicians in exchange for referrals, some of which apply regardless of the source of payment for care. These statutes typically impose criminal and civil penalties as well as loss of license.

In addition to the Anti-Kickback Statute, HIPAA provides for criminal penalties for healthcare fraud offenses that apply to all health benefit programs, including the payment of inducements to Medicare and Medicaid beneficiaries in order to influence those beneficiaries to order or receive services from a particular provider or practitioner. Federal enforcement officials have numerous enforcement mechanisms to combat fraud and abuse, including the Medicare Integrity Program and an incentive program under which individuals can receive up to $1,000 for providing information on Medicare fraud and abuse that leads to the recovery of at least $100 of Medicare funds. States that enact false claims laws that are comparable to the federal FCA are entitled to an increased share of false claims recoveries. Federal enforcement officials have the ability to exclude from Medicare and Medicaid any investors, officers and managing employees associated with business entities that have committed healthcare fraud.

Providers in the healthcare industry have been the subject of federal and state investigations, and we may become subject to investigations in the future. Both federal and state government agencies have heightened and coordinated civil and criminal enforcement efforts as part of numerous ongoing investigations of healthcare companies, as well as their executives and managers. These investigations relate to a wide variety of topics, including referral and billing practices. Further, the federal FCA permits private parties to bring "qui tam" whistleblower lawsuits against companies. Some states have adopted similar state whistleblower and false claims provisions.

From time to time, the OIG and the Department of Justice have established national enforcement initiatives that focus on specific billing practices or other suspected areas of abuse. Some of our activities could become the subject of governmental investigations or inquiries. For example, we have significant Medicare billings and we have joint venture arrangements involving physician investors. In addition, our executives and managers, some of whom have worked at other healthcare companies that are or may become the subject of federal and state investigations and private litigation, could be included in governmental investigations or named as defendants in private litigation. A governmental investigation of us, our executives or our managers could result in significant expense to us, as well as adverse publicity.

Item 1A. Risk Factors – (continued)

We are unable to predict the impact of the Health Reform Law. The Health Reform Law represents significant change across the healthcare industry. The Health Reform Law contains a number of provisions designed to reduce Medicare program spending, including an annual productivity adjustment that reduces payment updates to ASCs. However, the Health Reform Law also expands coverage of uninsured individuals through a combination of public program expansion and private sector health insurance reforms. For example, the implementation of the Health Reform Law has expanded eligibility under existing Medicaid programs in states that have not opted out of the expansion, created financial penalties on individuals who fail to carry insurance coverage, established affordability credits for those not enrolled in an employer-sponsored health plan, resulted in the establishment of, or participation in, a health insurance exchange for each state and allowed states to create federally funded, non-Medicaid plans for low-income residents not eligible for Medicaid. The Health Reform Law also establishes a number of private health insurance market reforms, including a ban on lifetime limits and pre-existing condition exclusions, new benefit mandates, and increased dependent coverage.

Many health plans are required to cover, without cost-sharing, certain preventive services designated by the U.S. Preventive Services Task Force, including screening colonoscopies. Medicare must also cover these preventive services without cost-sharing, and states that provide Medicaid coverage of these preventive services without cost-sharing receive a one percentage point increase in their federal medical assistance percentage for these services.

Health insurance market reforms that expand insurance coverage may result in an increased volume for certain procedures at our centers. However, certain of the provisions of the Health Reform Law are not currently effective, and the provisions may be amended, repealed or delayed or their impact could be offset by reductions in reimbursement under the Medicare program. It is unclear what the resulting impact of the Health Reform Law will be on the number of uninsured individuals or what the payment terms will be for individuals covered by the Medicaid expansion or who purchase coverage through health insurance exchanges, or what impact ACOs or other coordinated care models may have on our centers or the medical practices of our physician partners. Further, the employer mandate, which requires firms with 50 or more full-time employees to offer health insurance or pay fines, has been delayed until January 1, 2015 and will not be fully implemented until January 1, 2016. The federal online insurance marketplace experienced significant technical issues that negatively impacted the ability of individuals to purchase health insurance. These technical issues or additional implementation issues could lead to the delay of the individual mandate tax penalties past the current March 31, 2014 deadline, delays in individuals obtaining health insurance and a reduction in the number of individuals choosing to purchase health insurance rather than paying the individual mandate tax penalties.

If regulations or regulatory interpretations change, we may be obligated to buy out interests of physicians who are minority owners of the surgery centers. A majority of our limited partnership and operating agreements provide that if certain regulations or regulatory interpretations change, we will be obligated to purchase some or all of the noncontrolling interests of our physician partners. The regulatory changes that could trigger such obligations include changes that:

· make the referral of Medicare and other patients to our surgery centers by physicians affiliated with us illegal;

· create the substantial likelihood that cash distributions from the limited partnerships or limited liability companies to the affiliated physicians will be illegal; or

· cause the ownership by the physicians of interests in the limited partnerships or limited liability companies to be illegal.

The cost of repurchasing these noncontrolling interests would be substantial if a triggering event were to result in simultaneous purchase obligations at a substantial number or at all of our surgery centers. The purchase price to be paid in such event would be determined as specified in each of the limited partnership and operating agreements, which also provide for the payment terms, generally over four years. There can be no assurance, however, that our existing capital resources would be sufficient for us to meet the obligations, if they arise, to purchase these noncontrolling interests held by physicians. The determination of whether a triggering event has occurred generally would be made by the concurrence of our legal counsel and counsel for the physician partners or, in the absence of such concurrence, by a nationally recognized law firm having an expertise in healthcare law jointly selected by both parties. Such determinations therefore would not be within our control. The triggering of these obligations could have a material adverse effect on our financial condition and results of operations. While we believe physician ownership of ASCs as structured within our limited partnerships and limited liability companies is in compliance with applicable law, we can give no assurances that legislative or regulatory changes would not have an adverse impact on us. From time to time, the issue of physician ownership in ASCs is considered by some state legislatures and federal and state regulatory agencies.

We are liable for the debts and other obligations of the limited partnerships that own and operate certain of our surgery centers. In the limited partnerships in which one of our affiliates is the general partner, our affiliate is liable for 100% of the debts and other obligations of the limited partnership; however, the physician partners are generally required to guarantee their pro rata share of any indebtedness or lease agreements to which the limited partnership is a party in proportion to their ownership interest in the limited partnership. We also have primary liability for the bank debt that may be incurred for the benefit of the limited liability companies, and in turn, lend funds to these limited liability companies, although the

Item 1A. Risk Factors – (continued)

physician members also guarantee this debt. There can be no assurance that a third-party lender or lessor would seek performance of the guarantees rather than seek repayment from us of any obligation of the limited partnership or limited liability company if there is a default, or that the physician partners or members would have sufficient assets to satisfy their guarantee obligations.

We may be subject to liabilities for claims brought against our facilities. We are subject to litigation related to our business practices, including claims and legal actions by patients and others in the ordinary course of business alleging malpractice, product liability or other legal theories. See “Business – Legal Proceedings.” These actions could involve large claims and significant defense costs. If payments for claims exceed our insurance coverage or are not covered by insurance or our insurers fail to meet their obligations, our results of operations and financial position could be adversely affected.

We have a legal responsibility to the minority owners of the entities through which we own our surgery centers, which may conflict with our interests and prevent us from acting solely in our own best interests. As the owner of majority interests in the limited partnerships and limited liability companies that own our surgery centers, we owe a fiduciary duty to the noncontrolling interest holders in these entities and may encounter conflicts between our interests and that of the minority holders. In these cases, our representatives on the governing board of each joint venture are obligated to exercise reasonable, good faith judgment to resolve the conflicts and may not be free to act solely in our own best interests. In our role as manager of the limited partnership or limited liability company, we generally exercise our discretion in managing the business of the surgery center. Disputes may arise between us and the physician partners regarding a particular business decision or the interpretation of the provisions of the limited partnership agreement or limited liability company operating agreement. The agreements provide for arbitration as a dispute resolution process in some circumstances. We cannot assure you that any dispute will be resolved or that any dispute resolution will be on terms satisfactory to us.

We may write-off intangible assets, such as goodwill. As a result of purchase accounting for our various acquisition transactions, our balance sheet at December 31, 2013 contained an intangible asset designated as goodwill totaling approximately $1.8 billion. Additional purchases of interests in surgery centers that result in the recognition of additional intangible assets would cause an increase in these intangible assets. On an ongoing basis, we evaluate whether facts and circumstances indicate any impairment of the value of intangible assets. As circumstances change, we cannot assure you that the value of these intangible assets will be realized by us. If we determine that a significant impairment has occurred, we will be required to write-off the impaired portion of intangible assets, which could have a material adverse effect on our results of operations in the period in which the write-off occurs.

The Internal Revenue Service (“IRS”) may challenge tax deductions for certain acquired goodwill. For federal income tax purposes, goodwill and other intangibles acquired as part of the purchase of a business are deductible over a 15-year period. In 1997, the IRS published proposed regulations that applied "anti-churning" rules that call into question the deductibility of goodwill purchased in certain types of transactions structured similarly to some of our acquisitions that we had completed through that date. These regulations were finalized in 2000, and in response, we changed our methods of acquiring interests in ASCs so as to comply with guidance found in the final regulations. However, there is a risk that the IRS could challenge tax deductions for goodwill in acquisitions we completed prior to changing our approach. Loss of these tax deductions would increase the amount of our tax payments and could subject us to interest and penalties.

Item 1B. Unresolved Staff Comments

Not applicable.

Item 2. Properties

Our principal executive offices are located in Nashville, Tennessee and contain an aggregate of approximately 105,000 square feet of office space, which we lease from third-parties pursuant to agreements that expire in February 2015 and January 2018. On December 27, 2012, the Company entered into a lease agreement pursuant to which the Company has agreed to lease an approximately 110,000 square foot building to be constructed in Nashville, Tennessee. The Company intends that the building will serve as its principal executive offices beginning in 2015. Prior to taking possession, the Company may terminate the agreement if the landlord fails to satisfy certain construction milestones. We also lease office space for our regional offices in Miami, Florida, Tempe, Arizona, Dallas, Texas, and Conshohocken, Pennsylvania. Our affiliated limited partnerships and limited liability companies lease space for their surgery centers ranging from 1,000 to 29,000 square feet, with expected remaining lease terms ranging from one to 20 years.

Item 3. Legal Proceedings

On November 1, 2013, the United States District Court for the Eastern District of California in Sacramento issued an order unsealing a qui tam lawsuit filed against the Company, Gastroenterology Associates Endoscopy Center, LLC (“GAEC”), an entity that owns and operates an ambulatory surgery center located in Redding, California in which the Company owns a majority ownership interest, and certain other defendants. The lawsuit was filed in August 2012 by two certified registered nurse anesthetists who provided services as independent contractors to GAEC during the period from September 2010 through December 2010. GAEC terminated its contracts with the plaintiffs in December 2010. In the lawsuit, the plaintiffs assert claims pursuant to the Federal False Claims Act and the California False Claims Act relating to the alleged failure by GAEC to comply with applicable Federal and state regulatory requirements relating to pre-procedure medical histories and physical assessments. The lawsuit also asserts a claim for retaliatory discharge. According to the order entered by the District Court, both the United States and the State of California declined to intervene in the case. The plaintiffs filed an amended complaint in January 2014. The Company believes the claims in the lawsuit have no merit, and intends to vigorously defend the lawsuit.

Item 4. Mine Safety Disclosures

Not applicable.

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Our common stock trades under the symbol “AMSG” on the Nasdaq Global Select Market. The following table sets forth the high and low sales prices per share for the common stock for each of the quarters in 2012 and 2013, as reported on the Nasdaq Global Select Market:

		1^st		2^nd		3^rd		4^th
		Quarter		Quarter		Quarter		Quarter

2012:
	High	$	28.29	$	30.00	$	32.17	$	30.50
	Low	$	24.80	$	26.31	$	27.24	$	25.00

2013:
	High	$	33.78	$	36.76	$	41.00	$	48.71
	Low	$	29.02	$	31.72	$	35.11	$	39.31

At February 12, 2014, there were approximately 6,450 holders of our common stock, including 128 shareholders of record. We have never declared or paid a cash dividend on our common stock. We intend to retain our earnings to finance the growth and development of our business and do not expect to declare or pay any cash dividends in the foreseeable future. The declaration of dividends is within the discretion of our Board of Directors, subject to certain covenants which limit, but may not restrict, the Company’s ability to pay dividends.

Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

(d) Maximum

Number (or

Approximate Dollar

(a) Total

(c) Total Number of

Value) of Shares (or

Number of

(b) Average

Shares (or Units)

Units) That May Yet

Shares

Price Paid

Purchased as Part of

Be Purchased Under

(or Units)

per Share

Publicly Announced

the Plans or

Period

Purchased

(or Unit)

Plans or Programs

Programs

October 1, 2013 through

October 31, 2013

37,561,133

⁽¹⁾

November 1, through

November 30, 2013

233,557

44.87

233,557

27,078,575

December 1, 2013 through

December 31, 2013

27,078,575

Total

233,557

44.87

233,557

27,078,575

(1)	On August 9, 2013, we announced that our board of directors had authorized a stock repurchase program, allowing for the purchase of up to $40,000,000 of our outstanding common stock over an 18 month period through February 9, 2015.

Item 6. Selected Financial Data

The following tables summarize selected financial data and should be read in conjunction with our related consolidated financial statements and notes thereto. Certain prior year amounts below have been reclassified to reflect the impact of discontinued operations.

			Year Ended December 31,
			2013		2012		2011		2010		2009

			(Dollars in thousands, except per share data)
Consolidated Statement of Earnings Data:
Revenues			$	1,079,343	$	923,182	$	772,075	$	685,944	$	636,016
Operating expenses				746,666		643,993		534,094		464,233		422,137
Gain on deconsolidation				2,237		-		-		-		-
Equity in earnings of unconsolidated affiliates				3,151		1,564		613		-		-

	Operating income			338,065		280,753		238,594		221,711		213,879
Interest expense				29,538		16,967		15,327		13,471		7,751

	Earnings from continuing operations before income taxes			308,527		263,786		223,267		208,240		206,128
Income tax expense				49,754		42,364		34,973		32,654		33,265

	Net earnings from continuing operations			258,773		221,422		188,294		175,586		172,863
Discontinued operations:
	Earnings from operations of discontinued interests
		in surgery centers, net of income tax		169		2,196		3,363		7,642		9,189
	Gain (loss) on disposal of discontinued interests in
		surgery centers, net of income tax		2,602		25		(1,543)		(2,732)		(702)

	Net earnings from discontinued operations			2,771		2,221		1,820		4,910		8,487

	Net earnings			261,544		223,643		190,114		180,496		181,350
Less net earnings attributable to noncontrolling interests				188,841		161,080		140,117		130,671		129,202

	Net earnings attributable to AmSurg Corp. common shareholders		$	72,703	$	62,563	$	49,997	$	49,825	$	52,148
Amounts attributable to AmSurg Corp. common shareholders:
	Earnings from continuing operations, net of tax		$	72,653	$	62,235	$	50,025	$	49,576	$	49,297
	Discontinued operations, net of tax			50		328		(28)		249		2,851
	Net earnings attributable to AmSurg Corp. common shareholders		$	72,703	$	62,563	$	49,997	$	49,825	$	52,148

Earnings per share-basic:
	Net earnings from continuing operations attributable
		to AmSurg Corp. common shareholders	$	2.32	$	2.02	$	1.64	$	1.64	$	1.61
	Net earnings attributable to AmSurg Corp. common shareholders		$	2.32	$	2.03	$	1.64	$	1.65	$	1.71
Earnings per share-diluted:
	Net earnings from continuing operations attributable
		to AmSurg Corp. common shareholders	$	2.27	$	1.97	$	1.60	$	1.62	$	1.60
	Net earnings attributable to AmSurg Corp. common shareholders		$	2.28	$	1.98	$	1.60	$	1.62	$	1.69
Weighted average number of shares and share equivalents outstanding:
Basic				31,338		30,773		30,452		30,255		30,576
Diluted				31,954		31,608		31,211		30,689		30,862

Operating and Other Financial Data:
Continuing centers at end of year				242		237		221		195		188
Procedures performed during year				1,647,353		1,518,707		1,362,415		1,238,231		1,174,278
Same-center revenue increase (decrease)				1%		3%		1%		(2%)		0%
Cash flows provided by operating activities			$	332,824	$	295,652	$	243,423	$	230,575	$	232,584
Cash flows used in investing activities				(98,738)		(298,943)		(254,367)		(72,905)		(112,792)
Cash flows (used in) provided by financing activities				(229,644)		8,971		17,515		(152,900)		(121,963)

			At December 31,
			2013		2012		2011		2010		2009

			(In thousands)
Consolidated Balance Sheet Data:
Cash and cash equivalents			$	50,840	$	46,398	$	40,718	$	34,147	$	29,377
Working capital				121,155		107,768		109,561		89,393		80,161
Total assets				2,177,944		2,044,586		1,573,018		1,165,878		1,066,831
Long-term debt and other long-term liabilities				608,801		646,677		476,094		307,619		318,819
Non-redeemable and redeemable noncontrolling interests (1)				539,056		486,360		302,858		160,539		128,618
AmSurg Corp. shareholders’ equity				764,197		689,488		616,245		564,068		505,116

(1)	See “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies.”

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This report contains certain forward-looking statements (all statements other than statements with respect to historical fact) within the meaning of the federal securities laws, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve known and unknown risks and uncertainties including, without limitation, those described in Item 1A. Risk Factors, some of which are beyond our control. Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate. Therefore, there can be no assurance that the forward-looking statements included in this report will prove to be accurate. Actual results could differ materially and adversely from those contemplated by any forward-looking statement. In light of the significant risks and uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. We undertake no obligation to publicly release any revisions to any forward-looking statements in this discussion to reflect events and circumstances occurring after the date hereof or to reflect unanticipated events. Forward-looking statements and our liquidity, financial condition and results of operations may be affected by the risks set forth in Item 1A. Risk Factors or by other unknown risks and uncertainties.

Overview

We acquire, develop and operate ambulatory surgery centers, or “centers” or “ASC”s, in partnership with physicians. As of December 31, 2013, we operated 242 ASCs, of which we owned a majority interest (primarily 51%) in 236 ASCs and a minority interest in six ASCs (three of which are consolidated). The following table presents the number of procedures performed at our continuing centers and changes in the number of ASCs in operation, under development and under letter of intent for the years ended December 31, 2013, 2012 and 2011. An ASC is deemed to be under development when a limited partnership or limited liability company has been formed with the physician partners to develop the ASC.

	2013	2012	2011

Procedures	1,647,353	1,518,707	1,362,415
Continuing centers in operation, end of year (consolidated)	239	235	219
Continuing centers in operation, end of year (unconsolidated)	3	2	2
Average number of continuing centers in operation, during year	236	222	205
New centers added during year	6	18	27
Centers merged into existing centers	1	2	-
Centers discontinued during year	3	4	5
Centers under development, end of year	-	-	1
Centers under letter of intent, end of year	5	2	2

Of the continuing centers in operation at December 31, 2013, 151 centers performed gastrointestinal endoscopy procedures, 48 centers performed procedures in multiple specialties, 36 centers performed ophthalmology surgery procedures, and seven centers performed orthopaedic procedures. We intend to expand primarily through the acquisition and development of additional ASCs and through future same-center growth. During the year ended December 31, 2013, we experienced same-center revenue growth of 1%, which includes the effect of a statutory decrease in reimbursement for procedures associated with worker’s compensation claims at our centers in California and sequestration (see “— Sources of Revenues”). We expect to have a 1% to 2% increase in our same-center revenue for 2014, which includes positive rate adjustments from the Centers for Medicare and Medicaid Services or “CMS” in 2014. Our growth strategy also includes the acquisition and development of additional surgery centers, which on an annual basis would generate additional operating income of $25 million to $29 million. We anticipate that because the majority of these acquisitions would occur in the latter part of 2014, their contribution to our 2014 operating income would not be significant.

While we own less than 100% of each of the entities that own the centers, our consolidated statements of earnings include 100% of the results of operations of each of our consolidated entities, reduced by the noncontrolling partners’ interests share of the net earnings or loss of the surgery center entities. The noncontrolling ownership interest in each limited partnership or limited liability company is generally held directly or indirectly by physicians who perform procedures at the center. Our share of the profits and losses of three non-consolidated entities are reported in equity in earnings of unconsolidated affiliates in our statement of earnings.

Sources of Revenues

very narrow and payments are typically received within 15 to 45 days of billing. Except in certain limited instances, these estimates are not, however, established from billing system generated contractual adjustments based on fee schedules for the patient’s insurance plan for each patient encounter.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations – (continued)

ASCs depend upon third-party reimbursement programs, including governmental and private insurance programs, to pay for substantially all of the services rendered to patients. We derived approximately 25%, 27% and 29% of our revenues in the years ended December 31, 2013, 2012 and 2011, respectively, from governmental healthcare programs, primarily Medicare and managed Medicare programs, and the remainder from a wide mix of commercial payors and patient co-pays and deductibles. The Medicare program currently pays ASCs in accordance with predetermined fee schedules. Our surgery centers are not required to file cost reports and, accordingly, we have no unsettled amounts from governmental third-party payors.

The Budget Control Act of 2011, or “BCA”, requires automatic spending reductions of $1.2 trillion for FFYs 2013 through 2021, minus any deficit reductions enacted by Congress and debt service costs. The percentage reduction for Medicare may not be more than 2% for a FFY, with a uniform percentage reduction across all Medicare programs. These BCA-mandated spending cuts are commonly referred to as "sequestration." Sequestration began on March 1, 2013, and CMS imposed a 2% reduction on Medicare claims as of April 1, 2013. The Bipartisan Budget Act of 2013 extends these reductions through 2023. We cannot predict with certainty what other deficit reduction initiatives may be proposed by Congress, whether Congress will attempt to restructure or suspend sequestration or the impact sequestration may have on our centers. We estimate that the imposed spending reductions reduced our 2013 revenues and net earnings per diluted share by approximately $5.0 million and $0.05, respectively. Based on current volumes, we estimate that the imposed spending reductions will have an incremental negative impact on 2014 revenues of approximately $1.5 million.

The Health Reform Law represents significant change across the healthcare industry. The Health Reform Law contains a number of provisions designed to reduce Medicare program spending, including the annual productivity adjustment discussed above that reduces payment updates to ASCs. However, the Health Reform Law also expands coverage of uninsured individuals through a combination of public program expansion and private sector health insurance reforms. For example, the Health Reform Law has expanded eligibility under existing Medicaid programs in states that have not opted out of the expansion, created financial penalties on individuals who fail to carry insurance coverage, established affordability credits for those not enrolled in an employer-sponsored health plan, resulted in the establishment of, or participation in, a health insurance exchange for each state and allowed states to create federally funded, non-Medicaid plans for low-income residents not eligible for Medicaid. The Health Reform Law also required a number of private health insurance market reforms, including a ban on lifetime limits and pre-existing condition exclusions, new benefit mandates, and increased dependent coverage.

Many health plans are required to cover, without cost-sharing, certain preventive services designated by the U.S. Preventive Services Task Force, including screening colonoscopies. Medicare now covers these preventive services without cost-sharing, and states that provide Medicaid coverage of these preventive services without cost-sharing receive a one percentage point increase in their federal medical assistance percentage for these services.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations – (continued)

that may affect the Company. We are further unable to foresee how individuals and employers will respond to the choices afforded them by the Health Reform Law. Thus, we cannot predict the full impact of the Health Reform Law on the Company at this time.

We expect value-based purchasing programs, including programs that condition reimbursement on patient outcome measures, to become more common and to involve a higher percentage of reimbursement amounts. CMS has promulgated three national coverage determinations that prevent Medicare from paying for certain serious, preventable medical errors performed in any healthcare facility, such as surgery performed on the wrong patient or the wrong site. Several commercial payors also do not reimburse providers for certain preventable adverse events. CMS established a quality reporting program for ASCs under which ASCs that fail to report on certain required quality measures will receive a 2% reduction in reimbursement for calendar year 2014. We have implemented programs and procedures at each of our centers to comply with the quality reporting program prescribed by CMS. Further, as required by the Health Reform Law, HHS reported to Congress on its plan for implementing a value-based purchasing program for ASCs that would tie Medicare payments to quality and efficiency measures. As required by the Health Reform Law, HHS studied whether to expand to ASCs its current policy of not paying additional amounts for care provided to treat conditions acquired during an inpatient hospital stay and reported to Congress that it would not be feasible to expand the policy in its current form, but that further exploration of other payment policies aimed at this same goal should be undertaken.

Critical Accounting Policies

Our accounting policies are described in note 1 of our consolidated financial statements. We prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States, which require us to make estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosures at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. We consider the following policies to be most critical in understanding the judgments that are involved in preparing our financial statements and the uncertainties that could impact our results of operations, financial condition and cash flows.

Principles of Consolidation. The consolidated financial statements include our accounts, our subsidiaries accounts and the consolidated limited partnerships and LLCs. Consolidation of such limited partnerships and LLCs is necessary as our wholly owned subsidiaries have primarily 51% or more of the financial interest, are the general partner or majority member with all the duties, rights and responsibilities thereof, are responsible for the day-to-day management of the limited partnerships and LLCs, and have control of the entities. The responsibilities of our noncontrolling partners (limited partners and noncontrolling members) are to supervise the delivery of medical services, with their rights being restricted to those that protect their financial interests, such as approval of the acquisition of significant assets or the incurrence of debt which they are generally required to guarantee on a pro rata basis based upon their respective ownership interests. Intercompany profits, transactions and balances are eliminated. We also have an ownership interest of less than 51% in six of our limited partnerships and LLC’s, three of which we consolidate as we have substantive participation rights and three of which we do not consolidate as our rights are limited to protective rights only.

We identify and present ownership interests in subsidiaries held by noncontrolling parties in our consolidated financial statements within the equity section but separate from our equity. However, in instances in which certain redemption features that are not solely within our control are present, classification of noncontrolling interests outside of permanent equity is required. The amounts of consolidated net income attributable to us and to the noncontrolling interests are identified and presented on the face of the consolidated statements of earnings; changes in ownership interests are accounted for as equity transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary is measured at fair value. Lastly, the cash flow impact of certain transactions with noncontrolling interests is classified within financing activities.

Upon the occurrence of various fundamental regulatory changes, we would be obligated under the terms of our partnership and operating agreements to purchase the noncontrolling interests related to a majority of our partnerships. We believe that the likelihood of a change in current law that would

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations – (continued)

trigger such purchases was remote as of December 31, 2013, and the occurrence of such regulatory changes is outside of our control. As a result, these noncontrolling interests that are subject to this redemption feature are not included as part of our equity and are classified as noncontrolling interests – redeemable on our consolidated balance sheets.

Center profits and losses are allocated to our partners in proportion to their ownership percentages and reflected in the aggregate as net earnings attributable to noncontrolling interests. The partners of our center partnerships typically are organized as general partnerships, limited partnerships or limited liability companies that are not subject to federal income tax. Each partner shares in the pre-tax earnings of the center in which it is a partner. Accordingly, the earnings attributable to noncontrolling interests in each of our consolidated partnerships are generally determined on a pre-tax basis. Total net earnings attributable to noncontrolling interests are presented after net earnings. However, we consider the impact of the net earnings attributable to noncontrolling interests on earnings before income taxes in order to determine the amount of pre-tax earnings on which we must determine our tax expense. In addition, distributions from the partnerships are made to both our wholly owned subsidiaries and the partners on a pre-tax basis.

Investments in unconsolidated affiliates in which we exert significant influence but do not control or otherwise consolidate are accounted for using the equity method. These investments are included as investments in unconsolidated affiliates in our consolidated balance sheets. Our share of the profits and losses from these investments are reported in equity in earnings of unconsolidated affiliates in our consolidated statement of earnings. We monitor each investment for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the company and record a reduction in carrying value when necessary.

Each of our centers have similar economic characteristics and are aggregated into a single component. We operate this component as one reportable business segment, the ownership and operation of ambulatory surgery centers.

Revenue Recognition. Center revenues consist of billing for the use of the centers’ facilities, or facility fees, directly to the patient or third-party payor, and billing for anesthesia services provided by medical professionals employed or contracted by certain of our centers. Such revenues are recognized when the related surgical procedures are performed. Revenues exclude professional fees billed for physicians’ surgical services, which are billed separately by the physicians to the patient or third-party payor.

Allowance for Contractual Adjustments and Bad Debt Expense. Our revenues are recorded net of estimated contractual adjustments from third-party medical service payors, which we estimate based on historical trends of the surgery centers’ cash collections and contractual write-offs, accounts receivable agings, established fee schedules, contracts with payors and procedure statistics. In addition, we must estimate allowances for bad debt expense using similar information and analysis. These estimates are recorded and monitored monthly for each of our surgery centers as additional revenues are recognized. Our ability to accurately estimate contractual adjustments is dependent upon and supported by the fact that our surgery centers perform and bill for limited types of procedures, that the range of reimbursement for those procedures within each surgery center specialty is very narrow and that payments are typically received within 15 to 45 days of billing. In addition, our surgery centers are not required to file cost reports, and therefore, we have no risk of unsettled amounts from governmental third-party payors. Except in certain limited instances, these estimates are not, however, established from billing system-generated contractual adjustments based on fee schedules for the patient’s insurance plan for each patient encounter. While we believe that our allowances for contractual adjustments and bad debt expense are adequate, if the actual contractual adjustments and write-offs are in excess of our estimates, our results of operations may be overstated. During the years ended December 31, 2013, 2012 and 2011, we had no significant adjustments to our allowances for contractual adjustments and bad debt expense related to prior periods. At December 31, 2013 and 2012, net accounts receivable reflected allowances for contractual adjustments of $289.9 million and $216.4 million, respectively, and allowances for bad debt expense of $27.9 million and $22.4 million, respectively. The increase in our contractual allowance and allowances for bad debt expense is primarily related to allowances established for new centers acquired and increases in standard rates at existing centers during 2013. At December 31, 2013 and 2012, we had 36 and 33 days outstanding, respectively, reflected in our gross accounts receivable. The increase in our days outstanding is due to the acquisition of nine multi-specialty centers in the latter part of 2012, which have a longer collection cycle than the average collection cycle of those centers owned prior to 2012.

Purchase Price Allocation. We allocate the respective purchase price of our acquisitions by first determining the fair value of net tangible and identifiable intangible assets acquired. Secondly, the excess amount of purchase price is allocated to unidentifiable intangible assets (goodwill). The fair value of goodwill attributable to noncontrolling interests in centers acquired subsequent to December 31, 2008, is also reflected in the allocation and is based on significant inputs that are not observable in the market. Key inputs used to determine the fair value include financial multiples used in the purchase of noncontrolling interests in centers. Such multiples, based on earnings, are used as a benchmark for the discount to be applied for the lack of control or marketability. A significant portion of each surgery center’s purchase price historically has been allocated to goodwill due to the nature of the businesses acquired, the pricing and structure of our acquisitions and the absence of other factors indicating any significant value that could be attributable to separately identifiable intangible assets.

Goodwill. We evaluate goodwill for impairment at least on an annual basis. Impairment of carrying value will also be evaluated more frequently if certain indicators are encountered. Goodwill is required to be tested at the reporting unit level, defined as an operating segment or one level below an operating segment (referred to as a component), with the fair value of the reporting unit being compared to its carrying amount, including goodwill. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is not considered to be impaired. We have determined that we have one operating, as well as one reportable, segment. For impairment testing purposes, our centers each qualify as components of that operating segment. Because they have similar economic characteristics, they are aggregated and deemed a single reporting unit. We completed our annual impairment test as required as of December 31, 2013, and have determined that it is not necessary to recognize impairment in our goodwill as our reporting unit fair value is substantially in excess of its carrying value.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations – (continued)

Results of Operations

Our revenues are directly related to the number of procedures performed at our surgery centers. Our overall growth in procedure volume is impacted directly by the increase in the number of surgery centers in operation and the growth in procedure volume at existing centers. We increase our number of surgery centers through both acquisitions and developments. Procedure growth at an existing center may result from additional contracts entered into with third-party payors, increased market share of our physician partners, additional physicians utilizing the center and/or scheduling and operating efficiencies gained at the surgery center. A significant measurement of how much our revenues grow from year to year for existing centers is our same-center revenue percentage. We define our same-center group each year as those centers that contain full year-to-date operations in both comparable reporting periods, including the expansion of the number of operating centers associated with a limited partnership or limited liability company. Our 2013 same-center group, comprised of 218 centers and constituting approximately 90% of our total number of centers, had 1% revenue growth during the year ended December 31, 2013. Our same-center group in 2014 will be comprised of 234 centers, which constitutes approximately 97% of our total number of centers. We expect to have a 1% to 2% increase in our same-center revenue for 2014, which includes positive rate adjustments from CMS.

Expenses directly and indirectly related to procedures performed at our surgery centers include clinical and administrative salaries and benefits, supply cost and other operating expenses such as linen cost, repair and maintenance of equipment, billing fees and bad debt expense. The majority of our corporate salary and benefits cost is associated directly with the number of centers we own and manage and tends to grow in proportion to the growth of our centers in operation. Our centers and corporate offices also incur costs that are more fixed in nature, such as lease expense, legal fees, property taxes, utilities and depreciation and amortization.

Surgery center profits are allocated to our noncontrolling partners in proportion to their individual ownership percentages and reflected in the aggregate as total net earnings attributable to noncontrolling interests and are presented after net earnings. The noncontrolling partners of our center limited partnerships and limited liability companies typically are organized as general partnerships, limited partnerships or limited liability companies that are not subject to federal income tax. Each noncontrolling partner shares in the pre-tax earnings of the center of which it is a partner. Accordingly, net earnings attributable to the noncontrolling interests in each of our center limited partnerships and limited liability companies are generally determined on a pre-tax basis, and pre-tax earnings are presented before net earnings attributable to noncontrolling interests have been subtracted.

Accordingly, the effective tax rate on pre-tax earnings as presented is approximately 16%. However, the effective tax rate based on pre-tax earnings attributable to AmSurg Corp. common shareholders, on an annual basis, will remain near the historical percentage of 40%. We file a consolidated federal income tax return and numerous state income tax returns with varying tax rates. Our income tax expense reflects the blending of these rates.

Our interest expense results primarily from our borrowings used to fund acquisition and development activity, as well as interest incurred on capital leases.

Net earnings from continuing operations attributable to AmSurg Corp. common shareholders are disclosed on the consolidated statements of earnings.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations – (continued)

The following table shows certain statement of earnings items expressed as a percentage of revenues for the years ended December 31, 2013, 2012 and 2011:

			2013	2012	2011

Revenues			100.0%	100.0%	100.0%

Operating expenses:
	Salaries and benefits		30.9	31.4	30.9
	Supply cost		14.6	14.2	13.2
	Other operating expenses		20.6	20.9	21.8
	Depreciation and amortization		3.1	3.3	3.3

		Total operating expenses	69.2	69.8	69.2

Gain on deconsolidation			0.2	-	-
Equity in earnings of unconsolidated affiliates			0.3	0.2	0.1

		Operating income	31.3	30.4	30.9

Interest expense			2.7	1.8	2.0

	Earnings from continuing operations before income taxes		28.6	28.6	28.9

Income tax expense			4.6	4.6	4.5

	Net earnings from continuing operations		24.0	24.0	24.4

Discontinued operations:
	Earnings from operations of discontinued interests in surgery centers,
		net of income tax	-	0.2	0.4
	Gain (loss) on disposal of discontinued interests in surgery centers, net of income tax		0.2	-	(0.2)

		Net earnings from discontinued operations	0.2	0.2	0.2

		Net earnings	24.2	24.2	24.6

Less net earnings attributable to noncontrolling interests:
	Net earnings from continuing operations		17.2	17.2	17.9
	Net earnings from discontinued operations		0.3	0.2	0.2

		Total net earnings attributable to noncontrolling interests	17.5	17.4	18.1

		Net earnings attributable to AmSurg Corp. common shareholders	6.7%	6.8%	6.5%

Amounts attributable to AmSurg Corp. common shareholders:
	Earnings from continuing operations, net of income tax		6.7%	6.7%	6.5%
	Discontinued operations, net of income tax		-	0.1	-

		Net earnings attributable to AmSurg Corp. common shareholders	6.7%	6.8%	6.5%

Year Ended December 31, 2013 Compared to Year Ended December 31, 2012

The number of procedures performed in our ASCs increased by 128,646, or 8%, to 1,647,353 in 2013 from 1,518,707 in 2012. Revenues increased $156.2 million, or 17%, to $1.079 billion in 2013 from $923.2 million in 2012. The increase in procedures and revenues resulted primarily from:

· centers acquired or opened in 2012, which contributed $136.8 million of additional revenues during the year ended December 31, 2013 due to having a full period of operations in 2013;

· $5.4 million of revenue growth for the year ended December 31, 2013, recognized by our 2013 same-center group, reflecting a 1% increase, primarily as a result of procedure growth and net of the negative impact of sequestration and the reduced reimbursement rates of the California workers’ compensation program; and

· centers acquired in 2013, which generated $12.3 million in revenues during the year ended December 31, 2013.

The percentage increase in revenues in excess of the percentage increase in procedures is due primarily to the centers acquired in the latter half of 2012, the majority of which are multi-specialty centers and which have a higher average net revenue per procedure than the mix of centers we operated during the full year of 2012.

Salaries and benefits increased in total by 15% to $333.2 million in 2013, from $290.1 million in 2012. Salaries and benefits as a percentage of revenues decreased by 50 basis points in the year ended December 31, 2013, compared to the year ended December 31, 2012, primarily due to the centers acquired in the latter half of 2012, which operate with lower staffing costs as a percentage of revenue than the centers owned in 2012. Staff at

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations – (continued)

newly acquired and developed centers, as well as the additional staffing required at existing centers, resulted in a 16% increase in salaries and benefits at our surgery centers during the year ended December 31, 2013. Furthermore, we experienced a 11% increase in salaries and benefits at our corporate offices during 2013 over 2012 due to additional equity compensation expense, additional staff employed to manage additional centers and the impact of annual salary adjustments.

Supply cost was $157.8 million in 2013, an increase of $26.7 million, or 20%, compared to supply cost in 2012. This increase was primarily the result of additional procedure volume and an increase in our average supply cost per procedure by 11% in 2013. The increase in our average supply cost per procedure is a result of the acquisition of nine multi-specialty centers acquired in the latter part of 2012, which generally have higher supply cost per procedure than single specialty centers, due to a higher mix of orthopaedic procedures.

Other operating expenses increased $29.7 million, or 15%, to $222.7 million during 2013, from $193.0 million in 2012. The additional expense in the 2013 period resulted primarily from:

· centers acquired or opened during 2012, which resulted in an increase of $23.1 million in other operating expenses during 2013;

· an increase of $4.0 million in other operating expenses at our 2013 same-center group resulting primarily from general inflationary cost increases; and

· centers acquired during 2013, which resulted in an increase of approximately $3.0 million in other operating expenses.

Depreciation and amortization increased $3.2 million, or 11%, in 2013 over 2012, primarily as a result of centers acquired during 2012 and 2013.

We anticipate further increases in operating expenses in 2014, primarily due to additional acquired centers and potential additional start-up centers.

During 2013, we contributed a controlling interest in one center in exchange for a noncontrolling interest in an entity that, after the completion of the transaction, controls the contributed center and one additional center. As a result of the transaction, we recognized a gain on deconsolidation of approximately $2.2 million. Such gain was determined based on the difference between the fair value of our noncontrolling interest in the new entity and the carrying value of both the tangible and intangible assets of the contributed center immediately prior to the transaction. Subsequent to the completion of this transaction, the center contributed by the Company was merged into the acquired center.

Interest expense increased $12.6 million, or 74%, to $29.5 million in 2013 from $17.0 million during 2012 primarily due to the issuance in November 2012 of $250.0 million principal amount of 5.625% senior unsecured notes (the “Senior Unsecured Notes”) and a 2% interest rate increase effective in November 2012 for our senior secured notes. The impact of higher interest rates on our Senior Unsecured Notes and senior secured notes was mitigated in part by an amendment to our revolving credit facility, which lowered the interest rate under our credit agreement by approximately 25 basis points effective June 2012. We further amended our revolving credit agreement in June 2013 to extend the maturity date an additional year and to further reduce the interest rate. We expect that the interest rate under our credit agreement will be reduced by approximately 25 to 50 basis points, depending on our leverage ratio. See “— Liquidity and Capital Resources.”

We recognized income tax expense of $49.8 million in 2013 compared to $42.4 million in 2012. Our effective tax rate in 2013 was 16.1% of earnings from continuing operations before income taxes. This differs from the federal statutory income tax rate of 35.0% primarily due to the exclusion of the noncontrolling interests’ share of pre-tax earnings and the impact of state income taxes. Because we deduct goodwill amortization for tax purposes only, more than 60% of our income tax expense is deferred and our deferred tax liability continues to increase, which would only be due in part or in whole upon the disposition of a portion or all of our surgery centers.

During 2013, we classified three surgery centers in discontinued operations, of which two centers were sold and one center was closed during the year. We pursued the disposition of these centers due to our assessment of their limited growth opportunities. These centers’ results of operations and gains and losses associated with their dispositions have been classified as discontinued operations in all periods presented. We recognized an after tax gain on the disposition of interests in discontinued surgery centers of $2.6 million and $25,000 during the years ended December 31, 2013 and 2012, respectively. The net earnings derived from the operations of the discontinued surgery centers was $169,000 and $2.2 million during the year ended December 31, 2013 and 2012, respectively.

Noncontrolling interests in net earnings for 2013 increased $27.8 million, or 17%, from 2012, primarily as a result of noncontrolling interests in earnings at surgery centers added to operations. As a percentage of revenues, noncontrolling interests increased slightly to 17.5% during 2013 from 17.4% during 2012. The net earnings from discontinued operations attributable to noncontrolling interests were $2.7 million and $1.9 million during the years ended December 31, 2013 and 2012, respectively.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations – (continued)

Year Ended December 31, 2012 Compared to Year Ended December 31, 2011

The number of procedures performed in our ASCs increased by 156,292, or 11%, to 1,518,707 in 2012 from 1,362,415 in 2011. Revenues increased $151.1 million, or 20%, to $923.2 million in 2012 from $772.1 million in 2011. The increase in procedures and revenues resulted primarily from:

· centers acquired or opened in 2011, which contributed $114.3 million of additional revenues during the year ended December 31, 2012 due to having a full period of operations in 2012;

· $23.4 million of revenue growth for the year ended December 31, 2012, recognized by our 2012 same-center group, reflecting a 3% increase, primarily as a result of procedure growth; and

· centers acquired in 2012, which generated $11.2 million in revenues during the year ended December 31, 2012.

The percentage increase in revenues in excess of the percentage increase in procedures is due primarily to the centers acquired in the latter half of 2011 and 2012, the majority of which are multi-specialty centers and which have a higher average net revenue per procedure than the mix of centers we operated during the full year of 2011.

Salaries and benefits increased in total by 22% to $290.1 million in 2012, from $238.7 million in 2011. Salaries and benefits as a percentage of revenues increased by 50 basis points in the year ended December 31, 2012, compared to December 31, 2011. Staff at newly acquired and developed centers, as well as the additional staffing required at existing centers, resulted in a 20% increase in salaries and benefits at our surgery centers during the year ended December 31, 2012. Furthermore, we experienced a 29% increase in salaries and benefits at our corporate offices during 2012 over 2011 due to higher bonus expense in 2012 as compared to 2011, additional equity compensation expense, additional staff employed to manage additional centers and the impact of annual salary adjustments.

Supply cost was $131.1 million in 2012, an increase of $29.7 million, or 29%, compared to supply cost in 2011. This increase was the result of additional procedure volume and an increase in our average supply cost per procedure by 16% in 2012. The increase in our average supply cost per procedure is a result of the acquisition of 17 multi-specialty centers acquired in the latter part of 2011, which generally have higher supply cost per procedure than single specialty centers and an increase in certain drug costs at our gastroenterology centers due to supply shortages.

Other operating expenses increased $24.7 million, or 15%, to $193.0 million during 2012, from $168.3 million in 2011. The additional expense in the 2012 period resulted primarily from:

· centers acquired or opened during 2011, which resulted in an increase of $23.4 million in other operating expenses during 2012;

· an increase of $4.2 million in other operating expenses at our 2012 same-center group resulting primarily from general inflationary cost increases; and

· centers acquired during 2012, which resulted in an increase of approximately $2.6 million in other operating expenses.

Additionally, other operating expenses for 2011 included $3.5 million of transaction related costs associated with the acquisition of 17 centers from National Surgical Care, Inc. (“NSC”).

Depreciation and amortization increased $4.2 million, or 16%, in 2012 over 2011, primarily as a result of centers acquired during 2011 and 2012.

Interest expense increased $1.6 million, or 11%, to $17.0 million in 2012 from $15.3 million during 2011 primarily due to the issuance in November 2012 of $250.0 million principal amount of the Senior Unsecured Notes and a 2% interest rate increase associated with our senior secured notes effective November 2012. The impact of higher interest rates on our Senior Unsecured Notes and senior secured notes was mitigated in part by an amendment to our revolving credit facility, which lowered the interest rate under our credit agreement by approximately 25 basis points effective June 2012. See “— Liquidity and Capital Resources.”

We recognized income tax expense of $42.4 million in 2012 compared to $35.0 million in 2011. Our effective tax rate in 2012 was 16.1% of earnings from continuing operations before income taxes. This differs from the federal statutory income tax rate of 35.0% primarily due to the exclusion of the noncontrolling interests’ share of pre-tax earnings and the impact of state income taxes

During 2012, we classified four surgery centers in discontinued operations, of which three centers were sold and one center was closed during the year. We pursued the disposition of these centers due to our assessment of their limited growth opportunities. These centers’ results of operations and gains and losses associated with their dispositions have been classified as discontinued operations in all periods presented. We recognized an after tax gain on the disposition of interests in discontinued surgery centers of $25,000 during 2012 and an after-tax loss on disposition of discontinued interests in surgery centers of $1.5 million in 2011. The net earnings derived from the operations of the discontinued surgery centers was $2.2 million and $3.4 million during the years ended December 31, 2012 and 2011, respectively.

Noncontrolling interests in net earnings for 2012 increased $21.0 million, or 15%, from 2011, primarily as a result of noncontrolling interests in earnings at surgery centers added to operations. As a percentage of revenues, noncontrolling interests decreased to 17.4% during 2012 from 18.1% as a result of us owning a higher ownership percentage in centers acquired over the past year. The net earnings from discontinued operations attributable to noncontrolling interests were $1.9 million and $1.8 million during the years ended December 31, 2012 and 2011, respectively.

Liquidity and Capital Resources

Cash and cash equivalents at December 31, 2013 and 2012 were $50.8 million and $46.4 million, respectively. At December 31, 2013, we had working capital of $121.1 million, compared to $107.8 million at December 31, 2012. Operating activities for 2013 generated $332.8 million in cash

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations – (continued)

flow from operations compared to $295.7 million in 2012. The increase in operating cash flow resulted primarily from higher net earnings during 2013 compared to 2012 and a reduction in taxes paid in 2013 compared to 2012 due to additional goodwill amortization as a result of centers acquired in the latter half of 2012, offset by an increase of three days in our outstanding accounts receivable. Positive operating cash flows of individual centers are the sole source of cash used to make distributions to our wholly-owned subsidiaries, as well as to the partners, which we are obligated to make on a monthly basis in accordance with each partnership’s partnership or operating agreement. Distributions to noncontrolling interests in the years ended December 31, 2013 and 2012 were $184.1 million and $162.9 million, respectively. Distributions to noncontrolling interests increased $21.2 million, or 13%, primarily as a result of additional centers in operation.

The principal source of our operating cash flow is the collection of accounts receivable from commercial payors, governmental payors and individuals. Each of our surgery centers bills for services as delivered, usually within several days following the date of the procedure. Generally, unpaid amounts that are 30 days past due are rebilled based on a standard set of procedures. If amounts remain uncollected after 60 days, our surgery centers proceed with a series of late-notice notifications until amounts are either collected, contractually written off in accordance with contracted rates or determined to be uncollectible, typically after 90 to 120 days. Receivables determined to be uncollectible are written off and such amounts are applied to our estimate of allowance for bad debts as previously established in accordance with our policy for bad debt expense. The amount of actual write-offs of account balances for each of our surgery centers is continuously compared to established allowances for bad debt to ensure that such allowances are adequate. At December 31, 2013 and 2012, our accounts receivable represented 36 and 33 days of revenue outstanding, respectively. The increase in our days outstanding is due to the acquisition of nine multi-specialty centers in the latter part of 2012, which have a longer collection cycle than the average collection cycle of those centers owned prior to 2012.

During 2013, we had total acquisitions and capital expenditures of $102.5 million, which included:

· $73.6 million for acquisitions of interests in ASCs and related transactions; and

· $29.6 million for new or replacement property at existing centers, including $700,000 in new capital leases.

As of December 31, 2013, we had unfunded construction and equipment purchase commitments for centers under development or under renovation of approximately $953,000, which we intend to fund through additional borrowings of long-term debt, operating cash flow and capital contributions by our partners. During 2013, we received approximately $300,000 in capital contributions by our partners.

As of December 31, 2012, we had a contingent purchase price obligation of $2.7 million. During 2013, we paid $2.7 million to NSC as final settlement of such obligation.

We received approximately $3.6 million from the sale of our interests in three surgery centers during the year ended December 31, 2013. During 2012, we received approximately $7.3 million from the sale of our interest in three surgery centers. Cash from the sales was used to repay long-term debt.

On June 29, 2012, we amended our revolving credit agreement, which we utilize to, among other things, finance our acquisition and development projects and stock repurchase programs. As a result of the amendment, the availability under the credit agreement was increased $25.0 million to $475.0 million, the maturity date was extended and our interest rate spreads on our LIBOR option were reduced. On November 7, 2012, we further amended our revolving credit agreement and amended the note purchase agreement relating to our senior secured notes to allow for our issuance of the Senior Unsecured Notes (discussed below) and revise certain existing covenants. In connection with the amendment of the note purchase agreement relating to our senior secured notes, the interest rate on our senior secured notes increased to 8.04% from 6.04%. On June 14, 2013, we further amended our revolving credit agreement to adjust the interest rate spreads and extend the maturity date by one year from June 2017 to June 2018; and the interest rate spread on our LIBOR option was reduced to LIBOR plus 1.25% to 2.0% from LIBOR plus 1.50% to 2.25%. At December 31, 2013, we had $222.5 million available under our revolving credit agreement.

On November 20, 2012, we completed a private offering of the Senior Unsecured Notes. The net proceeds from the issuance of the Senior Unsecured Notes were used to pay down a portion of the outstanding obligations on our credit facility. The Senior Unsecured Notes are pari passu in right of payment with our existing and future senior debt and senior to our existing and future subordinated debt. Interest accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on May 30^th and November 30^th through the maturity date on November 30, 2020. At December 31, 2013, we had approximately $1.2 million in accrued interest associated with the Senior Unsecured Notes reflected in other accrued liabilities. The Senior Unsecured Notes contain certain covenants which, among other things, limit our ability to enter into or guarantee additional borrowing, sell preferred stock, pay dividends and repurchase stock, in each case subject to certain exceptions. In May 2013, the Company completed an exchange of the outstanding Senior Unsecured Notes for an equal amount of such notes that are registered under the Securities Act of 1933, as amended.

During the year ended December 31, 2013, we had net repayments on long-term debt of $39.9 million. At December 31, 2013, we had $252.5 million outstanding under our revolving credit agreement, $250.0 million outstanding pursuant to our Senior Unsecured Notes and $69.6 million outstanding pursuant to our senior secured notes. Our senior secured notes began to amortize in quarterly installments beginning in August 2013. As of December 31, 2013, we were in compliance with all covenants contained in our revolving credit agreement, the note purchase agreement governing our senior secured notes and the indenture governing our Senior Unsecured Notes.

During the year ended December 31, 2013, we received approximately $33.3 million from the exercise of stock options under our employee stock incentive plans. As a result of the exercise of those options and the vesting of restricted stock, we generated an excess tax benefit of $7.2 million, which combined with the $4.9 million of deferred tax assets previously recorded upon the initial expensing of these instruments, resulted in a $12.1 million reduction in our taxes payable.

On April 24, 2012, the Board of Directors authorized a stock purchase program for up to $40.0 million of our shares of common stock. We completed this repurchase program in August 2013. On August 9, 2013, our Board of Directors approved a stock repurchase program for up to $40.0

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations – (continued)

million of our shares of common stock to be purchased through February 9, 2015. As of December 31, 2013, there was approximately $27.1 million available under the stock repurchase program. We intend to fund the purchase price for shares acquired under the plan using cash generated from the proceeds received when employees exercise stock options, cash generated from our operations or borrowings under our revolving credit facility.

During the year ended December 31, 2013, we repurchased 1,154,378 shares for $42.7 million to mitigate the dilutive effect of shares issued pursuant to stock option exercises. In addition, we repurchased 102,252 shares with a value of approximately $3.3 million to cover payroll withholding taxes in connection with the vesting of restricted stock awards in accordance with the restricted stock agreements.

In December of 2012, we entered into a lease agreement with an initial term of 15 years plus renewal options pursuant to which we have agreed to lease an approximately 110,000 square foot building to be constructed in Nashville, Tennessee. We intend that the building will serve as our corporate headquarters beginning in 2015. Our annual rental obligation at the inception of the lease will be approximately $2.3 million and will increase by 1.9% annually thereafter during the initial term. In addition to base rent, we will pay additional rent consisting of, among other things, operating expenses, real estate taxes and insurance costs. The landlord will provide us with an allowance of approximately $4,400,000 for certain interior tenant improvements. During 2014, we expect to incur additional capital expenditures of approximately $10.0 million related to our corporate move, which includes the costs of furniture, equipment and additional tenant improvements. We intend to fund these purchases using cash generated from our operations or borrowings under our revolving credit facility.

The following schedule summarizes our contractual obligations by period as of December 31, 2013 (in thousands):

	Payments Due by Period
			Less than						More than
	Total		1 Year		1-3 Years		3-5 Years		5 Years

Long-term debt, including interest (1)	$	733,383	$	44,300	$	77,161	$	317,318	$	294,604
Capital lease obligations, including interest		14,304		2,039		3,077		2,184		7,004
Operating leases, including renewal option periods (2)		583,012		47,704		92,329		88,892		354,087
Construction in progress commitments		953		953		-		-		-
Liability for unrecognized tax benefits		6,888		-		6,888		-		-

Total contractual cash obligations	$	1,338,540	$	94,996	$	179,455	$	408,394	$	655,695

(1)	Our long-term debt may increase based on future acquisition activity. We will use our operating cash flow to repay our existing long-term debt under our revolving credit facility, our senior secured notes and our Senior Unsecured Notes prior to or on their maturity dates.
(2)	Operating lease obligations do not include common area maintenance, or CAM, insurance or tax payments for which we were also obligated. Total expense related to CAM, insurance and taxes for 2013 was approximately $8.6 million.

In addition, as of February 26, 2014, we had available under our revolving credit agreement $189.0 million for acquisition borrowings.

Based upon our current operations and anticipated growth, we believe our operating cash flow and borrowing capacity will be adequate to meet our working capital and capital expenditure requirements for the next 12 to 18 months. In addition to acquiring and developing single ASCs, we may from time to time consider other acquisitions or strategic joint ventures involving other companies, multiple-center chains or networks of ASCs. Such acquisitions, joint ventures or other opportunities may require an amendment to our current debt agreements or additional external financing. As previously discussed, we cannot assure you that any required financing will be available, or will be available on terms acceptable to us.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

We are subject to market risk primarily from exposure to changes in interest rates based on our financing, investing and cash management activities. We utilize a balanced mix of maturities along with both fixed rate and variable rate debt to manage our exposures to changes in interest rates. Our variable debt instruments are primarily indexed to the prime rate or LIBOR. Interest rate changes would result in gains or losses in the market value of our fixed rate debt portfolio due to differences in market interest rates and the rates at the inception of the debt agreements. Based upon our indebtedness at December 31, 2013, a 100 basis point interest rate change would impact our net earnings and cash flow by approximately $1.5 million annually. Although there can be no assurances that interest rates will not change significantly, we do not expect changes in interest rates to have a material effect on our net earnings or cash flows in 2014.

In November of 2012, we issued $250.0 million principal amount of the Senior Unsecured Notes. The issuance of the Senior Unsecured Notes and the amendment to our senior secured notes resulted in an increase in our interest paid in 2013 compared to 2012. Also in 2012, in connection with the issuance of the Senior Unsecured Notes, we amended our senior secured notes which resulted in an increase in the applicable interest rate from 6.04% to 8.04%.

The table below provides information as of December 31, 2013 about our long-term debt obligations based on maturity dates that are sensitive to changes in interest rates, including principal cash flows and related weighted average interest rates by expected maturity dates (in thousands, except percentage data):

																Fair
																Value at
		Years Ended December 31,														December 31,
		2014		2015		2016		2017		2018		Thereafter		Total		2013

Fixed rate		$	20,134	$	17,119	$	14,325	$	13,097	$	12,206	$	272,077	$	348,958	$	364,349
Average interest
	rate		6.1%		6.4%		7.0%		7.4%		7.6%		5.8%

Variable rate		$	710	$	632	$	578	$	325	$	252,831	$	108	$	255,184	$	255,184
Average interest
	rate		3.1%		3.2%		3.1%		2.5%		2.1%		2.5%

The average interest rates on these borrowings at December 31, 2013 remained consistent as compared to December 31, 2012. The maturities of our long term debt remain relatively consistent from 2012 to 2013. The overall reduction in our total borrowings from 2012 to 2013 principally resulted from the use of our cash flow generated from operations to pay down our revolving credit facility.

Item 8. Financial Statements and Supplementary Data

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders of

AmSurg Corp.
Nashville, Tennessee

We have audited the accompanying consolidated balance sheets of AmSurg Corp. and subsidiaries (the "Company") as of December 31, 2013 and 2012, and the related consolidated statements of earnings, comprehensive income, changes in equity, and cash flows for each of the three years in the period ended December 31, 2013. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, such consolidated financial statements present fairly, in all material respects, the financial position of AmSurg Corp. and subsidiaries as of December 31, 2013 and 2012, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2013, in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the Company's internal control over financial reporting as of December 31, 2013, based on the criteria established in Internal Control—Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 26, 2014 expressed an unqualified opinion on the Company's internal control over financial reporting.

/s/ DELOITTE & TOUCHE LLP

Nashville, Tennessee
February 26, 2014

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Consolidated Balance Sheets

December 31, 2013 and 2012

(In thousands)

				2013		2012

Assets

Current assets:
	Cash and cash equivalents			$	50,840	$	46,398
	Accounts receivable, net of allowance of $27,862 and $22,379, respectively				105,072		96,752
	Supplies inventory				18,414		18,406
	Deferred income taxes				3,097		3,088
	Prepaid and other current assets				33,602		27,537

			Total current assets		211,025		192,181

Property and equipment, net					169,895		166,612
Investments in unconsolidated affiliates and long-term notes receivable					16,392		11,274
Goodwill					1,758,970		1,652,002
Intangible assets, net					21,662		22,517

			Total assets	$	2,177,944	$	2,044,586

Liabilities and Equity

Current liabilities:
	Current portion of long-term debt			$	20,844	$	17,407
	Accounts payable				27,501		23,509
	Accrued salaries and benefits				32,294		29,251
	Other accrued liabilities				9,231		14,246

			Total current liabilities		89,870		84,413

Long-term debt					583,298		620,705
Deferred income taxes					176,020		137,648
Other long-term liabilities					25,503		25,972
Commitments and contingencies
Noncontrolling interests – redeemable					177,697		175,382
Preferred stock, no par value, 5,000 shares authorized, no shares issued or outstanding					-		-

Equity:
	Common stock, no par value, 70,000 shares authorized, 32,353 and 31,941
		shares outstanding, respectively			185,873		183,867
	Retained earnings				578,324		505,621

			Total AmSurg Corp. equity		764,197		689,488
			Noncontrolling interests – non-redeemable		361,359		310,978

			Total equity		1,125,556		1,000,466

			Total liabilities and equity	$	2,177,944	$	2,044,586

See accompanying notes to the consolidated financial statements.

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Consolidated Statements of Earnings

Years Ended December 31, 2013, 2012 and 2011

(In thousands, except earnings per share)

					2013		2012		2011

Revenues					$	1,079,343	$	923,182	$	772,075

Operating expenses:
	Salaries and benefits					333,190		290,063		238,738
	Supply cost					157,771		131,055		101,364
	Other operating expenses					222,677		193,025		168,347
	Depreciation and amortization					33,028		29,850		25,645

				Total operating expenses		746,666		643,993		534,094

Gain on deconsolidation						2,237		-		-
Equity in earnings of unconsolidated affiliates						3,151		1,564		613

				Operating income		338,065		280,753		238,594

Interest expense						29,538		16,967		15,327

	Earnings from continuing operations before income taxes					308,527		263,786		223,267

Income tax expense						49,754		42,364		34,973

	Net earnings from continuing operations					258,773		221,422		188,294

Discontinued operations:
	Earnings from operations of discontinued interests in surgery centers,
		net of income tax				169		2,196		3,363
	Gain (loss) on disposal of discontinued interests in surgery centers, net of income tax					2,602		25		(1,543)

			Net earnings from discontinued operations			2,771		2,221		1,820

	Net earnings					261,544		223,643		190,114

Less net earnings attributable to noncontrolling interests:
	Net earnings from continuing operations					186,120		159,187		138,269
	Net earnings from discontinued operations					2,721		1,893		1,848

			Total net earnings attributable to noncontrolling interests			188,841		161,080		140,117

			Net earnings attributable to AmSurg Corp. common shareholders		$	72,703	$	62,563	$	49,997

Amounts attributable to AmSurg Corp. common shareholders:
	Earnings from continuing operations, net of income tax				$	72,653	$	62,235	$	50,025
	Discontinued operations, net of income tax					50		328		(28)

				Net earnings attributable to AmSurg Corp. common shareholders	$	72,703	$	62,563	$	49,997

Earnings per share-basic:
	Net earnings from continuing operations attributable to
		AmSurg Corp. common shareholders			$	2.32	$	2.02	$	1.64
	Net earnings from discontinued operations attributable to
		AmSurg Corp. common shareholders				-		0.01		-

			Net earnings attributable to AmSurg Corp. common shareholders		$	2.32	$	2.03	$	1.64

Earnings per share-diluted:
	Net earnings from continuing operations attributable to
		AmSurg Corp. common shareholders			$	2.27	$	1.97	$	1.60
	Net earnings from discontinued operations attributable to
		AmSurg Corp. common shareholders				-		0.01		-

			Net earnings attributable to AmSurg Corp. common shareholders		$	2.28	$	1.98	$	1.60

Weighted average number of shares and share equivalents outstanding:
	Basic					31,338		30,773		30,452
	Diluted					31,954		31,608		31,211

See accompanying notes to the consolidated financial statements.

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Consolidated Statements of Comprehensive Income

Years Ended December 31, 2013, 2012 and 2011

(In thousands)

			2013		2012		2011

Net earnings			$	261,544	$	223,643	$	190,114

Other comprehensive income, net of income tax:
	Unrealized gain on interest rate swap, net of income tax			-		-		515

		Comprehensive income, net of income tax		261,544		223,643		190,629

	Less comprehensive income attributable to noncontrolling interests			188,841		161,080		140,117

		Comprehensive income attributable to AmSurg Corp. common shareholders	$	72,703	$	62,563	$	50,512

See accompanying notes to the consolidated financial statements.

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Consolidated Statements of Changes in Equity

Years Ended December 31, 2013, 2012 and 2011

(In thousands)

			AmSurg Corp. Shareholders
														Non-
										Non-				Controlling
								Accumulated		Controlling				Interests –
								Other		Interests –		Total		Redeemable
			Common Stock			Retained		Comprehensive		Non-		Equity		(Temporary		Net
			Shares	Amount		Earnings		Income (Loss)		Redeemable		(Permanent)		Equity)		Earnings

Balance at January 1, 2011			31,040	$	171,522	$	393,061	$	(515)	$	12,799	$	576,867	$	147,740
	Issuance of restricted common stock		277		-		-		-		-		-		-
	Cancellation of restricted common stock		(1)		(9)		-		-		-		(9)		-
	Stock options exercised		374		6,872		-		-		-		6,872		-
	Stock repurchased		(406)		(10,007)		-		-		-		(10,007)		-
	Share-based compensation		-		6,178		-		-		-		6,178		-
	Tax benefit related to exercise
		of stock options	-		649		-		-		-		649		-
	Net earnings		-		-		49,997		-		10,181		60,178		129,936	$	190,114
	Distributions to noncontrolling
		interests, net of capital contributions	-		-		-		-		(9,502)		(9,502)		(129,979)
	Purchase of noncontrolling interest		-		195		-		-		(817)		(622)		(788)
	Sale of noncontrolling interest		-		(1,702)		-		-		439		(1,263)		1,771
	Acquisitions and other transactions
		impacting noncontrolling interests	-		-		-		-		122,276		122,276		21,390
	Disposals and other transactions
		impacting noncontrolling interests	-		(511)		-		-		(3,154)		(3,665)		566
	Gain on interest rate swap, net of
		income tax expense of $332	-		-		-		515		-		515		-

Balance at December 31, 2011			31,284		173,187		443,058		-		132,222		748,467		170,636
	Issuance of restricted common stock		281		-		-		-		-		-		-
	Cancellation of restricted common stock		(2)		-		-		-		-		-		-
	Stock options exercised		842		18,214		-		-		-		18,214		-
	Stock repurchased		(464)		(13,101)		-		-		-		(13,101)		-
	Share-based compensation		-		6,692		-		-		-		6,692		-
	Tax benefit related to exercise
		of stock options	-		1,834		-		-		-		1,834		-
	Net earnings		-		-		62,563		-		26,303		88,866		134,777	$	223,643
	Distributions to noncontrolling
		interests, net of capital contributions	-		-		-		-		(26,514)		(26,514)		(136,356)
	Purchase of noncontrolling interest		-		252		-		-		(421)		(169)		(81)
	Sale of noncontrolling interest		-		(2,794)		-		-		4,352		1,558		-
	Acquisitions and other transactions
		impacting noncontrolling interests	-		-		-		-		175,036		175,036		7,038
	Disposals and other transactions
		impacting noncontrolling interests	-		(417)		-		-		-		(417)		(632)

Balance at December 31, 2012			31,941	$	183,867	$	505,621	$	-	$	310,978	$	1,000,466	$	175,382

See accompanying notes to the consolidated financial statements.

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Consolidated Statements of Changes in Equity – (continued)

Years Ended December 31, 2013, 2012 and 2011

(In thousands)

			AmSurg Corp. Shareholders
														Non-
										Non-				Controlling
								Accumulated		Controlling				Interests –
								Other		Interests –		Total		Redeemable
			Common Stock			Retained		Comprehensive		Non-		Equity		(Temporary		Net
			Shares	Amount		Earnings		Income (Loss)		Redeemable		(Permanent)		Equity)		Earnings

Balance at December 31, 2012			31,941	$	183,867	$	505,621	$	-	$	310,978	$	1,000,466	$	175,382
	Issuance of restricted common stock		292		-		-		-		-		-		-
	Cancellation of restricted common stock		(16)		-		-		-		-		-		-
	Stock options exercised		1,393		33,349		-		-		-		33,349		-
	Stock repurchased		(1,257)		(45,964)								(45,964)
	Share-based compensation		-		8,321		-		-		-		8,321		-
	Tax benefit related to exercise
		of stock options	-		7,247		-		-		-		7,247		-
	Net earnings		-		-		72,703		-		49,789		122,492		139,052	$	261,544
	Distributions to noncontrolling
		interests, net of capital contributions	-		-		-		-		(49,533)		(49,533)		(134,298)
	Purchase of noncontrolling interest		-		679		-		-		(1,926)		(1,247)		(319)
	Sale of noncontrolling interest		-		(1,626)		-		-		2,327		701		852
	Acquisitions and other transactions
		impacting noncontrolling interests	-		-		-		-		50,041		50,041		-
	Disposals and other transactions
		impacting noncontrolling interests	-		-		-		-		(317)		(317)		(2,972)

Balance at December 31, 2013			32,353	$	185,873	$	578,324	$	-	$	361,359	$	1,125,556	$	177,697

See accompanying notes to the consolidated financial statements.

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Consolidated Statements of Cash Flows

Years Ended December 31, 2013, 2012 and 2011

(In thousands)

							2013		2012		2011

Cash flows from operating activities:
	Net earnings						$	261,544	$	223,643	$	190,114
	Adjustments to reconcile net earnings to net cash flows provided by
		operating activities:
			Depreciation and amortization					33,028		29,850		25,645
			Net gain on sale of long-lived assets					(1,468)		(1,065)		(1,518)
			Gain on deconsolidation					(2,237)		-		-
			Share-based compensation					8,321		6,692		6,178
			Excess tax benefit from share-based compensation					(7,247)		(1,784)		(977)
			Deferred income taxes					38,363		24,558		23,623
			Equity in earnings of unconsolidated affiliates					(3,151)		(1,564)		(613)
			Increase (decrease) in cash and cash equivalents, net of effects of acquisitions and
				dispositions, due to changes in:
					Accounts receivable, net			(1,297)		8,061		(2,122)
					Supplies inventory			132		110		168
					Prepaid and other current assets			(5,308)		(4,651)		838
					Accounts payable			441		579		(2,205)
					Accrued expenses and other liabilities			6,693		7,550		2,329
					Other, net			5,010		3,673		1,963

						Net cash flows provided by operating activities		332,824		295,652		243,423

Cash flows from investing activities:
	Acquisition of interests in surgery centers and related transactions							(73,594)		(277,388)		(239,223)
	Acquisition of property and equipment							(28,856)		(28,864)		(22,170)
	Proceeds from sale of interests in surgery centers							3,553		7,309		7,026
	Other							159		-		-

						Net cash flows used in investing activities		(98,738)		(298,943)		(254,367)

Cash flows from financing activities:
	Proceeds from long-term borrowings							162,204		565,566		288,869
	Repayment on long-term borrowings							(202,083)		(394,164)		(129,107)
	Distributions to noncontrolling interests							(184,149)		(162,941)		(138,724)
	Proceeds from issuance of common stock upon exercise of stock options							33,349		18,214		6,872
	Repurchase of common stock							(45,964)		(13,101)		(10,007)
	Capital contributions and ownership transactions by noncontrolling interests							1,074		1,595		660
	Excess tax benefit from share-based compensation							7,247		1,784		977
	Financing cost incurred							(1,322)		(7,982)		(2,025)

						Net cash flows (used in) provided by financing activities		(229,644)		8,971		17,515

Net increase in cash and cash equivalents								4,442		5,680		6,571
Cash and cash equivalents, beginning of year								46,398		40,718		34,147

Cash and cash equivalents, end of year							$	50,840	$	46,398	$	40,718

See accompanying notes to the consolidated financial statements.

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Notes to the Consolidated Financial Statements

1. Summary of Significant Accounting Policies

a. Principles of Consolidation

AmSurg Corp. (the “Company”), through its wholly owned subsidiaries, owns interests, primarily 51%, in limited partnerships and limited liability companies (“LLCs”) which own and operate ambulatory surgery centers (“centers”). The Company does not have an ownership interest in a limited partnership or LLC greater than 51% which it does not consolidate. The Company has ownership interests of less than 51% in six limited partnerships and LLCs, three of which it consolidates as the Company has substantive participation rights and three of which it does not consolidate as the Company’s rights are limited to protective rights only. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and the consolidated limited partnerships and LLCs. Consolidation of such limited partnerships and LLCs is necessary as the Company’s wholly owned subsidiaries have primarily 51% or more of the financial interest, are the general partner or majority member with all the duties, rights and responsibilities thereof, are responsible for the day-to-day management of the limited partnerships and LLCs, and have control of the entities. The responsibilities of the Company’s noncontrolling partners (limited partners and noncontrolling members) are to supervise the delivery of medical services, with their rights being restricted to those that protect their financial interests, such as approval of the acquisition of significant assets or the incurrence of debt which they are generally required to guarantee on a pro rata basis based upon their respective ownership interests. Intercompany profits, transactions and balances have been eliminated. All limited partnerships and LLCs and noncontrolling partners are referred to herein as (“partnerships”) and (“partners”), respectively.

Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company’s equity. However, in instances in which certain redemption features that are not solely within the control of the Company are present, classification of noncontrolling interests outside of permanent equity is required. Consolidated net income attributable to the Company and to the noncontrolling interests are identified and presented on the consolidated statements of income; changes in ownership interests are accounted for as equity transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary is measured at fair value. Certain transactions with noncontrolling interests are also classified within financing activities in the consolidated statements of cash flows.

As further described in note 14, upon the occurrence of various fundamental regulatory changes, the Company would be obligated, under the terms of certain partnership and operating agreements, to purchase the noncontrolling interests related to a substantial majority of the Company’s partnerships. While the Company believes that the likelihood of a change in current law that would trigger such purchases was remote as of December 31, 2013, the occurrence of such regulatory changes is outside the control of the Company. As a result, these noncontrolling interests that are subject to this redemption feature are not included as part of the Company’s equity and are classified as noncontrolling interests – redeemable on the Company’s consolidated balance sheets.

Center profits and losses of consolidated entities are allocated to the Company’s partners in proportion to their ownership percentages and reflected in the aggregate as net earnings attributable to noncontrolling interests. The partners of the Company’s center partnerships typically are organized as general partnerships, limited partnerships or limited liability companies that are not subject to federal income tax. Each partner shares in the pre-tax earnings of the center in which it is a partner. Accordingly, the earnings attributable to noncontrolling interests in each of the Company’s consolidated partnerships are generally determined on a pre-tax basis, and total net earnings attributable to noncontrolling interests are presented after net earnings. However, the Company considers the impact of the net earnings attributable to noncontrolling interests on earnings before income taxes in order to determine the amount of pre-tax earnings on which the Company must determine its tax expense. In addition, distributions from the partnerships are made to both the Company’s wholly owned subsidiaries and the partners on a pre-tax basis.

Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. These investments are included as investments in unconsolidated affiliates and long-term notes receivable in the accompanying consolidated balance sheets. The Company’s share of the profits and losses from these investments are reported in equity in earnings of unconsolidated affiliates in the accompanying consolidated statement of earnings and comprehensive income. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the companies and records reductions in carrying values when necessary.

Each of the Company’s centers have similar economic characteristics and are aggregated into a single component. The Company operates this component as one reportable business segment, the ownership and operation of ambulatory surgery centers.

b. Cash and Cash Equivalents

Cash and cash equivalents are comprised principally of demand deposits at banks and other highly liquid short-term investments with maturities of less than three months when purchased.

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Notes to the Consolidated Financial Statements – (continued)

c. Accounts Receivable

The determination of contractual and bad debt allowances constitutes a significant estimate. Some of the factors considered by management in determining the amount of such allowances are the historical trends of the centers’ cash collections and contractual and bad debt write-offs, accounts receivable agings, established fee schedules, contracts with payors and procedure statistics. Accordingly, net accounts receivable at December 31, 2013 and 2012 reflect allowances for contractual adjustments of $289,937,000 and $216,363,000, respectively, and allowance for bad debt expense of $27,862,000 and $22,379,000, respectively.

d. Supplies Inventory

Supplies inventory consists of medical and drug supplies and is recorded at cost on a first-in, first-out basis.

e. Prepaid and Other Current Assets

At December 31, 2013, prepaid and other current assets were comprised of short-term investments of $13,313,000, other prepaid expenses of $7,099,000, prepaid insurance expense of $5,631,000, other current receivables of $6,126,000 and other current assets of $1,433,000. At December 31, 2012, prepaid and other current assets were comprised of short-term investments of $8,804,000, other prepaid expenses of $6,462,000, prepaid insurance expense of $4,963,000, other current receivables of $5,926,000 and other current assets of $1,382,000.

f. Property and Equipment, net

Property and equipment are stated at cost. Equipment held under capital leases is stated at the present value of minimum lease payments at the inception of the related leases. Depreciation for buildings and improvements is recognized under the straight-line method over 20 to 40 years or, for leasehold improvements, over the remaining term of the lease plus renewal options for which failure to renew the lease imposes a penalty on the Company in such an amount that a renewal appears, at the inception of the lease, to be reasonably assured. The primary penalty to which the Company is subject is the economic detriment associated with existing leasehold improvements which might be impaired if a decision is made not to continue the use of the leased property. Depreciation for movable equipment and software and software development costs is recognized over useful lives of three to ten years.

g. Goodwill

The Company evaluates goodwill for impairment at least on an annual basis and more frequently if certain indicators are encountered. Goodwill is to be tested at the reporting unit level, defined as an operating segment or one level below an operating segment (referred to as a component), with the fair value of the reporting unit being compared to its carrying amount, including goodwill. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is not considered to be impaired. The Company has determined that it has one operating, as well as one reportable, segment. For impairment testing purposes, the centers qualify as components of that operating segment. Because they have similar economic characteristics, the components are aggregated and deemed a single reporting unit. The Company completed its annual impairment test as of December 31, 2013, and determined that goodwill was not impaired.

h. Intangible Assets

Intangible assets consist primarily of deferred financing costs of the Company and certain amortizable and non-amortizable non-compete and customer agreements. Deferred financing costs and amortizable non-compete agreements and customer agreements are amortized over the term of the related debt as interest expense and the contractual term or estimated life (five to ten years) of the agreements as amortization expense, respectively.

i. Other Long-Term Liabilities

At December 31, 2013, other long-term liabilities are comprised of deferred rent of $14,637,000, tax-effected unrecognized benefits of $6,888,000 (see note 1(k)), unfavorable lease liability of $3,034,000 and other long-term liabilities of $944,000. At December 31, 2012, other long-term liabilities are comprised of deferred rent of $12,134,000, tax-effected unrecognized benefits of $10,113,000 (see note 1(k)), unfavorable lease liability of $3,559,000 and other long-term liabilities of $166,000.

j. Revenue Recognition

Center revenues consist of billing for the use of the centers’ facilities directly to the patient or third-party payor and, at certain of our centers (primarily centers that perform gastrointestinal endoscopy procedures), billing for anesthesia services provided by medical professionals employed or contracted by our centers. Such revenues are recognized when the related surgical procedures are performed. Revenues exclude any amounts billed for physicians’ surgical services, which are billed separately by the physicians to the patient or third-party payor.

Revenues from centers are recognized on the date of service, net of estimated contractual adjustments from third-party medical service payors including Medicare and Medicaid. During the years ended December 31, 2013, 2012 and 2011, the Company derived approximately 25%, 27% and

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Notes to the Consolidated Financial Statements – (continued)

29%, respectively, of its revenues from government healthcare programs, primarily Medicare, and managed Medicare programs. Concentration of credit risk with respect to other payors is limited due to the large number of such payors.

k. Operating Expenses

Substantially all of the Company’s operating expenses relate to the cost of revenues and the delivery of care at the Company’s surgery centers. Such costs primarily include the surgery centers’ clinical and administrative salaries and benefits, supply cost, rent and other variable expenses, such as linen cost, repair and maintenance of equipment, billing fees and bad debt expense. Bad debt expense for continuing operations was approximately $21,947,000, $20,005,000 and $18,230,000 for the years ended December 31, 2013, 2012 and 2011, respectively.

l. Income Taxes

The Company files a consolidated federal income tax return. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company applies recognition thresholds and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return as it relates to accounting for uncertainty in income taxes. In addition, it is the Company’s policy to recognize interest accrued and penalties, if any, related to unrecognized benefits as income tax expense in its statement of earnings. The Company does not expect significant changes to its tax positions or liability for tax uncertainties during the next 12 months.

The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various state jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal or state income tax examinations for years prior to 2010.

m. Earnings Per Share

Basic earnings per share is computed by dividing net earnings attributable to AmSurg Corp. common shareholders by the combined weighted average number of common shares, while diluted earnings per share is computed by dividing net earnings attributable to AmSurg Corp. common shareholders by the weighted average number of such common shares and dilutive share equivalents.

n. Share-Based Compensation

Transactions in which the Company receives employee and non-employee services in exchange for the Company’s equity instruments or liabilities that are based on the fair value of the Company’s equity securities or may be settled by the issuance of these securities are accounted using a fair value method. The Company applies the Black-Scholes method of valuation in determining share-based compensation expense.

Benefits of tax deductions in excess of recognized compensation cost are reported as a financing cash flow, thus reducing the Company’s net operating cash flows and increasing its financing cash flows by $7,247,000, $1,784,000 and $977,000 for the years ended December 31, 2013, 2012 and 2011, respectively.

The Company examines its concentrations of holdings, its historical patterns of award exercises and forfeitures as well as forward-looking factors, in an effort to determine if there were any discernible employee populations. From this analysis, the Company has identified three employee populations, consisting of senior executives, officers and all other recipients. The expected volatility rate applied was estimated based on historical volatility. The expected term assumption applied is based on contractual terms, historical exercise and cancellation patterns and forward-looking factors where present for each population identified. The risk-free interest rate used is based on the U.S. Treasury yield curve in effect at the time of the grant. The pre-vesting forfeiture rate is based on historical rates and forward-looking factors for each population identified. The Company will adjust the estimated forfeiture rate to its actual experience. The Company intends to retain its earnings to finance growth and development of the business and does not expect to disclose or pay any cash dividends in the foreseeable future.

o. Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

p. Reclassifications

Certain prior year amounts in the accompanying consolidated financial statements and these notes have been reclassified to reflect the impact of additional discontinued operations as further discussed in note 3.

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Notes to the Consolidated Financial Statements – (continued)

2. Acquisitions and Investments in Unconsolidated Affiliates

As a significant part of its growth strategy, the Company primarily acquires controlling interests in centers. The Company accounts for its business combinations under the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer be identified for each business combination. The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control. The assets acquired, liabilities assumed and any noncontrolling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination. Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method. Equity method investments are initially recorded at cost, unless such investments are a result of the Company entering into a transaction whereby the Company loses control of a previously controlled entity but retains a noncontrolling interest. Such transactions, which result in the deconsolidation of a previously consolidated entity, are measured at fair value.

During 2013 and 2012, the Company, through a wholly owned subsidiary, acquired a controlling interest in five centers and 17 centers, respectively. One of the centers acquired during 2012 was immediately merged into an existing center.

The aggregate amount paid for the centers acquired and for settlement of purchase price payable obligations during December 31, 2013 and 2012 was approximately $73,594,000 and $277,388,000, respectively, and was paid in cash and funded by a combination of operating cash flow and borrowings under the Company’s revolving credit facility. The total fair value of an acquisition includes an amount allocated to goodwill, which results from the centers’ favorable reputations in their markets, their market positions and their ability to deliver quality care with high patient satisfaction consistent with the Company’s business model.

In conjunction with the Company’s acquisition of 17 centers from National Surgical Care, Inc. (“NSC”) on September 1, 2011, the Company agreed to pay as additional consideration an amount up to $7,500,000 based on a multiple of the excess earnings over the targeted earnings of the acquired centers, if any, from the period of January 1, 2012 to December 31, 2012. At December 31, 2012, the Company had a contingent purchase price obligation of $2,744,000, which was paid during 2013 as final settlement of the additional consideration due in accordance with the purchase agreement.

The acquisition date fair value of the total consideration transferred and acquisition date fair value of each major class of consideration for the acquisitions completed during 2013 and 2012, including post acquisition date adjustments recorded to finalize purchase price allocations, are as follows (in thousands):

		2013		2012

Accounts receivable		$	4,011	$	11,572
Supplies inventory, prepaid and other current assets			2,014		4,750
Property and equipment			6,894		23,546
Goodwill			116,243		429,504
Other intangible assets			-		800
Accounts payable			(2,214)		(3,199)
Other accrued liabilities			(532)		(2,387)
Long-term debt			(3,028)		(6,954)
Other long-term liabilities			(254)		-

	Total fair value		123,134		457,632
	Less: Fair value attributable to noncontrolling interests		49,792		182,073

	Acquisition date fair value of total consideration transferred	$	73,342	$	275,559

Fair value attributable to noncontrolling interests is based on significant inputs that are not observable in the market. Key inputs used to determine the fair value include financial multiples used in the purchase of noncontrolling interests in centers. Such multiples, based on earnings, are used as a benchmark for the discount to be applied for the lack of control or marketability. The fair value of noncontrolling interests for acquisitions where the purchase price allocation is not finalized may be subject to adjustment as the Company completes its initial accounting for acquired intangible assets. During 2013 and 2012, approximately $70,147,000 and $260,547,000, respectively, of goodwill recorded was deductible for tax purposes. Associated with the transactions discussed above, the Company incurred and expensed in other operating expenses in the accompanying consolidated statements of earnings approximately $300,000 and $700,000 in acquisition related costs during 2013 and 2012, respectively.

Revenues and net earnings included in the years ended December 31, 2013 and 2012 associated with these acquisitions are as follows (in thousands):

		2013		2012

Revenues		$	15,616	$	11,247

Net earnings			4,596		3,441
Less: Net earnings attributable to noncontrolling interests			2,603		1,977

	Net earnings attributable to AmSurg Corp. common shareholders	$	1,993	$	1,464

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Notes to the Consolidated Financial Statements – (continued)

The unaudited consolidated pro forma results for the years ended December 31, 2013 and 2012, assuming all 2013 acquisitions had been consummated on January 1, 2012 and all 2012 acquisitions had been consummated on January 1, 2011, are as follows (in thousands, except per share data):

			2013		2012

Revenues			$	1,108,686	$	1,116,214
Net earnings				269,903		261,251
Amounts attributable to AmSurg Corp. common shareholders:
	Net earnings from continuing operations			75,411		76,893
	Net earnings			75,461		77,221
	Net earnings from continuing operations per common share:
		Basic	$	2.41	$	2.50
		Diluted	$	2.36	$	2.43
	Net earnings:
		Basic	$	2.41	$	2.51
		Diluted	$	2.36	$	2.44
	Weighted average number of shares and share equivalents:
		Basic		31,338		30,773
		Diluted		31,954		31,608

During 2013, the Company entered into a transaction whereby it contributed cash plus a controlling interest in one center in exchange for a noncontrolling interest in an entity that, after the completion of the transaction, controls the contributed center and one additional center. Management of the Company believes this structure provides both economies of scale and potential future growth opportunities in the market. As a result of the transaction, the Company recorded in the accompanying consolidated balance sheets the fair value of the noncontrolling interest in the entity which now controls the contributed centers of approximately $5,201,000 as a component of investments in unconsolidated affiliates and long term notes receivable. The Company also recognized a gain on deconsolidation in the accompanying consolidated statements of earnings and comprehensive income of approximately $2,237,000. Such gain was determined based on the difference between the fair value of the Company’s noncontrolling interest in the new entity and the carrying value of both the tangible and intangible assets of the contributed center immediately prior to the transaction. The fair value of the Company’s noncontrolling interest was based on various estimates of the expected future earnings under likely scenarios which were weighted by the probability of each outcome using a range of expected probability of 5% to 30%. Subsequent to the completion of this transaction, the center contributed by the Company was merged into the acquired center.

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Notes to the Consolidated Financial Statements – (continued)

3. Dispositions

The Company initiated the dispositions of certain of its centers primarily due to management’s assessment of the limited growth opportunities at these centers and as a result of certain market driven strategies. Results of operations of the centers discontinued for the years ended December 31, 2013, 2012 and 2011, are as follows (in thousands):

	2013		2012		2011

Cash proceeds from disposal	$	3,553	$	7,309	$	7,026
Net earnings from discontinued operations		2,771		2,221		1,820
Net gain (loss) from discontinued operations attributable to AmSurg Corp.		50		328		(28)

The results of operations of discontinued centers have been classified as discontinued operations in all periods presented. Results of operations of the combined discontinued surgery centers for the years ended December 31, 2013, 2012 and 2011 are as follows (in thousands):

	2013		2012		2011

Revenues	$	3,224	$	10,975	$	18,814
Earnings before income taxes		227		2,724		4,318
Net earnings		169		2,196		3,363

4. Property and Equipment

Property and equipment at December 31, 2013 and 2012 were as follows (in thousands):

		2013		2012

Building and improvements		$	161,805	$	151,270
Movable equipment and software			228,212		208,541
Construction in progress			2,321		2,313

			392,338		362,124
Less accumulated depreciation			(222,443)		(195,512)

	Property and equipment, net	$	169,895	$	166,612

The Company capitalized interest in the amount of $24,000, $43,000 and $85,000 for the years ended December 31, 2013, 2012 and 2011, respectively. At December 31, 2013, the Company and its partnerships had unfunded construction and equipment purchases of approximately $953,000 in order to complete construction in progress. Depreciation expense for continuing and discontinued operations for the years ended December 31, 2013, 2012 and 2011 was $32,974,000, $30,072,000 and $26,068,000, respectively.

5. Goodwill and Intangible Assets

The changes in the carrying amount of goodwill for the years ended December 31, 2013 and 2012 are as follows (in thousands):

		2013		2012

Balance, beginning of period		$	1,652,002	$	1,229,298
Goodwill acquired, including post acquisition adjustments			112,951		429,504
Goodwill disposed, including impact of deconsolidation transaction			(5,983)		(6,800)

	Balance, end of period	$	1,758,970	$	1,652,002

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Notes to the Consolidated Financial Statements – (continued)

Amortizable intangible assets at December 31, 2013 and 2012 consisted of the following (in thousands):

		2013						2012
		Gross						Gross
		Carrying		Accumulated				Carrying		Accumulated
		Amount		Amortization		Net		Amount		Amortization		Net

Deferred financing cost		$	15,814	$	(4,953)	$	10,861	$	14,523	$	(3,029)	$	11,494
Agreements, contracts and other intangible assets			3,448		(2,472)		976		3,448		(2,250)		1,198

	Total amortizable intangible assets	$	19,262	$	(7,425)	$	11,837	$	17,971	$	(5,279)	$	12,692

Amortization of intangible assets for the years ended December 31, 2013, 2012 and 2011 was $2,178,000, $1,415,000 and $1,472,000, respectively. During 2012, deferred financing costs increased approximately $6,200,000 related to the issuance of the senior unsecured notes. Estimated amortization of intangible assets for the five years and thereafter subsequent to December 31, 2013, with a weighted average amortization period of 5.7 years, is $2,243,000, $2,242,000, $2,242,000, $1,988,000, $1,424,000 and $1,698,000.

At December 31, 2013 and 2012, other non-amortizable intangible assets related to restrictive covenant arrangements were $9,825,000, respectively.

6. Long-term Debt

Long-term debt at December 31, 2013 and 2012 was comprised of the following (in thousands):

		2013		2012

Revolving credit agreement (average rate of 2.1%)		$	252,500	$	279,780
Senior Unsecured Notes due 2020 (5.625%)			250,000		250,000
Senior Secured Notes due 2020 (8.04%)			69,643		75,000
Other debt at an average rate of 3.6%, due through 2025			21,149		21,350
Capitalized lease arrangements at an average rate of 5.3%, due through 2026			10,850		11,982

			604,142		638,112
Less current portion			20,844		17,407

	Long-term debt	$	583,298	$	620,705

Principal payments required on the Company’s long-term debt and capital leases in the five years and thereafter subsequent to December 31, 2013 are $20,844,000, $17,751,000, $14,903,000, $13,422,000, $265,037,000, and $272,185,000.

a. Credit Facility

On June 29, 2012, the Company amended its revolving credit agreement to increase the borrowing capacity and adjust the interest rate spreads. On November 7, 2012, the Company further amended its revolving credit agreement to allow for the Company’s issuance of the 5.625% senior unsecured notes (discussed below), which resulted in certain adjustments to the existing covenants. On June 14, 2013, the Company amended its revolving credit agreement to adjust the interest rate spreads and extend the maturity date by one year. The revolving credit agreement, as amended, permits the Company to borrow up to $475,000,000 at an interest rate equal to, at the Company’s option, the base rate plus 0.25% to 1.00% or LIBOR plus 1.25% to 2.00%, or a combination thereof; provides for a fee of 0.25% to 0.40% of unused commitments; and contains certain covenants relating to the ratio of debt to operating performance measurements, interest coverage ratios and minimum net worth. Borrowings under the revolving credit agreement mature in June 2018 and are secured by a pledge of the stock of the Company’s wholly-owned subsidiaries and the Company’s partnership and membership interests in the limited partnerships and limited liability companies. The Company was in compliance with the covenants contained in the revolving credit agreement at December 31, 2013.

b. Senior Unsecured Notes

On November 20, 2012, the Company completed a private offering of $250,000,000 aggregate principal amount of 5.625% senior unsecured notes due 2020 (the “Senior Unsecured Notes”). The net proceeds from the issuance of the Senior Unsecured Notes were used to reduce the outstanding indebtedness under the Company’s existing revolving credit agreement. In connection with the issuance of the Senior Unsecured Notes, the Company entered into a registration rights agreement, dated November 20, 2012 (the “Registration Rights Agreement”). On May 2, 2013, under the terms of the Registration Rights Agreement, the Company commenced an offer to exchange the outstanding Senior Unsecured Notes for an equal amount of such notes that are registered under the Securities Act of 1933, as amended. The exchange offer was completed on May 31, 2013 and all holders of the Senior Unsecured Notes participated in the exchange. The Senior Unsecured Notes are general unsecured obligations of the Company and are guaranteed by its existing and subsequently acquired or organized wholly owned domestic subsidiaries. The Senior Unsecured Notes are pari passu in right of payment with all the existing and future senior debt of the Company and senior to all existing and future subordinated debt of the Company. Interest on the Senior

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Notes to the Consolidated Financial Statements – (continued)

Unsecured Notes accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on May 30 and November 30, through the maturity date of November 30, 2020.

Prior to November 30, 2015, the Company may redeem up to 35% of the aggregate principal amount of the Senior Unsecured Notes at a redemption price of 105.625% of the principal amount thereof, plus accrued and unpaid interest and liquidated damages, if any, using proceeds of one or more equity offerings. On or after November 30, 2015, the Company may redeem the Senior Unsecured Notes in whole or in part. The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve-month period beginning on November 30 of the years indicated below:

Period		Redemption Price
2015		104.219%
2016		102.813%
2017		101.406%
2018 and thereafter		100.000%

The Senior Unsecured Notes contain certain covenants which, among other things, limit, but may not restrict the Company’s ability to enter into or guarantee additional borrowings, sell preferred stock, pay dividends and repurchase stock. The Company was in compliance with the covenants contained in the indenture relating to the Senior Unsecured Notes at December 31, 2013.

c. Senior Secured Notes

The Company issued $75,000,000 principal amount of senior secured notes (the “Senior Secured Notes”) on May 28, 2010 pursuant to a note purchase agreement. The Senior Secured Notes mature on May 28, 2020. The Senior Secured Notes, which were originally issued with a stated interest rate of 6.04%, were amended on November 7, 2012 to allow for the Company’s issuance of the Senior Unsecured Notes, which resulted in an increase in the annual interest rate of 2.00% to 8.04%, and included certain other adjustments to the existing covenants. The Senior Secured Notes are pari passu with the indebtedness under the Company’s revolving credit agreement and the Senior Unsecured Notes and principal payments began in August 2013. The note purchase agreement governing the Senior Secured Notes contains covenants similar to the covenants in the revolving credit agreement and includes a make whole provision in the event of any prepayment of principle. The Company was in compliance with the covenants contained in the note purchase agreement relating to the Senior Secured Notes at December 31, 2013.

d. Other Debt

Certain partnerships included in the Company’s consolidated financial statements have loans with local lending institutions, included above in other debt, which are collateralized by certain assets of the centers with a book value of approximately $74,150,000. The Company and the partners have guaranteed payment of the loans in proportion to the relative partnership interests.

7. Derivative Instruments

The Company entered into an interest rate swap agreement in April 2006, the objective of which was to hedge exposure to the variability of the future expected cash flows attributable to the variable interest rate of a portion of the Company’s outstanding balance under its revolving credit agreement. The interest rate swap matured in April 2011. Prior to April 2011, the interest rate swap had a notional amount of $50,000,000. The Company paid to the counterparty a fixed rate of 5.365% of the notional amount of the interest rate swap and received a floating rate from the counterparty based on LIBOR. In the opinion of management and as permitted by Accounting Standards Codification Topic 815, Derivatives and Hedging (“ASC 815”), the interest rate swap (as a cash flow hedge) was a fully effective hedge. Payments or receipts of cash under the interest rate swap were shown as a part of operating cash flows, consistent with the interest expense incurred pursuant to the revolving credit agreement. An increase in the fair value of the interest rate swap, net of tax, of $515,000 was included in other comprehensive income in the year ended December 31, 2011.

8. Fair Value Measurements

The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The inputs used by the Company to measure fair value are classified into the following fair value hierarchy:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices included in Level 1 that are observable for the asset or liability through corroboration with market data at the measurement date.

Level 3: Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.

In determining the fair value of assets and liabilities that are measured on a recurring basis at December 31, 2013 and 2012, with the exception of the contingent purchase price payable, the Company utilized Level 2 inputs to perform such measurements methods which were commensurate with the

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Notes to the Consolidated Financial Statements – (continued)

market approach. The Company utilized Level 3 inputs, which utilizes unobservable data, to measure the fair value of the contingent purchase price payable (in thousands):

		2013		2012

Assets:
	Supplemental executive retirement savings plan investments - Level 2	$	13,313	$	8,804

Liabilities:
	Contingent purchase price payable - Level 3 (see note 2)	$	-	$	2,744

The fair value of the supplemental executive and director retirement savings plan investments, which are included in prepaid and other current assets, was determined using the calculated net asset values obtained from the plan administrator and observable inputs of similar public mutual fund investments. The fair value of the contingent purchase price payable related to the centers acquired from NSC as of December 31, 2012, was determined utilizing the actual earnings of those centers during the earnout period, January 1, 2012 to December 31, 2012, in accordance with the purchase agreement. During the year ended December 31, 2013, the Company paid $2,744,000 as final settlement of the contingent purchase price payable using its revolving credit facility. There were no transfers to or from Levels 1 and 2 during the year ended December 31, 2013.

Cash and cash equivalents, receivables and payables are reflected in the financial statements at cost, which approximates fair value. The fair value of fixed rate long-term debt, with a carrying value of $348,958,000, was approximately $364,349,000 at December 31, 2013. The fair value of variable-rate long-term debt approximates its carrying value of $255,184,000 at December 31, 2013. The fair value of fixed rate long-term debt, with a carrying value of $354,105,000, was approximately $379,036,000 at December 31, 2012. The fair value of variable-rate long-term debt approximates its carrying value of $284,007,000 at December 31, 2012.With the exception of the Company’s Senior Unsecured Notes, the fair value of fixed rate debt (Level 2) is determined based on an estimation of discounted future cash flows of the debt at rates currently quoted or offered to the Company for similar debt instruments of comparable maturities by its lenders. The fair value of the Company’s Senior Unsecured Notes (Level 1) is determined based on quoted prices in an active market.

9. Leases

The Company has entered into various building and equipment capital and operating leases for its surgery centers in operation and under development and for office space, expiring at various dates through 2033. Future minimum lease payments, including payments during expected renewal option periods, at December 31, 2013 were as follows (in thousands):

		Capitalized		Operating
Year Ended December 31,		Equipment Leases		Leases

2014		$	2,040	$	47,704
2015			1,673		46,557
2016			1,404		45,772
2017			1,184		45,174
2018			1,000		43,718
Thereafter			7,003		354,087

	Total minimum rentals		14,304	$	583,012
Less amounts representing interest at rates ranging from 2.9% to 11.8%			3,454

	Capital lease obligations	$	10,850

At December 31, 2013, buildings and equipment with a cost of approximately $13,950,000 and accumulated depreciation of approximately $3,635,000 were held under capital leases. The Company and the partners in the partnerships have guaranteed payment of certain of these leases. Rental expense for continuing and discontinued operations for operating leases for the years ended December 31, 2013, 2012 and 2011 was approximately $52,641,000, $47,278,000 and $42,413,000, respectively.

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Notes to the Consolidated Financial Statements – (continued)

10. Shareholders’ Equity

a. Common Stock

On April 24, 2012, the Board of Directors authorized a stock purchase program for up to $40,000,000 of the Company’s shares of common stock. The Company completed this repurchase program in August 2013. On August 9, 2013, the Board of Directors authorized a stock purchase program for up to $40,000,000 of the Company’s shares of common stock to be purchased through February 9, 2015. As of December 31, 2013, there was approximately $27,100,000 available under the stock repurchase program.

During the year ended 2013, the Company purchased 1,154,378 shares of the Company’s common stock for approximately $42,652,000, at an average price of $36.93 per share, in order to mitigate the dilutive effect of shares issued upon the exercise of stock options pursuant to the Company’s stock incentive plans. During the year ended 2012, the Company purchased 415,084 shares of the Company’s common stock for approximately $11,838,000, at an average price of $28.50 per share. In addition, during 2013 and 2012, the Company repurchased 102,252 shares and 48,139 shares, respectively, of common stock for approximately $3,312,000 and $1,263,000, respectively, to cover payroll withholding taxes in connection with the vesting of restricted stock awards in accordance with the restricted stock agreements.

b. Stock Incentive Plans

In May 2006, the Company adopted the AmSurg Corp. 2006 Stock Incentive Plan. The Company also has options outstanding under the AmSurg Corp. 1997 Stock Incentive Plan, under which no additional awards may be granted. Under these plans, the Company has granted restricted stock and non-qualified options to purchase shares of common stock to employees and outside directors from its authorized but unissued common stock. At December 31, 2013, 2,760,250 shares were authorized for grant under the 2006 Stock Incentive Plan and 895,822 shares were available for future equity grants, including 733,704 shares available for issuance as restricted stock. Restricted stock granted to outside directors prior to 2012 vested over a two year period and restricted stock granted to outside directors in 2012 and 2013 vest over a one year period. Shares held by outside directors are subject to certain holding restrictions. Restricted stock granted to employees during 2010 and thereafter vests over four years in three equal installments beginning on the second anniversary of the date of grant. Restricted stock granted to employees prior to 2010 vests at the end of four years from the date of grant. Shares held by the Company’s senior management are subject to certain holding restrictions. The fair value of restricted stock is determined based on the closing bid price of the Company’s common stock on the grant date.

No options have been issued subsequent to 2008 and all outstanding options are fully vested. Options were granted at market value on the date of the grant and vested over four years. Outstanding options have a term of ten years from the date of grant.

Other information pertaining to share-based activity for the years ended December 31, 2013, 2012 and 2011 was as follows (in thousands):

	2013		2012		2011

Share-based compensation expense	$	8,321	$	6,692	$	6,178
Fair value of shares vested		11,742		6,425		7,356
Cash received from option exercises		33,349		18,214		6,872
Tax benefit from option exercises		7,247		1,784		977

As of December 31, 2013, the Company had total unrecognized compensation cost of approximately $7,426,000 related to non-vested awards, which the Company expects to recognize through 2017 and over a weighted-average period of 1.0 year.

Average outstanding share-based awards to purchase approximately 20,000 and 923,000 shares of common stock that had an exercise price in excess of the average market price of the common stock during the years ended December 31, 2012 and 2011, respectively, were not included in the calculation of diluted securities under the treasury method for purposes of determining diluted earnings per share due to their anti-dilutive impact. During the year ended December 31, 2013, there were no options that were anti-dilutive.

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Notes to the Consolidated Financial Statements – (continued)

A summary of the status of and changes for non-vested restricted shares for the three years ended December 31, 2013, is as follows:

			Weighted
		Number	Average
		of	Grant
		Shares	Price

Non-vested shares at January 1, 2011		664,909	$	22.16
	Shares granted	276,869		21.78
	Shares vested	(208,949)		23.11
	Shares forfeited	(417)		24.75

Non-vested shares at December 31, 2011		732,412	$	21.91
	Shares granted	281,429		26.78
	Shares vested	(183,019)		25.98
	Shares forfeited	(2,136)		26.26

Non-vested shares at December 31, 2012		828,686	$	22.50
	Shares granted	291,863		31.66
	Shares vested	(360,337)		21.55
	Shares forfeited	(16,343)		23.11

Non-vested shares at December 31, 2013		743,869	$	26.54

A summary of stock option activity for the three years ended December 31, 2013 is summarized as follows:

					Weighted
					Average
			Weighted		Remaining
		Number	Average		Contractual
		of	Exercise		Term
		Shares	Price		(in years)

Outstanding at January 1, 2011		2,901,989	$	22.49	4.5
	Options exercised with total intrinsic value of $2,482,000	(374,350)		18.36
	Options terminated	(17,585)		25.42

Outstanding at December 31, 2011		2,510,054	$	23.09	3.4
	Options exercised with total intrinsic value of $6,287,000	(841,599)		21.64
	Options terminated	(5,625)		21.85

Outstanding at December 31, 2012		1,662,830	$	23.82	2.9
	Options exercised with total intrinsic value of $33,349,000	(1,392,366)		23.95

Outstanding at December 31, 2013 with aggregate intrinsic value of $6,156,000		270,464	$	23.16	2.5

Vested or expected to vest at December 31, 2013 with total intrinsic value of $6,156,000		270,464	$	23.16	2.5

Exercisable at December 31, 2013 with total intrinsic value of $6,156,000		270,464	$	23.16	2.5

The aggregate intrinsic value represents the total pre-tax intrinsic value received by the option holders on the exercise date or that would have been received by the option holders had all holders of in-the-money outstanding options at December 31, 2013 exercised their options at the Company’s closing stock price on December 31, 2013.

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Notes to the Consolidated Financial Statements – (continued)

c. Earnings per Share

The following is a reconciliation of the numerator and denominators of basic and diluted earnings per share (in thousands, except per share amounts):

						Per
			Earnings		Shares	Share
			(Numerator)		(Denominator)	Amount

For the year ended December 31, 2013:
	Net earnings from continuing operations attributable to
		AmSurg Corp. per common share (basic)	$	72,653	31,338	$	2.32
	Effect of dilutive securities options and non-vested shares			-	616

	Net earnings from continuing operations attributable to
		AmSurg Corp. per common share (diluted)	$	72,653	31,954	$	2.27

	Net earnings attributable to AmSurg Corp. per common share (basic)		$	72,703	31,338	$	2.32
	Effect of dilutive securities options and non-vested shares			-	616

	Net earnings attributable to AmSurg Corp. per common share (diluted)		$	72,703	31,954	$	2.28

For the year ended December 31, 2012:
	Net earnings from continuing operations attributable to
		AmSurg Corp. per common share (basic)	$	62,235	30,773	$	2.02
	Effect of dilutive securities options and non-vested shares			-	835

	Net earnings from continuing operations attributable to
		AmSurg Corp. per common share (diluted)	$	62,235	31,608	$	1.97

	Net earnings attributable to AmSurg Corp. per common share (basic)		$	62,563	30,773	$	2.03
	Effect of dilutive securities options and non-vested shares			-	835

	Net earnings attributable to AmSurg Corp. per common share (diluted)		$	62,563	31,608	$	1.98

For the year ended December 31, 2011:
	Net earnings from continuing operations attributable to
		AmSurg Corp. per common share (basic)	$	50,025	30,452	$	1.64
	Effect of dilutive securities options and non-vested shares			-	759

	Net earnings from continuing operations attributable to
		AmSurg Corp. per common share (diluted)	$	50,025	31,211	$	1.60

	Net earnings attributable to AmSurg Corp. per common share (basic)		$	49,997	30,452	$	1.64
	Effect of dilutive securities options and non-vested shares			-	759

	Net earnings attributable to AmSurg Corp. per common share (diluted)		$	49,997	31,211	$	1.60

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Notes to the Consolidated Financial Statements – (continued)

11. Income Taxes

Total income taxes expense (benefit) for the years ended December 31, 2013, 2012 and 2011 was included within the following sections of the consolidated financial statements as follows (in thousands):

		2013		2012		2011

Income from continuing operations		$	49,754	$	42,364	$	34,973
Discontinued operations			(1,091)		1,574		3,032
Shareholders’ equity			(7,381)		(1,581)		(649)
Other comprehensive income			-		-		332

	Total	$	41,282	$	42,357	$	37,688

Income tax expense from continuing operations for the years ended December 31, 2013, 2012 and 2011 was comprised of the following (in thousands):

		2013		2012		2011

Current:
	Federal	$	8,437	$	15,326	$	11,671
	State		3,724		4,974		3,541
Deferred:
	Federal		31,909		18,488		17,502
	State		5,684		3,576		2,259

	Income tax expense	$	49,754	$	42,364	$	34,973

Income tax expense from continuing operations for the years ended December 31, 2013, 2012 and 2011 differed from the amount computed by applying the U.S. federal income tax rate of 35% to earnings before income taxes as a result of the following (in thousands):

		2013		2012		2011

Statutory federal income tax		$	107,984	$	92,325	$	78,143
Less federal income tax assumed directly by noncontrolling interests			(65,142)		(55,715)		(48,394)
State income taxes, net of federal income tax benefit			5,539		5,309		3,642
Increase in valuation allowances			924		419		1,622
Interest related to unrecognized tax benefits			(155)		(109)		(83)
Other			604		135		43

	Income tax expense	$	49,754	$	42,364	$	34,973

The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense. Decreases in interest obligations of $189,000, $132,000 and $109,000 were recognized in the consolidated statement of earnings for the years ended December 31, 2013, 2012 and 2011, respectively, resulting in a total recognition of interest obligations of approximately $943,000 and $1,132,000 in the consolidated balance sheet at December 31, 2013 and 2012, respectively. No amounts for penalties have been recorded.

The Company primarily has unrecognized tax benefits that represent an amortization deduction which is temporary in nature. A reconciliation of the beginning and ending amount of the liability associated with unrecognized tax benefits for the years ended December 31, 2013, 2012 and 2011 is as follows (in thousands):

		2013		2012		2011

Balance at beginning of year		$	9,235	$	7,252	$	7,144
Additions for tax positions of current year			46		119		342
Increases (decreases) for tax positions taken during a prior period			-		1,985		(190)
Lapse of statute of limitations			(2,951)		(121)		(44)

	Balance at end of year	$	6,330	$	9,235	$	7,252

The Company believes that the total amount of increases in unrecognized tax benefits within the next 12 months will not be significant. The total amount of unrecognized tax benefits that would affect the Company’s effective tax rate if recognized is approximately $150,000.

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Notes to the Consolidated Financial Statements – (continued)

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2013 and 2012 were as follows (in thousands):

			2013		2012

Deferred tax assets:
	Allowance for uncollectible accounts		$	897	$	884
	Accrued assets and other			5,292		5,212
	Valuation allowances			(2,021)		(2,084)

		Total current deferred tax assets		4,168		4,012

	Share-based compensation			7,635		9,500
	Interest on unrecognized tax benefits			230		363
	Accrued liabilities and other			3,629		3,077
	Operating and capital loss carryforwards			9,185		9,169
	Valuation allowances			(7,665)		(7,265)

		Total non-current deferred tax assets		13,014		14,844

		Total deferred tax assets		17,182		18,856

Deferred tax liabilities:
	Prepaid expenses			1,071		925
	Property and equipment, principally due to differences in depreciation			4,137		3,997
	Goodwill, principally due to differences in amortization			184,897		148,494

		Total deferred tax liabilities		190,105		153,416

		Net deferred tax liabilities	$	172,923	$	134,560

The net deferred tax liabilities at December 31, 2013 and 2012 were recorded as follows (in thousands):

		2013		2012

Current deferred income tax assets		$	3,097	$	3,088
Non-current deferred income tax liabilities			176,020		137,648

	Net deferred tax liabilities	$	172,923	$	134,560

The Company has provided valuation allowances on its gross deferred tax assets to the extent that management does not believe that it is more likely than not that such asset will be realized. Capital loss carryforwards will begin to expire in 2014, and state net operating losses will begin to expire in 2015.

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Notes to the Consolidated Financial Statements – (continued)

12. Related Party Transactions

Certain surgery centers lease space from entities affiliated with their physician partners at negotiated rates that management believes were equal to fair market value at the inception of the leases based on relevant market data. Certain surgery centers reimburse their physician partners for salaries and benefits and billing fees related to time spent by employees of their practices on activities of the centers at current market rates. In addition, certain centers compensate at market rates their physician partners for physician advisory services provided to the surgery centers, including medical director and performance improvement services.

Related party payments for the years ended December 31, 2013, 2012 and 2011 were as follows (in thousands):

	2013		2012		2011

Operating leases	$	29,240	$	29,079	$	29,137
Salaries and benefits		72,892		65,908		64,830
Billing fees		11,591		11,126		11,240
Medical advisory services		2,993		2,671		2,575

The Company also reimburses their physician partners for operating expenses paid by the physician partners to third party providers on the behalf of the surgery center. The Company believes that the foregoing transactions are reasonably expected to benefit the Company and that the amount of reimbursed expenses included in other operating expenses in the accompanying consolidated statements of earnings for each of the years ended December 31, 2013, 2012 and 2011 were not significant.

It is the Company’s policy that all transactions by the Company with officers, directors, five percent shareholders and their affiliates be entered into only if such transactions are on terms no less favorable to the Company than could be obtained from unaffiliated third parties, are reasonably expected to benefit the Company and are approved by the Nominating and Corporate Governance Committee of the Company’s Board of Directors.

13. Employee Benefit Programs

The Company maintains the AmSurg 401(k) Plan and Trust. This plan is a defined contribution plan covering substantially all employees of the Company and provides for voluntary contributions by these employees, subject to certain limits. Company contributions are based on specified percentages of employee compensation. The Company funds contributions as accrued. The Company’s contributions for the years ended December 31, 2013, 2012 and 2011 were approximately $1,095,000, $1,031,000 and $594,000, respectively, and vest immediately or incrementally over five years, depending on the tenures of the respective employees for which the contributions were made.

The Company maintains the Supplemental Executive and Director Retirement Savings Plan. This plan is a defined contribution plan covering all officers of the Company and provides for voluntary contributions of up to 50% of employee annual compensation. Company contributions are at the discretion of the Compensation Committee of the Board of Directors and vest incrementally over five years. The employee and employer contributions are placed in a Rabbi Trust and recorded in the accompanying consolidated balance sheets in prepaid and other current assets. Employer contributions to this plan for the years ended December 31, 2013, 2012 and 2011 were approximately $2,338,000, $1,693,000 and $915,000, respectively. On December 30, 2011, this plan was amended to allow non-employee directors to voluntarily contribute up to 100% of annual director cash compensation to the plan.

14. Commitments and Contingencies

The Company and its subsidiaries are insured with respect to medical malpractice risk on a claims-made basis. The Company also maintains insurance for general liability, director and officer liability and property. Certain policies are subject to deductibles. In addition to the insurance coverage provided, the Company indemnifies its officers and directors for actions taken on behalf of the Company and its subsidiaries. Management is not aware of any claims against it or its subsidiaries which would have a material financial impact on the Company.

Certain of the Company’s wholly owned subsidiaries, as general partners in the limited partnerships, are responsible for all debts incurred but unpaid by the limited partnership. As manager of the operations of the limited partnerships, the Company has the ability to limit potential liabilities by curtailing operations or taking other operating actions.

In the event of a change in current law that would prohibit the physicians’ current form of ownership in the partnerships, the Company would be obligated to purchase the physicians’ interests in a majority of the Company’s partnerships. The purchase price to be paid in such event would be determined by a predefined formula, as specified in the partnership agreements. The Company believes the likelihood of a change in current law, which would trigger such purchases, was remote as of December 31, 2013.

On December 27, 2012, the Company entered into a lease agreement with an initial term of 15 years plus renewal options, pursuant to which the Company has agreed to lease an approximately 110,000 square foot building to be constructed in Nashville, Tennessee. The Company intends that the building will serve as its corporate headquarters beginning in 2015. Prior to taking possession, the Company may terminate the agreement if the landlord fails to satisfy certain construction milestones. The Company’s annual rental obligation at the inception of the lease, which will occur upon completion of

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Notes to the Consolidated Financial Statements – (continued)

construction currently estimated to occur in late 2014, is approximately $2,300,000 and increases by 1.9% annually thereafter during the initial term. In addition to base rent, the Company will pay additional rent consisting of, among other things, operating expenses, real estate taxes and insurance costs. The landlord will provide the Company with an allowance of approximately $4,400,000 for certain interior tenant improvements.

15. Supplemental Cash Flow Information

Supplemental cash flow information for the years ended December 31 2013, 2012 and 2011 is as follows (in thousands):

		2013		2012		2011

Cash paid during the period for:
	Interest	$	28,378	$	14,786	$	13,815
	Income taxes, net of refunds		7,756		19,615		10,232

Non-cash investing and financing activities:
	Increase in accounts payable associated with acquisition of property and equipment		884		248		659
	Capital lease obligations		738		1,096		466

16. Financial Information for the Company and Its Subsidiaries

The Senior Unsecured Notes, issued in 2012, are senior unsecured obligations of the Company and are guaranteed by the Company and certain of its existing and subsequently acquired or organized wholly owned domestic subsidiaries. The Senior Unsecured Notes are guaranteed on a full and unconditional and joint and several basis, with limited exceptions considered customary for such guarantees, including the release of the guarantee when a subsidiary's assets are sold. The following condensed consolidating financial statements present the Company (as parent issuer), the subsidiary guarantors, the subsidiary non-guarantors and consolidating adjustments. These condensed consolidating financial statements have been prepared and presented in accordance with SEC Regulation S-X Rule 3-10 "Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered." The operating and investing activities of the separate legal entities are fully interdependent and integrated. Accordingly, the results of the separate legal entities are not representative of what the operating results would be on a stand-alone basis.

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Notes to the Consolidated Financial Statements – (continued)

Condensed Consolidating Balance Sheet - December 31, 2013 (In thousands)

						Guarantor		Non-Guarantor		Consolidating		Total
				Parent Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated

Assets
Current assets:
	Cash and cash equivalents			$	6,710	$	-	$	44,130	$	-	$	50,840
	Accounts receivable, net				-		-		105,072		-		105,072
	Supplies inventory				33		-		18,381		-		18,414
	Deferred income taxes				3,097		-		-		-		3,097
	Prepaid and other current assets				23,993		-		13,971		(4,362)		33,602
		Total current assets			33,833		-		181,554		(4,362)		211,025
Property and equipment, net					9,829		-		160,066		-		169,895
Investments in unconsolidated affiliates and long-term notes receivable					1,484,974		1,453,596		-		(2,922,178)		16,392
Goodwill and other intangible assets, net					20,684		-		978		1,758,970		1,780,632
			Total assets	$	1,549,320	$	1,453,596	$	342,598	$	(1,167,570)	$	2,177,944
Liabilities and Equity
Current liabilities:
	Current portion of long-term debt			$	10,714	$	-	$	10,130	$	-	$	20,844
	Accounts payable				1,972		-		29,487		(3,958)		27,501
	Other accrued liabilities				27,419		-		14,510		(404)		41,525
		Total current liabilities			40,105		-		54,127		(4,362)		89,870
Long-term debt					561,429		-		53,246		(31,377)		583,298
Deferred income taxes					176,020		-		-		-		176,020
Other long-term liabilities					7,569		-		17,934		-		25,503
Noncontrolling interests – redeemable					-		-		63,704		113,993		177,697
Equity:
		Total AmSurg Corp. equity			764,197		1,453,596		114,671		(1,568,267)		764,197
		Noncontrolling interests – non-redeemable			-		-		38,916		322,443		361,359
		Total equity			764,197		1,453,596		153,587		(1,245,824)		1,125,556
			Total liabilities and equity	$	1,549,320	$	1,453,596	$	342,598	$	(1,167,570)	$	2,177,944

Condensed Consolidating Balance Sheet - December 31, 2012 (In thousands)

						Guarantor		Non-Guarantor		Consolidating		Total
				Parent Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated

Assets
Current assets:
	Cash and cash equivalents			$	7,259	$	-	$	39,139	$	-	$	46,398
	Accounts receivable, net				-		-		96,752		-		96,752
	Supplies inventory				-		-		18,406		-		18,406
	Deferred income taxes				3,088		-		-		-		3,088
	Prepaid and other current assets				19,342		-		13,160		(4,965)		27,537
		Total current assets			29,689		-		167,457		(4,965)		192,181
Property and equipment, net					9,199		-		157,413		-		166,612
Investments in unconsolidated affiliates and long-term notes receivable					1,413,061		1,381,596		-		(2,783,383)		11,274
Goodwill and other intangible assets, net					21,311		-		1,206		1,652,002		1,674,519
			Total assets	$	1,473,260	$	1,381,596	$	326,076	$	(1,136,346)	$	2,044,586
Liabilities and Equity
Current liabilities:
	Current portion of long-term debt			$	5,357	$	-	$	12,050	$	-	$	17,407
	Accounts payable				1,379		-		26,035		(3,905)		23,509
	Other accrued liabilities				29,380		-		15,177		(1,060)		43,497
		Total current liabilities			36,116		-		53,262		(4,965)		84,413
Long-term debt					599,423		-		52,747		(31,465)		620,705
Deferred income taxes					137,648		-		-		-		137,648
Other long-term liabilities					10,585		-		15,387		-		25,972
Noncontrolling interests – redeemable					-		-		61,939		113,443		175,382
Equity:
		Total AmSurg Corp. equity			689,488		1,381,596		108,412		(1,490,008)		689,488
		Noncontrolling interests – non-redeemable			-		-		34,329		276,649		310,978
		Total equity			689,488		1,381,596		142,741		(1,213,359)		1,000,466
			Total liabilities and equity	$	1,473,260	$	1,381,596	$	326,076	$	(1,136,346)	$	2,044,586

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Notes to the Consolidated Financial Statements – (continued)

Condensed Consolidating Statement of Earnings and Comprehensive Income - Year Ended December 31, 2013 (In thousands)

							Guarantor		Non-Guarantor		Consolidating		Total
					Parent Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated

Revenues					$	24,167	$	-	$	1,072,694	$	(17,518)	$	1,079,343
Operating expenses:
	Salaries and benefits					61,038		-		272,619		(467)		333,190
	Supply cost					-		-		157,771		-		157,771
	Other operating expenses					22,660		-		217,068		(17,051)		222,677
	Depreciation and amortization					3,186		-		29,842		-		33,028
		Total operating expenses				86,884		-		677,300		(17,518)		746,666
Gain on deconsolidation						2,237		2,237		-		(2,237)		2,237
Equity in earnings of unconsolidated affiliates						204,962		204,962		-		(406,773)		3,151
		Operating income				144,482		207,199		395,394		(409,010)		338,065
Interest expense						27,282		-		2,256		-		29,538
	Earnings from continuing operations before income taxes					117,200		207,199		393,138		(409,010)		308,527
Income tax expense						48,239		-		1,515		-		49,754
	Net earnings from continuing operations					68,961		207,199		391,623		(409,010)		258,773
	Net earnings (loss) from discontinued operations					3,742		-		(971)		-		2,771
		Net earnings				72,703		207,199		390,652		(409,010)		261,544
Less net earnings attributable to noncontrolling interests:
	Net earnings from continuing operations					-		-		186,120		-		186,120
	Net earnings from discontinued operations					-		-		2,721		-		2,721
		Total net earnings attributable to noncontrolling interests				-		-		188,841		-		188,841
			Net earnings attributable to AmSurg Corp. common shareholders		$	72,703	$	207,199	$	201,811	$	(409,010)	$	72,703
Amounts attributable to AmSurg Corp. common shareholders:
	Earnings from continuing operations, net of income tax				$	68,961	$	207,199	$	205,503	$	(409,010)	$	72,653
	Discontinued operations, net of income tax					3,742		-		(3,692)		-		50
			Net earnings attributable to AmSurg Corp. common shareholders		$	72,703	$	207,199	$	201,811	$	(409,010)	$	72,703

Net earnings and comprehensive income, net of income tax					$	72,703	$	207,199	$	390,652	$	(409,010)	$	261,544
	Less comprehensive income attributable to noncontrolling interests					-		-		188,841		-		188,841
		Comprehensive income attributable to AmSurg Corp.
				common shareholders	$	72,703	$	207,199	$	201,811	$	(409,010)	$	72,703

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Notes to the Consolidated Financial Statements – (continued)

Condensed Consolidating Statement of Earnings and Comprehensive Income - Year Ended December 31, 2012 (In thousands)

							Guarantor		Non-Guarantor		Consolidating		Total
					Parent Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated

Revenues					$	19,907	$	-	$	918,176	$	(14,901)	$	923,182
Operating expenses:
	Salaries and benefits					54,895		-		235,618		(450)		290,063
	Supply cost					-		-		131,055		-		131,055
	Other operating expenses					20,499		-		186,977		(14,451)		193,025
	Depreciation and amortization					2,860		-		26,990		-		29,850
		Total operating expenses				78,254		-		580,640		(14,901)		643,993
Equity in earnings of unconsolidated affiliates						178,137		178,137		-		(354,710)		1,564
		Operating income				119,790		178,137		337,536		(354,710)		280,753
Interest expense						14,803		-		2,164		-		16,967
	Earnings from continuing operations before income taxes					104,987		178,137		335,372		(354,710)		263,786
Income tax expense						40,810		-		1,554		-		42,364
	Net earnings from continuing operations					64,177		178,137		333,818		(354,710)		221,422
	Net (loss) earnings from discontinued operations					(1,614)		-		3,835		-		2,221
		Net earnings				62,563		178,137		337,653		(354,710)		223,643
Less net earnings attributable to noncontrolling interests:
	Net earnings from continuing operations					-		-		159,187		-		159,187
	Net earnings from discontinued operations					-		-		1,893		-		1,893
		Total net earnings attributable to noncontrolling interests				-		-		161,080		-		161,080
			Net earnings attributable to AmSurg Corp. common shareholders		$	62,563	$	178,137	$	176,573	$	(354,710)	$	62,563
Amounts attributable to AmSurg Corp. common shareholders:
	Earnings from continuing operations, net of income tax				$	64,177	$	178,137	$	174,631	$	(354,710)	$	62,235
	Discontinued operations, net of income tax					(1,614)		-		1,942		-		328
			Net earnings attributable to AmSurg Corp. common shareholders		$	62,563	$	178,137	$	176,573	$	(354,710)	$	62,563

Net earnings and comprehensive income, net of income tax					$	62,563	$	178,137	$	337,653	$	(354,710)	$	223,643
	Less comprehensive income attributable to noncontrolling interests					-		-		161,080		-		161,080
		Comprehensive income attributable to AmSurg Corp.
				common shareholders	$	62,563	$	178,137	$	176,573	$	(354,710)	$	62,563

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Notes to the Consolidated Financial Statements – (continued)

Condensed Consolidating Statement of Earnings and Comprehensive Income - Year Ended December 31, 2011 (In thousands)

							Guarantor		Non-Guarantor		Consolidating		Total
					Parent Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated

Revenues					$	11,253	$	-	$	768,823	$	(8,001)	$	772,075
Operating expenses:
	Salaries and benefits					42,739		-		196,358		(359)		238,738
	Supply cost					-		-		101,364		-		101,364
	Other operating expenses					19,468		-		156,521		(7,642)		168,347
	Depreciation and amortization					2,487		-		23,158		-		25,645
		Total operating expenses				64,694		-		477,401		(8,001)		534,094
Equity in earnings of unconsolidated affiliates						152,409		152,409		-		(304,205)		613
		Operating income				98,968		152,409		291,422		(304,205)		238,594
Interest expense						13,195		-		2,132		-		15,327
	Earnings from continuing operations before income taxes					85,773		152,409		289,290		(304,205)		223,267
Income tax expense						33,806		-		1,167		-		34,973
	Net earnings from continuing operations					51,967		152,409		288,123		(304,205)		188,294
	Net (loss) earnings from discontinued operations					(1,970)		-		3,790		-		1,820
		Net earnings				49,997		152,409		291,913		(304,205)		190,114
Less net earnings attributable to noncontrolling interests:
	Net earnings from continuing operations					-		-		138,269		-		138,269
	Net earnings from discontinued operations					-		-		1,848		-		1,848
		Total net earnings attributable to noncontrolling interests				-		-		140,117		-		140,117
			Net earnings attributable to AmSurg Corp. common shareholders		$	49,997	$	152,409	$	151,796	$	(304,205)	$	49,997
Amounts attributable to AmSurg Corp. common shareholders:
	Earnings from continuing operations, net of income tax				$	51,967	$	152,409	$	149,854	$	(304,205)	$	50,025
	Discontinued operations, net of income tax					(1,970)		-		1,942		-		(28)
			Net earnings attributable to AmSurg Corp. common shareholders		$	49,997	$	152,409	$	151,796	$	(304,205)	$	49,997

Net earnings					$	49,997	$	152,409	$	291,913	$	(304,205)	$	190,114
Other comprehensive income, net of income tax:
	Unrealized gain on interest rate swap, net of income tax					515		-		-		-		515
		Comprehensive income, net of income tax				50,512		152,409		291,913		(304,205)		190,629
	Less comprehensive income attributable to noncontrolling interests					-		-		140,117		-		140,117
		Comprehensive income attributable to AmSurg Corp.
				common shareholders	$	50,512	$	152,409	$	151,796	$	(304,205)	$	50,512

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Notes to the Consolidated Financial Statements – (continued)

Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2013 (In thousands)

			Parent		Guarantor		Non-Guarantor		Consolidating		Total
			Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated

Cash flows from operating activities:
		Net cash flows provided by operating activities	$	45,127	$	208,773	$	426,572	$	(347,648)	$	332,824
Cash flows from investing activities:
	Acquisition of interests in surgery centers and related transactions			-		(74,288)		-		694		(73,594)
	Acquisition of property and equipment			(3,693)		-		(25,163)		-		(28,856)
	Proceeds from sale of interests in surgery centers			-		3,553		-		-		3,553
	Other			-		159		-		-		159
		Net cash flows used in investing activities		(3,693)		(70,576)		(25,163)		694		(98,738)
Cash flows from financing activities:
	Proceeds from long-term borrowings			152,700		-		9,504		-		162,204
	Repayment on long-term borrowings			(188,081)		-		(14,002)		-		(202,083)
	Distributions to owners, including noncontrolling interests			-		(138,875)		(392,922)		347,648		(184,149)
	Changes in intercompany balances with affiliates, net			88		-		(88)		-		-
	Other financing activities, net			(6,690)		678		1,090		(694)		(5,616)
		Net cash flows used in financing activities		(41,983)		(138,197)		(396,418)		346,954		(229,644)
Net increase (decrease) in cash and cash equivalents				(549)		-		4,991		-		4,442
Cash and cash equivalents, beginning of year				7,259		-		39,139		-		46,398
Cash and cash equivalents, end of year			$	6,710	$	-	$	44,130	$	-	$	50,840

Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2012 (In thousands)

			Parent		Guarantor		Non-Guarantor		Consolidating		Total
			Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated

Cash flows from operating activities:
		Net cash flows provided by (used in) operating activities	$	(83,605)	$	182,851	$	379,257	$	(182,851)	$	295,652
Cash flows from investing activities:
	Acquisition of interests in surgery centers and related transactions			(90,029)		(280,189)		-		92,830		(277,388)
	Acquisition of property and equipment			(3,681)		-		(25,183)		-		(28,864)
	Proceeds from sale of interests in surgery centers			-		7,309		-		-		7,309
		Net cash flows used in investing activities		(93,710)		(272,880)		(25,183)		92,830		(298,943)
Cash flows from financing activities:
	Proceeds from long-term borrowings			560,000		-		5,566		-		565,566
	Repayment on long-term borrowings			(381,220)		-		(12,944)		-		(394,164)
	Distributions to owners, including noncontrolling interests			-		-		(345,792)		182,851		(162,941)
	Capital contributions			-		90,029		-		(90,029)		-
	Changes in intercompany balances with affiliates, net			(2,666)		-		2,666		-		-
	Other financing activities, net			(70)		-		3,381		(2,801)		510
		Net cash flows provided by (used in) financing activities		176,044		90,029		(347,123)		90,021		8,971
Net increase (decrease) in cash and cash equivalents				(1,271)		-		6,951		-		5,680
Cash and cash equivalents, beginning of year				8,530		-		32,188		-		40,718
Cash and cash equivalents, end of year			$	7,259	$	-	$	39,139	$	-	$	46,398

Item 8. Financial Statements and Supplementary Data – (continued)

AmSurg Corp.

Notes to the Consolidated Financial Statements – (continued)

Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2011 (In thousands)
��
			Parent		Guarantor		Non-Guarantor		Consolidating		Total
			Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated

Cash flows from operating activities:
		Net cash flows provided by (used in) operating activities	$	(67,911)	$	151,558	$	311,334	$	(151,558)	$	243,423
Cash flows from investing activities:
	Acquisition of interests in surgery centers and related transactions			(84,597)		(243,429)		-		88,803		(239,223)
	Acquisition of property and equipment			(2,858)		-		(19,312)		-		(22,170)
	Proceeds from sale of interests in surgery centers			-		7,274		(248)		-		7,026
		Net cash flows used in investing activities		(87,455)		(236,155)		(19,560)		88,803		(254,367)
Cash flows from financing activities:
	Proceeds from long-term borrowings			281,100		-		7,769		-		288,869
	Repayment on long-term borrowings			(118,100)		-		(11,007)		-		(129,107)
	Distributions to owners, including noncontrolling interests			-		-		(290,282)		151,558		(138,724)
	Capital contributions			-		84,597		-		(84,597)		-
	Changes in intercompany balances with affiliates, net			(178)		-		178		-		-
	Other financing activities, net			(3,609)		-		4,292		(4,206)		(3,523)
		Net cash flows provided by (used in) financing activities		159,213		84,597		(289,050)		62,755		17,515
Net increase in cash and cash equivalents				3,847		-		2,724		-		6,571
Cash and cash equivalents, beginning of year				4,683		-		29,464		-		34,147
Cash and cash equivalents, end of year			$	8,530	$	-	$	32,188	$	-	$	40,718

17. Subsequent Events

The Company assessed events occurring subsequent to December 31, 2013 for potential recognition and disclosure in the consolidated financial statements. In January 2014, the Company, through a wholly owned subsidiary, acquired a majority interest in a surgery center for a purchase price of approximately $5,100,000. Other than as previously described, no events have occurred that would require adjustment to or disclosure in the consolidated financial statements.

Item 8. Financial Statements and Supplementary Data – (continued)

Quarterly Statement of Earnings Data (Unaudited)

The following table presents certain quarterly statement of earnings data for the years ended December 31, 2013 and 2012. The quarterly statement of earnings data set forth below was derived from the Company’s unaudited financial statements and includes all adjustments, consisting of normal recurring adjustments, which the Company considers necessary for a fair presentation thereof. Results of operations for any particular quarter are not necessarily indicative of results of operations for a full year or predictive of future periods.

		2013								2012
		Q1		Q2		Q3		Q4		Q1		Q2		Q3		Q4

		(In thousands, except per share data)

Revenues		$	259,043	$	268,099	$	267,631	$	284,570	$	227,567	$	228,955	$	223,885	$	242,775
Earnings from continuing operations
	before income taxes		74,496		78,398		73,989		81,644		66,110		66,611		63,211		67,854
Net earnings from continuing operations			62,203		65,640		62,562		68,368		55,349		55,541		53,148		57,384
Net earnings (loss) from
	discontinued operations (1)		70		196		(295)		2,800		(410)		4		617		2,010
Net earnings			62,273		65,836		62,267		71,168		54,939		55,545		53,765		59,394

Net earnings (loss) attributable to
	AmSurg Corp. common shareholders:
	Continuing		17,785		18,489		17,056		19,323		15,488		15,939		15,196		15,612
	Discontinued		26		74		(285)		235		(712)		(403)		241		1,202

	Net earnings	$	17,811	$	18,563	$	16,771	$	19,558	$	14,776	$	15,536	$	15,437	$	16,814


Diluted net earnings from
	continuing operations per common share	$	0.56	$	0.58	$	0.53	$	0.60	$	0.49	$	0.50	$	0.48	$	0.49

Diluted net earnings per common share		$	0.56	$	0.58	$	0.52	$	0.61	$	0.47	$	0.49	$	0.49	$	0.53

(1) Certain previously reported amounts have been reclassified for current year presentation for discontinued operations.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Not applicable.

Item 9A. Controls and Procedures

Management’s Report on Internal Control Over Financial Reporting

We are responsible for the preparation and integrity of the consolidated financial statements appearing in our Annual Report. The consolidated financial statements were prepared in conformity with United States generally accepted accounting principles and include amounts based on management’s estimates and judgments. All other financial information in this report has been presented on a basis consistent with the information included in the consolidated financial statements.

We are also responsible for establishing and maintaining adequate internal controls over financial reporting. We maintain a system of internal controls that is designed to provide reasonable assurance as to the fair and reliable preparation and presentation of the consolidated financial statements, as well as to safeguard assets from unauthorized use or disposition. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs.

Our control environment is the foundation for our system of internal controls over financial reporting and is embodied in our Code of Conduct. It sets the tone of our organization and includes factors such as integrity and ethical values. Our internal controls over financial reporting are supported by formal policies and procedures which are reviewed, modified and improved as changes occur in business conditions and operations.

We conducted an evaluation of effectiveness of our internal controls over financial reporting based on the framework in Internal Control – Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission. This evaluation included review of the documentation of controls, effectiveness of controls and a conclusion on this evaluation. Although there are inherent limitations in the effectiveness of any system of internal controls over financial reporting, based on our evaluation, we have concluded that our internal controls over financial reporting were effective as of December 31, 2013.

The effectiveness of the Company’s internal control over financial reporting has been audited by Deloitte & Touche LLP, an independent registered public accounting firm, and they have issued an attestation report on the Company’s internal control over financial reporting which is set forth in the Report of Independent Registered Public Accounting Firm in Part II, Item 9A of this Annual Report on Form 10-K.

/s/ Christopher A. Holden

Christopher A. Holden

President and Chief Executive Officer

/s/ Claire M. Gulmi

Claire M. Gulmi

Executive Vice President and Chief Financial Officer

Item 9A. Controls and Procedures – (continued)

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Shareholders of
AmSurg Corp.
Nashville, Tennessee

We have audited the internal control over financial reporting of AmSurg Corp. and subsidiaries (the "Company") as of December 31, 2013, based on criteria established in Internal Control — Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission. The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company's internal control over financial reporting is a process designed by, or under the supervision of, the company's principal executive and principal financial officers, or persons performing similar functions, and effected by the company's board of directors, management, and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of the inherent limitations of internal control over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may not be prevented or detected on a timely basis. Also, projections of any evaluation of the effectiveness of the internal control over financial reporting to future periods are subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2013, based on the criteria established in Internal Control — Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated financial statements as of and for the year ended December 31, 2013 of the Company and our report dated February 26, 2014 expressed an unqualified opinion on those financial statements.

/s/ DELOITTE & TOUCHE LLP

Nashville, Tennessee

February 26, 2014

Item 9A. Controls and Procedures – (continued)

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management team, including our chief executive officer and chief financial officer, we conducted an evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of December 31, 2013. Based on that evaluation, our chief executive officer (principal executive officer) and chief financial officer (principal accounting officer) have concluded that our disclosure controls and procedures are effective.

Changes in Internal Control Over Financial Reporting

During the fourth fiscal quarter of the period covered by this report, there has been no change in our internal control over financial reporting that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.

Item 9B. Other Information

Not applicable.

Part III

Item 10. Directors, Executive Officers and Corporate Governance

Information with respect to our directors, set forth in our Definitive Proxy Statement for the Annual Meeting of Shareholders to be held May 20, 2014, under the caption “Election of Directors,” is incorporated herein by reference. Pursuant to General Instruction G(3), information concerning our executive officers is included in Part I of this Annual Report on Form 10-K under the caption “Executive Officers of the Registrant.”

Information with respect to compliance with Section 16(a) of the Securities Exchange Act of 1934, set forth in our Definitive Proxy Statement for the Annual Meeting of Shareholders to be held May 20, 2014, under the caption “Section 16(a) Beneficial Ownership Reporting Compliance,” is incorporated herein by reference.

Information with respect to our code of ethics, set forth in our Definitive Proxy Statement for the Annual Meeting of Shareholders to be held May 20, 2014, under the caption “Code of Conduct” and “Code of Ethics,” is incorporated herein by reference.

Information with respect to our audit committee and audit committee financial experts, set forth in our Definitive Proxy Statement for the Annual Meeting of Shareholders to be held May 20, 2014, under the caption “Election of Directors,” is incorporated herein by reference.

Item 11. Executive Compensation

Information required by this caption, set forth in our Definitive Proxy Statement for the Annual Meeting of Shareholders to be held May 20, 2014, under the caption “Executive Compensation,” is incorporated herein by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Information with respect to security ownership of certain beneficial owners and management and related stockholder matters, set forth in our Definitive Proxy Statement for the Annual Meeting of Shareholders to be held May 20, 2014, under the caption “Stock Ownership” and information with respect to our equity compensation plans at December 31, 2013, set forth in our Definitive Proxy Statement for the Annual Meeting of Shareholders to be held May 20, 2014, under the caption “Equity Compensation Plan Information,” is incorporated herein by reference.

Item 13. Certain Relationships and Related Transactions, and Director Independence

Information with respect to certain relationships and related transactions, set forth in our Definitive Proxy Statement for the Annual Meeting of Shareholders to be held May 20, 2014, under the caption “Certain Relationships and Related Transactions,” is incorporated herein by reference.

Information with respect to the independence of our directors, set forth in our Definitive Proxy Statement for the Annual Meeting of Shareholders to be held May 20, 2014, under the caption “Corporate Governance,” is incorporated herein by reference.

Item 14. Principal Accounting Fees and Services

Information with respect to the fees paid to and services provided by our principal accountant, set forth in our Definitive Proxy Statement for the Annual Meeting of Shareholders to be held May 20, 2014, under the caption “Fees Billed to Us by Deloitte & Touche LLP During 2013 and 2012,” is incorporated herein by reference.

Part IV

Item 15. Exhibits and Financial Statement Schedules

(a) Financial Statements, Financial Statement Schedules and Exhibits

(1) Financial Statements: See Item 8 herein.
(2) Financial Statement Schedules:
	Report of Independent Registered Public Accounting Firm	S-1
	Schedule II – Valuation and Qualifying Accounts	S-2
	(All other schedules are omitted because they are not applicable or not required, or because the required information is included in the consolidated financial statements or notes thereto.)
(3) Exhibits: See the exhibit listing set forth below.

(3) Exhibits

Exhibit		Description

2.1		Asset Purchase Agreement, dated August 23, 2011, by and among AmSurg, AmSurg Holdings, Inc. and National Surgical Care, Inc. (incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K, dated August 29, 2011)

2.2		Amendment No. 1 to Asset Purchase Agreement, dated September 1, 2011, by and among AmSurg, AmSurg Holdings, Inc. and National Surgical Care, Inc. (incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K, dated September 2, 2011)

3.1		Second Amended and Restated Charter of AmSurg, as amended (incorporated by reference to Exhibit 3.1 to the Quarterly Report on Form 10-Q for the quarter ended June 30, 2012)

3.2		Second Amended and Restated Bylaws of AmSurg, as amended (incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K, dated May 22, 2012)

4.1		Specimen common stock certificate (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form 10/A-4 (filed with the Commission on July 13, 2001))

4.2		Indenture, dated as of November 20, 2012, among AmSurg Corp., the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K, dated November 20, 2012)

4.3		Registration Rights Agreement, dated as of November 20, 2012, AmSurg Corp., the subsidiary guarantors listed therein, and SunTrust Robinson Humphrey, Inc., acting on behalf of itself and as the representative of the several Initial Purchasers listed therein (incorporated by reference to Exhibit 4.2 of the Current Report on Form 8-K, dated November 20, 2012)

10.1	*	Form of Indemnification Agreement with directors, executive officers and advisors (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K (filed with the Commission on February 4, 2014))

10.2		Revolving Credit Agreement, dated as of May 28, 2010, among AmSurg, SunTrust Bank, as Administrative Agent, and various banks and other financial institutions (incorporated by reference to Exhibit 99.1 of the Current Report on Form 8-K, dated June 2, 2010)

10.3		First Amendment to Revolving Credit Agreement, dated as of April 6, 2011, among AmSurg, SunTrust Bank, as Administrative Agent, and various banks and other financial institutions (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K, dated April 12, 2011)

10.4		Second Amendment to Revolving Credit Agreement, dated as of April 6, 2011, among AmSurg, SunTrust Bank, as Administrative Agent, and various banks and other financial institutions (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K, dated April 12, 2011)

10.5		Third Amendment to Revolving Credit Agreement, dated as of August 30, 2011, among AmSurg, SunTrust Bank, as Administrative Agent, and various banks and other financial institutions (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K, dated September 2, 2011)

10.6		Fourth Amendment to Revolving Credit Agreement, dated as of June 29, 2012, among AmSurg Corp., the banks and other financial institutions from time to time party thereto, and SunTrust Bank, in its capacity as Administrative Agent for the lenders (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K, dated June 29, 2012)

10.7		Fifth Amendment to Revolving Credit Agreement, dated as of November 7, 2012, among AmSurg Corp., the banks and other financial institutions from time to time party thereto, and SunTrust Bank, in its capacity as Administrative Agent for the lenders (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K, dated November 20, 2012)

10.8		Sixth Amendment to Revolving Credit Agreement and First Amendment to Subsidiary Guarantee Agreement, dated as of June 14, 2013, among AmSurg Corp., each of the wholly-owned subsidiaries of the Company a party thereto, the banks and other financial institutions from time to time party thereto, and SunTrust Bank, in its capacity as Administrative Agent for the lenders (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 18, 2013)

10.9		Note Purchase Agreement, dated as of May 28, 2010 among AmSurg, The Prudential Life Insurance Company of America, and various other financial institutions (incorporated by reference to Exhibit 99.2 of the Current Report on Form 8-K, dated June 2, 2010)

10.10		First Amendment to Note Purchase Agreement, dated as of April 6, 2011, among AmSurg, The Prudential Life Insurance Company of America, and various other financial institutions (incorporated by reference to Exhibit 10.3 of the Current Report on Form 8-K, dated April 12, 2011)

(3) Exhibits – (continued)

Exhibit		Description

10.11		Second Amendment to Note Purchase Agreement, dated as of August 30, 2011, among AmSurg, The Prudential Life Insurance Company of America, and various other financial institutions (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K, dated September 2, 2011)

10.12		Third Amendment to Note Purchase Agreement, dated as of June 29, 2012, among AmSurg Corp. and the holders of Notes party thereto (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K, dated June 29, 2012)

10.13		Fourth Amendment to Note Purchase Agreement, dated as of November 7, 2012, among AmSurg Corp. and the holders of Notes party thereto (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K, dated November 20, 2012)

10.14	*	Amended and Restated 1997 Stock Incentive Plan (incorporated by reference to Exhibit 4.1 to the Quarterly Report on Form 10-Q for the quarter ended June 30, 2004)

10.15	*	First Amendment to Amended and Restated 1997 Stock Incentive Plan (incorporated by reference to Exhibit 99.2 to the Current Report on Form 8-K, dated November 21, 2006)

10.16	*	Form of Non-Qualified Stock Option Agreement – 1997 Incentive Plan (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K, dated February 2, 2005)

10.17	*	Form of Restricted Stock Agreement for Non-Employee Directors – 1997 Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, dated May 24, 2005)

10.18		Lease Agreement dated February 24, 1999 between Burton Hills III, LLC and AmSurg (incorporated by reference to Exhibit 10.1 of the Quarterly Report on Form 10-Q for the quarter ended June 30, 1999)

10.19		First Amendment to Lease Agreement dated June 27, 2001 by and between Burton Hills III, LLC and AmSurg (incorporated by reference to Exhibit 10 of the Quarterly Report on Form 10-Q for the quarter ended September 30, 2002)

10.20		Second Amendment to Lease Agreement dated January 31, 2003 by and between Burton Hills III Partnership and AmSurg (incorporated by reference to Exhibit 10.14 to the Annual Report on Form 10-K for the year ended December 31, 2003)

10.21		Third Amendment to Lease Agreement dated September 1, 2003 by and between Burton Hills III Partnership and AmSurg (incorporated by reference to Exhibit 10.15 to the Annual Report on Form 10-K for the year ended December 31, 2003)

10.22		Fourth Amendment to Lease Agreement dated October 31, 2003 by and between Burton Hills III Partnership and AmSurg (incorporated by reference to Exhibit 10.16 to the Annual Report on Form 10-K for the year ended December 31, 2003)

10.23		Fifth Amendment to Lease Agreement, dated November 9, 2012, between Burton Hills III Investments and AmSurg Corp. (incorporated by reference to Exhibit 10.22 to the Annual Report on Form 10-K for the year ended December 31, 2012)

10.24		Sixth Amendment to Lease Agreement, dated December 27, 2012, between Burton Hills III Investments and AmSurg Corp. (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K, dated January 3, 2013)

10.25		Lease Agreement, dated December 27, 2012, between Burton 6, LLC and AmSurg Corp. (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K, dated January 3, 2013)

10.26		First Amendment to Lease Agreement, dated February 15, 2013, between Burton 6, LLC and AmSurg Corp. (incorporated by reference to Exhibit 10.25 to the Annual Report on Form 10-K for the year ended December 31, 2012)

10.27		Second Amendment to Lease Agreement, dated April 11, 2013, between Burton 6, LLC and AmSurg Corp.

10.28		Third Amendment to Lease Agreement, dated October 13, 2013, between Burton 6, LLC and AmSurg Corp.

10.29	*	Amended and Restated AmSurg Corp. Supplemental Executive & Director Retirement Savings Plan (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K dated January 6, 2012)

(3) Exhibits – (continued)

Exhibit		Description

10.30	*	AmSurg Corp. 2006 Stock Incentive Plan, as amended (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K, filed on November 22, 2013)

10.31	*	Form of Restricted Share Award Agreement for Non-Employee Directors – 2006 Incentive Plan (incorporated by reference to Exhibit 99.3 to the Current Report on Form 8-K, dated February 21, 2007)

10.32	*	Form of Non-Qualified Stock Option Agreement for Executive Officers – 2006 Incentive Plan (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K, dated February 21, 2007)

10.33	*	Form of Restricted Share Award for Employees – 2006 Incentive Plan (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K, dated May 26, 2010)

10.34	*	AmSurg Corp. Long-Term Care Plan (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q for the quarter ended June 30, 2005)

10.35	*	Second Amended and Restated Employment Agreement, dated November 21, 2013, between AmSurg and Christopher A. Holden (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, dated November 22, 2013)

10.36	*	Third Amended and Restated Employment Agreement, dated January 30, 2014, between AmSurg and Claire M. Gulmi (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K, dated February 4, 2014)

10.37	*	Third Amended and Restated Employment Agreement, dated January 30, 2014, between AmSurg and David L. Manning (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K, dated February 4, 2014)

10.38	*	Amended and Restated Employment Agreement, dated January 30, 2014, between AmSurg and Kevin D. Eastridge (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K, dated February 4, 2014)

10.39	*	Amended and Restated Employment Agreement, dated January 30, 2014, between AmSurg and Phillip A. Clendenin (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K, dated February 4, 2014)

10.40	*	Schedule of Non-employee Director Compensation

12.1		Statement of Computation of Ratios of Earnings to Fixed Charges

21.1		Subsidiaries of AmSurg

23.1		Consent of Independent Registered Public Accounting Firm

24.1		Power of Attorney (appears on page 74)

31.1		Certification of Chief Executive Officer pursuant to Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2		Certification of Chief Financial Officer pursuant to Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101		Interactive data files pursuant to Rule 405 of Regulation S-T; (i) the Consolidated Balance Sheets at December 31, 2013 and December 31, 2012, (ii) the Consolidated Statements of Earnings for the years ended December 31, 2013, 2012 and 2011, (iii) the Consolidated Statements of Comprehensive Income for the years ended December 31, 2013, 2012 and 2011, (iv) the Consolidated Statements of Changes in Equity for the years ended December 31, 2013, 2012 and 2011, (v) the Consolidated Statements of Cash Flows for the years ended December 31, 2013, 2012 and 2011, and (vi) the Notes to the Consolidated Financial Statements for the years ended December 31, 2013, 2012 and 2011.
	*	Management contract or compensatory plan, contract or arrangement

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	AMSURG CORP.

Date: February 26, 2014

	By:	/s/ Christopher A. Holden
		Christopher A. Holden
		(President and Chief Executive Officer)

KNOW ALL MEN BY THESE PRESENTS, each person whose signature appears below hereby constitutes and appoints Christopher A. Holden and Claire M. Gulmi, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this report, and to file the same with all exhibits thereto and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Signature	Title	Date

/s/ Christopher A. Holden	President, Chief Executive Officer and Director (Principal Executive Officer)	February 26, 2014
Christopher A. Holden		February 26, 2014

/s/ Claire M. Gulmi	Executive Vice President, Chief Financial Officer, Secretary and Director (Principal Financial and Accounting Officer)	February 26, 2014
Claire M. Gulmi


/s/ Steven I. Geringer	Chairman of the Board	February 26, 2014
Steven I. Geringer

/s/ Thomas G. Cigarran	Director	February 26, 2014
Thomas G. Cigarran

/s/ James A. Deal	Director	February 26, 2014
James A. Deal

/s/ Henry D. Herr	Director	February 26, 2014
Henry D. Herr

/s/ Joey A. Jacobs	Director	February 26, 2014
Joey A. Jacobs

/s/ Kevin P. Lavender	Director	February 26, 2014
Kevin P. Lavender

/s/ Cynthia S. Miller	Director	February 26, 2014
Cynthia S. Miller

/s/ John W. Popp, Jr., M.D.	Director	February 26, 2014
John W. Popp, Jr., M.D.

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders of

AmSurg Corp.

Nashville, Tennessee

We have audited the consolidated financial statements of AmSurg Corp. and subsidiaries (the “Company”) as of December 31, 2013 and 2012, and for each of the three years in the period ended December 31, 2013, and the Company’s internal control over financial reporting as of December 31, 2013, and have issued our reports thereon dated February 26, 2014; such consolidated financial statements and reports are included elsewhere in this Form 10-K. Our audits also included the consolidated financial statement schedule of the Company listed in Item 15. This consolidated financial statement schedule is the responsibility of the Company’s management. Our responsibility is to express an opinion based on our audits. In our opinion, such consolidated financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a whole, presents fairly, in all material respects, the information set forth therein.

/s/ DELOITTE & TOUCHE LLP

Nashville, Tennessee

February 26, 2014

S-1

AmSurg Corp.

Schedule II – Valuation and Qualifying Accounts

For the Years Ended December 31, 2013, 2012 and 2011

(In thousands)

				Additions				Deductions

		Balance at		Charged to		Charged to		Charge-off		Balance
		Beginning		Cost and		Other		Against		at End of
		of Period		Expenses		Accounts (1)		Allowances		Period

Allowance for uncollectible accounts included under
	the balance sheet caption “Accounts receivable”:

Year ended December 31, 2013		$	22,379	$	21,983	$	6,410	$	(22,910)	$	27,862

Year ended December 31, 2012		$	18,844	$	20,340	$	4,561	$	(21,366)	$	22,379

Year ended December 31, 2011		$	13,070	$	18,501	$	3,967	$	(16,694)	$	18,844

(1)	Valuation of allowance for uncollectible accounts as of the acquisition date of physician practice-based surgery centers, net of dispositions. See “Item 8. Financial Statements and Supplementary Data – Notes to the Consolidated Financial Statements – Note 2.”

S-2

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

Amsurg (AMSG) Inactive 10-K2013 FY Annual report

Content analysis

Washington, D.C. 20549

FORM 10-K

Part I

Item 1. Business

PART II